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LOWER URINARY TRACT SYMPTOMS IN GENERAL PRACTICE
In this thesis we studied the evidence used in, and the possibilities of an implementation 
strategy for the guidelines on lower urinary tract symptoms (LUTS).1;2 From a recent 
nationwide monitoring of the clinical management by the general practitioner (GP) there 
is some doubt whether these guidelines are followed by the Dutch GP.3 Implementing a 
guideline would mean giving account for the guideline itself and for possible barriers 
and facilitators to change.4 Before presenting the studies we conducted, LUTS and some 
of the clinical difficulties related to it will be illustrated as an introduction. Then the 
present evidence used in the clinical management of LUTS will be highlighted and the 
patients and physicians perspective on LUTS will be explored. Subsequently a possible 
implementation strategy for the 1997 update of the guideline is worked out. In the end the 
research questions surfacing from this aims of the research of this thesis will be formulated 
and the outline of the thesis is drawn.
In 1977 a program of the National Institutes of Health (NIH) in the United States started 
developing ‘consensus statements’ in clinical management.5 They have been developed 
for many clinical conditions to assist practitioner and patient in their decisions about 
appropriate health care.5 In 1982 the NIH initiative was followed in the Netherlands by 
the Dutch Institute for Health care Improvement (CBO) developing consensus guidelines for 
medical specialists. Seven years later the first guideline on Diabetes care in the general 
practice was published by the Nederlands Huisartsen Genootschap (NHG) (Dutch College of 
General Practitioners).6 In the following years some eighty guidelines more were developed 
by the Dutch College. These guidelines distinguish themselves from the CBO-guidelines 
as they are in general guidelines developed by and for GPs. The NHG guidelines played 
an important role in professionalizing general practice in the Netherlands.7
Benign Prostatic Hyperplasia (BPH) as a clinical diagnosis is very common; Continuous 
Morbidity Registration and the recent Second National Study show a prevalence of 
6.8-15 per 1000 men, with an incidence of 2.5-4 men per 1000 per year.8;9 The problem 
in BPH is that the relation between complaints and results of additional examinations 
is weak; furthermore there is a fear among patients and physicians of (missing) prostate 
related malignancies. These might lead to inadequate clinical management of patients 
presenting themselves at the surgery. In 1994 a first guideline on voiding problems in the 
elderly male was published as the 42nd guideline of the Dutch College covering the clinical 
management of the problems related to BPH.10 This guideline was updated in 19971 and 
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adapted to a document that could be used as the basis for a shared care protocol with the 
urologists one year later.2 
LOWER URINARY TRACT SYMPTOMS
Traditionally, a benign enlargement of the prostate (Benign Prostatic Hyperplasia, or BPH) 
is thought to be the cause of voiding problems. Located below the bladder and in front 
of the rectum, the prostate is surrounding the urethra and normally has about the same 
size and shape as a walnut. The prostate gland is part of the male reproductive system 
producing fluid for semen, it normally evolves quickly at puberty and then maintains its 
size. BPH refers to a benign hyperplasia in which the prostate (pathologically) enlarges, 
usually a�er the age of 40. BPH is found in 60% of men over 60 years of age, and in up 
to 80% of men over 80 years of age. As the prostate enlarges it may cause obstruction of 
the urethra, resulting in problems when urinating. In the early stages of BPH, the bladder 
muscle can force urine through the narrowed urethra, but due to gradually increasing 
obstruction the bladder muscle gets stronger, thicker and more sensitive with complaints 
like urgency as a consequence. In some cases, the patient may be confronted with an 
emergency of an acute urinary retention.
Although BPH may cause no problems at all, about one third of men with BPH eventually 
will be bothered by their symptoms or develop other related problems that require 
treatment. Examples of symptoms are the feeling of urine retention a�er voiding, a weak 
urine stream, or nycturia.
Bladder
Vas deferens
Prostate
Urethra
Ureters
Seminal vesicle
Rectum
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Nowadays experts no longer think urinary tract symptoms are always caused by the 
prostate, but that they may also be the effect of conditions in other organs, such as the 
bladder; since some patients may have symptoms without having a large prostate. While the 
exact cause of symptoms cannot always be found, symptoms may be due to a combination 
of both prostate growth and increased muscle tightness in the neck of the bladder and 
in the prostate. It may be concluded that these complaints are neither sex, or age related, 
nor disease specific and so today they are referred to as Lower Urinary Tract Symptoms 
(LUTS).11-13 LUTS are a very common, but generally not a life threatening, problem. Several 
studies have indicated that, in an open population, 30% of men over 50 years of age have 
LUTS that may be called bothersome and thus requiring treatment.14-17 The treatment 
possibilities have increased during the last decades; with a spectrum from a considered 
watchful waiting, via medication and minimal interventions to surgical techniques. In 
general practice α-blocking medication is frequently prescribed. It can decrease the urine 
outflow resistance by influencing the muscle tone in the prostate and urinary tract. When the 
α-blockers are effective, the largest effect is reached within two weeks. However, medication 
has a limited effect on the complaints, both compared to placebo and invasive treatment 
methods. So, making a proper treatment choice is not simple and will mean carefully 
weighing the options. For example, a surgical treatment may relieve symptoms to a 
greater degree than a medical treatment, and for a longer period of time, but surgery also 
has a greater risk of complications, and requires a hospital stay, an anaesthetic and several 
weeks of recovery time.
The prostate is also o�en associated with prostate carcinoma. With 6897 new patients 
in 2001 this is the malignancy with the highest incidence in men (lung carcinoma: 6188 
and colon carcinoma: 4825).18 Prostate carcinoma has no specific early symptoms of the 
disease, so it is not unlikely that a patient and his physician relate voiding problems to 
prostate cancer (although there is no relation between prostate cancer and LUTS19;20). 
As a consequence many patients and physicians fear overlooking a carcinoma in men 
presenting with these complaints;21 they try to decrease their fear by doing a PSA test. 
Prostate Specific Antigen (PSA) is a glycoprotein produced by cells of the prostatic ductal 
epithelium and is present in the serum of all men. PSA is more specific then the previously 
used acid phosphatase test in the diagnosis of prostate carcinoma, but it has not yet proven 
to be an adequate screening test for prostate cancer.22-25
The GP who is confronted with this diagnostic uncertainty in everyday practice is not 
helped with the PSA test, but with support to discuss evidence on these items and so 
making rational decisions in clinical management and be able to give adequate patient 
education.
12
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THE EVIDENCE: CLINICAL GUIDELINES
As the population is ageing and public awareness is rising, there is a growing demand 
for appropriate diagnosis and effective treatment of LUTS. The increasing availability 
of non-invasive treatments, such as new drugs, may suggest that voiding problems can 
be treated more easily than before.26 Furthermore, in the last decade the management of 
LUTS has increasingly shi�ed from the specialist to the GP in various countries.27-32 These 
changes resulted in an increase of complicated questions for physicians in relation to the 
clinical management of voiding problems in the elder male. Guidelines could help in 
this by providing clear and unambiguous recommendations based on the best available 
evidence.
Under the auspices of the World Health Organization an international consensus commi�ee 
made recommendations concerning the diagnosis of BPH in Paris 1991.33 In 1994 the 
Dutch College of General Practitioners decided to develop national general practice 
guidelines10 separately from the guidelines published by the National Association of 
Urologists one year earlier.34 Simultaneously, guidelines on benign prostatic hyperplasia 
were developed in the United States (1994);35 followed by professional organizations in 
various other countries as France (1995),36 Australia (1997),37 the United Kingdom (1997)38 
and Germany(1999).39;40 
These clinical practice guidelines can be defined as systematically developed statements to 
assist practitioner and patient decisions about appropriate health care for specific clinical 
circumstances.5 Although the guidelines based on expert’s opinion are not considered 
to be of poor quality,41;42 most guidelines are evidence based in the sense that specific 
recommendations for practice are explicitly linked to the supporting evidence, if possible.43 
The evidence supporting the guidelines is in a process of constant change. Over the period 
1999 - 2003 there were no less then 2497 journal articles in MEDLINE alone with the 
MESH term ‘Prostatic-Hyperplasia’ (almost 500 annually). It has been calculated that to 
keep guidelines valid they have to be updated every 5 years.44 The guideline by the Dutch 
College of General Practitioners had a first revision in 1997;1 as a consequence an update 
was needed in 2002 to keep the recommendations in line with the current state of art. 
Guideline makers have in principle access to the same science resources of research 
evidence (e.g., MEDLINE, Cochrane Library), and therefore, one would expect guidelines 
to be similar. Recently, two studies compared international guidelines on benign prostatic 
hyperplasia. They found that most guidelines gave largely similar recommendations, 
although there were differences with respect to PSA testing and imagining of the urinary 
tract.45;46 A recent study on the recommendations given in diabetes guidelines showed 
12
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there was only a minor overlap between the references in the different guidelines.47 It is 
not known whether differences in the evidence used are a possible explanation to variation 
in recommendations in guidelines on LUTS.
CLINICAL MANAGEMENT OF LUTS: EXPLORATION OF THE PROBLEM
THE PATIENTS’ PERSPECTIVE
LUTS may have a significant impact on men’s life in terms of degree of bother, worry, 
interference with daily living and psychological well-being.48;49 Many studies explored 
reasons for doctors visits in patients with complaints of LUTS (Box 1).These studies show 
that men with moderate to severe symptoms are more likely to seek medical care than 
men with mild symptoms. Care seeking is not determined by symptom level alone, one 
may conclude that patients are not only seeking treatment for their physical complaints, 
but there is also a need for information on their condition.50
An epidemiologic study conducted in 1961 showed that far out the majority of the health 
problems perceived in the population are managed by the patients themselves and only 
some will seek medical a�endance. These figures are 40 years later still applicable.62 Many 
men with LUTS will be perfectly capable of caring for their own condition as well and thus 
Box 1: Factors related to doctor visits in patients with LUTS
Demographic patient characteristics:
age51-53
marital status51
educational level54-56
income51
Level of complaints:
symptom severity51-54;56-61
bothersomeness52;54;55;57;59
interference with daily activities in daily living53;54;57;59
Psychological factors:
worry55
depression56
sexual desire56
shame55
Others:
co-morbidity54
smoking56
14
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they do not seek medical care.50;56;57;59-61;63-66 They accept their chronic condition as part of 
their ageing process,50;57;67 and this has to be regarded as adequate health behaviour.
But there may be other reasons influencing their decision not to present themselves to 
medical care, as there may be a feelings of shame and fear.50;57 The man’s perception of the 
care provider’s ability to give relevant information or effective treatment is important as 
well as the patient’s ability to cope with the LUTS himself.68 Knowing what’s on a man’s 
mind may help to bring those, who will benefit the most from medical care, and where 
non-a�endance is inappropriate, to consult their family doctor in time.
Further detailed insight in the factors that determine consultation for LUTS is essential for 
optimal advice and education focused on patients needs and on expectations of the elderly 
male population. 
THE PHYSICIANS’ PERSPECTIVE
In the Netherlands, almost all patients are registered with a GP in a general practice and to 
the majority of these patients their GP functions as a gatekeeper to specialist care. So, most 
patients with LUTS are initially seen by GPs, referring selected cases to a urologists. With 
the introduction of α-blocking medication it has become more feasible to treat these 
complaints completely in general practice; leading to a more active role for GPs in the 
diagnosis and management of lower urinary tract symptoms.27-29;69
Before developing an implementation strategy it is important to be aware of the GPs’ 
a�itude towards the guideline on LUTS and possible barriers in using it in daily care. To 
explore physicians’ views on the recommendations in the guideline a 35 item questionnaire 
has been distributed among 141 GPs on possible facilitators and barriers with respect to the 
Dutch College of General Practitioners guideline on LUTS. The items where 25% or more 
Table 1: Survey of 141 General Practitioners in relation to the guideline on Lower Urinary Tract 
Symptoms
Reactions recommendations made in the guideline on LUTS % disagreement
PSA should only be tested in patients under the age of 70 yeas with a normal life expectancy 59.6
PSA should only be tested in patients with a dubious digital rectal examination 52.1
Medication is only indicated in men with severe complaints and not able or willing to be 
operated
51.1
The number of additional tests should mainly be determined by the severity of the 
complaints
46.1
In all men above the age of 50 years with LUTS percussion of the bladder should be 
performed
39.0
14
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of the respondents disagreed upon are presented in Table 1. From this one can conclude 
that the recommendations on PSA testing, prescription of medication and percussion of 
the bladder are controversial. 
To examine the physicians perspective in more detail semi structured interviews were 
conducted in 20 GPs on motives for their clinical management in patients with LUTS 
(quotes are presented in Box 2).
In general LUTS were not perceived as a life threatening disease, physicians also felt that 
their knowledge of this condition was adequate. They saw it as a disease area of minor 
significance compared to, for instance, diabetes or cardiovascular and pulmonary diseases. 
As a consequence they experienced no urge to follow an intensive training programme on 
LUTS. 
The GPs interviewed had the perception that most patients would a�end the surgery only 
if the LUTS became a nuisance (for them or their social network) or in case of an acute 
Box 2: A selection of quotes by 20 GPs in relation to the clinical management of LUTS
Percussion / palpation of the bladder:
Only if history raised suspicion:
…There has to be a clear story of an acute urinary retention, then I wil consider it, but ist is no part of the routine 
examination…
It is a difficult skill:
… Many men are obese…men have to have a considerable retention when I would be able to find it by 
percussion, depending on your technique. In these cases the history will be obvious as well…
PSA-testing:
Fear of missing a carcinoma:
…In such a small town this (missing a carcinoma) will spread around, so one will be more defensive and will order 
the test…
…But I can recall at least three patients where we only discovered the prostate carcinoma when they already had 
pathological fractures, then the diagnosis is missed…
…men can have a prostate carcinoma without knowing and if they visit the surgery and I did not consider it to be 
useful to test for PSA and later a carcinoma is discovered; I’ll be up a tree…
Patient education costs time:
…if they want a check up. I will try to explain…but I will do the test, I don’t want to pay to much attention to it…
…It depends if there is time…someone must be able to deal with it as well…
…PSA testing is not that expensive…within the time I have explained why this is not an appropriate test…the test 
is already ordered, one knows more and one has more certainty…
As part of clinical management:
…when I doubt referral, I will order PSA as additional diagnostics…
…if I prescribe medication I always order PSA as a routine…
Medication is only indicated in men with severe complaints and not able or willing to be 
operated:
Surgery is a more aggressive form of therapy
…medication offers more…and if one can prevent or postpone possible complications of surgery…
…complaints in general develop gradually…one can try medications and after half a year one can consider 
discontinuation…after stopping some patients may stay symptom free…
…most are better helped with medication…I would prefer it myself…
16
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urinary retention; other reasons for the patient were a need for information or fear of / 
questions about prostate cancer.
All interviewees thought of the digital rectal examination as a sensible, cheap and feasible 
examination that at least has to be done once in patients with complaints, but only three 
of the GPs were totally confident about their skills. An abdominal palpation or percussion 
was only performed in patients were history taking raised suspicion for a possible urinary 
bladder distension, with doubts in relation to its sensitivity.
PSA testing is common use as most physicians perform tests on a routine basis, although 
all were aware from their deviance of the recommendations in the guideline. Fear of 
missing a carcinoma was present in half of the doctors.
In cases where watchful waiting failed, GPs felt confident with the prescription of 
α-blocking agents (as tamsulosine and alfluzosine). All of them thought this to be in 
line with the preferences of patients and urologists, and with recommendations in local 
formularies. They further argued that surgery brings on certain risks, and always remains 
a possibility. The choice for medication or referral is normally le� to the patient, except for 
more urgent conditions as defined in the guideline (i.e. complicated LUTS, suspicion of a 
carcinoma, failing medication).
From these explorations of the physicians’ perspective it may be concluded that support 
in the communication between physician and patient on treatment possibilities of LUTS 
and on the potential (fear of) prostate cancer is needed. Can the guidelines on LUTS be 
implemented in a be�er way when a�ention is focused on these items.
A proper evaluation of men with complaints of LUTS is not always easy, as the prostate, 
the bladder, the urethra or combinations of these could be the cause of the symptoms. 
Although the GP is able to get an impression of the bother of the elderly patients; 
complaints concerning LUTS are o�en difficult to interpret on basis of history taking 
only.70-76 In order to keep up to the rising number of patients a be�er tuning of general 
practice and specialist care is needed. 
One possibility to streamline the patient evaluation is the implementation of the shared 
care protocol on LUTS; promoting urologists and GPs to make local arrangements for 
referral.77 Making inter-professional arrangements was expected to prevent redundant 
work and to contribute to the efficiency of health care.78 The studies published until now 
present the effect of the shared care clinics on the daily practice of the urologist. Potential 
effects of these clinics on the clinical management of the GP have not been reported. So 
before concluding that shared care is the solution to expected problems of the capacity 
in health care the effects of shared care on GPs’ clinical management has to be studied in 
more detail.
16
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Another way in fine-tuning might be the introduction of diagnostic tools from specialist 
to general practice care. When in doubt a GP could refer a patient to a urologist. In 84% of 
all patients referred to a urology outpatient clinic uroflowmetry is performed.79 Although 
uroflowmetry has its limitations it may be helpful in differentiating between BPH and 
non-BPH causes of the patients complaints. In recent years portable uroflowmetry devices 
have been developed and tested, delivering results comparable with measurements on the 
outpatient department.80-82 The portable devices can be taken home and so provides an 
instrument giving a good insight into the voiding pa�erns. With these instruments it has 
become more feasible to do a flowmetry in general practice, and so assist a more adequate 
referral. On the other hand there are some doubts on the feasibility of uroflowmetry 
in general practice; the number of new patients are not very high so one may question 
whether the GP will have enough routine for adequate interpretation of the diagrams and 
since there is no special charge for this medical examination it is not sure whether the GP 
is willing to make the investments to acquire the instrument. Furthermore there is li�le 
known about the willingness and ability of the patient fulfil the home measurements. 
So, before introduction of portable uroflowmetry in general practice on a large scale it is 
important to study its feasibility.
THE IMPLEMENTATION OF CLINICAL GUIDELINES
The 1997 Dutch College for General Practitioners guideline and the shared care protocol 
developed in cooperation with the National Association of Urologists recommend detailed 
history taking, without using symptoms scores or voiding dairies.1;2 These guidelines can 
be summarised as follows. Digital rectal examination (DRE), percussion of the bladder 
and urine analysis are considered as good clinical practice. A serum creatinine is limited 
to patients with suspicion of renal failure and PSA testing is restricted to few conditions 
(family history of prostate carcinoma, inconclusive DRE, start of medication for LUTS and 
a life expectancy of more than 10 years). In patients with bothersome symptoms who are 
not able or willing to have surgical treatment the medication of choice is an α-blocking 
agent, where 5α-reductase blockers are reserved for specialist care. Referral should be 
considered in men with complicated LUTS.
There is some doubt whether this guideline is followed by the Dutch general practitioner. 
Guideline monitoring data of a non random sample of GPs showed that PSA was tested in 
almost two thirds of all patients with voiding problems and this number is rising.3;83
18
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There is a large quantity of literature on guideline implementation. In general, evidence 
shows that none of the approaches for transferring evidence to practice is superior to all 
changes in all situations. On the other hand, it may be concluded that the approach has 
to be focused on different levels (doctor, patient and wider environment) and tailored 
to specific se�ings. The implementation strategy should account for the guideline and 
barriers and facilitators to change.4
Preparatory interviews with 20 GPs on possible facilitators and barriers for changing 
routines (described before) and other explorations resulted in the development of an 
intervention to implement the 1997 update of the guideline on LUTS. From these interviews 
we extracted targets for behavioural change. In general LUTS were not perceived as 
a clinical problem and no urge was felt to follow an intensive training programme on 
LUTS. Just sending recommendations showed conflicting results,84 on the other hand 
distance learning,85 and consultation supporting materials,86-88 have shown effects on self 
rated competence and care delivered. Given the relative low priority of the subject for 
GPs, we needed a simple, relevant, easy to participate, educational programme aimed 
at encouraging physicians to inform patients and facilitate shared decision making. The 
Programme for Individual Learning (PIL) could meet these characteristics. This interactive 
Continuous Medical Education programme consists of small booklets developed by the 
Dutch College of General Practitioners as one of their implementation strategies for 
clinical guidelines. Just educating physicians in order to improve their knowledge will not 
be enough, this knowledge will have to be shared with the patient as well. The role of the 
patient is changing, as patients are increasingly involved in the management of their illness 
and health care providers should support them in this role.89 In the management of patients 
with LUTS it is considered to be important to involve the patient in making decisions 
based on his own preferences and needs.90 As a consequence, patient education and shared 
decision-making based on the available research evidence are crucial for the adequate 
management of LUTS and for helping patients to cope with their illness. And patients 
should be educated in problem solving skills in order to promote self-management.91
From this it can be concluded that implementation of the recommendations made in the 
guideline require an easy accessible, interactive educational programme, supported by 
tools that can be used in the communication during the consultation of patients a�ending 
the surgery because of LUTS. It is not known what the effect of such a multifaceted 
implementation would be on the actual clinical management of the GP, nor what 
implications it would have on patient’s self management. 
18
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RESEARCH QUESTIONS
Further research to the problems mentioned above has to be done. As a consequence the 
following research questions were formulated.
THE EVIDENCE: CLINICAL GUIDELINES
What is currently the recommended clinical management of lower urinary tract symptoms 
in general practice in the Netherlands according to evidence found in international 
literature?
What is the methodological quality of recently published national guidelines on LUTS in 
different countries?
To what extent can conflicting recommendations be explained by differences in the 
references used in support of these recommendations?
CLINICAL MANAGEMENT OF LUTS: EXPLORATION OF THE PROBLEM 
Which factors explain the decision to visit a GP for lower urinary tract symptoms?
To what extent is the clinical management of patients with uncomplicated LUTS by general 
practitioners and urologists different and what are the potential effects of shared care on 
their clinical management?
What is the feasibility of a protocol for uroflowmetry in routine general practice?
THE IMPLEMENTATION OF CLINICAL GUIDELINES
What is the effect of a distance learning programme on the clinical management in general 
practice for patients with LUTS older than 50 years?
What are the effects of a GP oriented distant learning programme on patient outcomes, 
particularly patient enablement and patient evaluation of care?
What are the costs in relation to the effects of distance learning on the management of 
LUTS in patients older than 50 years in general practice?
THE OUTLINE OF THE THESIS
This thesis is presented in three sections. The evidence on clinical management is presented 
in the first two chapters. The three chapters in the second section concern an exploration 
of contemporary management of men with LUTS. The last section is reporting the effects 
20
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of a trial studying the effect of an implementation strategy of the 1997 update of the Dutch 
College of General Practitioners guideline on LUTS . 
Chapter 1 provides the most recent (2004) update of the guideline on the clinical 
management of men of 50 years or older with lower urinary tract symptoms as formulated 
by the Dutch College of General Practitioners. This update is based on the systematic 
research by the commi�ee with respect to changes in terminology, a new understanding 
of relations between LUTS and prostate carcinoma and changes in clinical management of 
LUTS. The summary of the guideline presented in this chapter is an update of the guideline 
published in 1997, the last has been used as the starting point for the rest of this thesis.
Chapter 2 presents a study concerning five recently published guidelines on LUTS. 
First a systematic assessment of the quality of these guidelines was performed. Then, 
recommendations with regards to the initial clinical management were identified and 
citations linked to these recommendations were collected. The evidence used in ‘conflicting’ 
recommendations was explored in a qualitative manner.
In chapter 3 the patient’s perspective on LUTS is explored by a survey among 3500 men 
above the age of 50 years. It reports on factors determining visit to the doctor, or refraining 
from it, in relation to the complaints experienced. 
Chapter 4 reports a survey on the knowledge of the GPs and the urologists of the guidelines 
and the shared care protocol on LUTS. It studies the potential effects of a shared care clinic 
on the clinical management of GPs and urologists.
In chapter 5 a pilot study is presented on the feasibility of uroflowmetry as an additional 
diagnostic instrument in general practice. Based on the literature a protocol was 
formulated ensuring a proper evaluation of the complaints experienced by the patient. This 
protocol was tested for 14 months in two different se�ings; comparing direct accessible 
uroflowmetry in the own practice with accessibility via a central laboratory.
The last section comprises three chapters reporting the effects of the randomised trial 
on the implementation of the 1997 update of the Dutch College of General Practitioners 
guideline on LUTS. This study was performed in the practices of 63 GPs during 14 months 
a�er the intervention. In this section chapter 6 reports of the effects of the intervention on 
the actual clinical management of the 183 included patient with LUTS by the GP. Chapter 
7 presents the effects on the care as perceived by the patient; here the evaluation of care 
and the level to which the patient felt enabled by the GP were measured. The effects of the 
intervention on costs were evaluated in chapter 8.
Finally in the general discussion the results of the different studies are discussed and the 
main conclusions are presented.
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Abstract
The underlying cause of lower urinary tract symptoms (LUTS) in middle-aged and elderly men is 
an improperly functioning voiding mechanism of the bladder because of ageing. Symptoms are not 
simply due to prostate-enlargement. In uncomplicated LUTS patients’ perception of the amount of 
bother is very important in considering and choosing therapeutic options. 
In general, for symptom relief invasive treatment is more effective than medical treatment, although 
invasive treatment causes more adverse effects. 
LUTS and prostate cancer are different entities, and having LUTS is not associated with an increased 
risk of prostate cancer. This issue is discussed to clarify underlying thoughts and the practical use 
of this guideline.
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CHAPTER 1
INTRODUCTION
The Dutch College of General Practitioners (NHG) guideline on lower urinary tract 
symptoms that was published in 1997 needed revision because of new insights with 
regards to terminology, diagnostics and treatment possibilities. In this summary we focus 
on these new insights and the changes in comparison with the previous version of the 
guideline. Full text and the evidence used are published in Huisarts en Wetenschap1 and on 
the website of the Dutch College of General Practitioners.2 The guideline was summarized 
on page 30 and 31.
BACKGROUND
Lower urinary tract symptoms are defined as a change in voiding leading to symptoms as 
difficulties in starting micturation, a weak flow, urge, difficulty in emptying the bladder 
and an increase in the voiding frequency during day and night. Terms as prostatism and 
benign prostatic hyperplasia were used for these complaints in the past. 
The relation between the voiding problems and the size of the prostate or to what extend 
the urethra was obstructed was limited. In international literature the term lower urinary 
tract symptoms (LUTS) has been increasingly used.3 Benign prostatic hyperplasia will be 
reserved to described histological changes of the prostate.
RECOMMENDATIONS FOR DIAGNOSTICS
With respect to history taking it is not only important to ask for the actual severity of 
symptoms, but also the bother perceived. The bother can be limited due to the gradual 
development and the changes in the natural course of the symptoms. On the other hand 
an underlying fear of prostate cancer could augment the bother perceived.4 The bother 
perceived plays an important role in the clinical management.
The recommendation to perform a percussion of the bladder in every patient in order 
to identify urine retention in the bladder was removed from the new guideline. In daily 
care percussion is laborious and on second look the clinical relevance of a bladder residue 
was limited. A�er voiding almost all men appear to have some residue, and moreover 
Urinary diffi culty: changes in urination that lead to complaints such as hesitation before urine fl ow starts, weak or 
intermittent urinary stream, an urgent need to urinate, the feeling that the bladder has not emptied completely and 
increased frequency of urination.
Ask about:
- hesitation before urine fl ow starts, weak or intermittent urinary stream, urgent need to urinate, the feeling that the 
bladder has not emptied completely, changes in urinary pattern during the day and at night;
- rate of onset or rate of deterioration of the complaints;
- does it affect the night’s sleep, or cause social limitations during the day, incontinence;
- pain during urination, perineal pain;
- general malaise, previous urinary tract infections.
Pay attention to:
- relevant comorbidity: diabetes mellitus, neurological disorders (e.g. CVA, Parkinson’s disease, multiple sclerosis), 
previous urethritis (sexually transmitted diseases);
- previous urological investigations, history of urological treatment or indwelling catheter;
- medication that infl uences micturition: antipsycholics, (tricyclic) antidepressives, anti-Parkinson drugs, (classic) 
antihistamines, opiates, loopdiuretics.
CONCEPTS
GUIDELINES FOR DIAGNOSTICS
GUIDELINE POLICY
Physical examination
« Check for possible  scar tissue  on lower abdomen, phimosis.
« Percussion of the bladder on suspicion of neurogenic bladder, bladder overfl ow and acute urine retention (see 
evaluation). 
« Conduct a digital rectal examination: pay attention to shape, texture, size and sensitivity to pressure.
« Examine urine for signs of urinary tract infection (see NHG Guideline Urinary Tract Infections).
« If general malaise, recurring urinary tract infections or urine retention: ultrasound of the urinary tract (exclude 
hydronephrosis) and serum creatinine analysis.
There are strong indications of urinary diffi culty when older men complain of urination problems and there are no signs 
of a specifi c cause as:
- prostatitis: complaints developed rapidly, perineal pain, pressure sensitive prostate during digital rectal examination;
- urinary tract infection: positive urine sediment, nitrite test or culture;
- urine incontinence: involuntarily urinary loss,  ≥ 2 times a month;
- refl ex bladder: dull percussion sounds or post voiding residual urine and diabetes mellitus or a neurological disease;
- overfl ow bladder: continuous loss of small amounts of urine without feeling the urge, and post voiding residual urine;
- urethral stricture: history of local trauma, urological intervention or urethritis;
- acute urine retention: incompetent to urinate spontaneously within a few hours, despite a (painfull) urge and after 
multiple attempts and dull percussion sounds.
« Complaints can be caused by age-related changes in bladder function and sometimes by obstruction around the 
urethra and in the prostate.
« The common occurrence of the disorder, its benign character and varying course.
« The management policy depends strongly on the patient’s wishes 
« Certain types of medication can aggravate the complaints.
Supplementary tests
Evaluation
Anamnesis
Patient education and wait-and-see policy
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« Advice the patient to go to the toilet regularly.
« It is important the patient takes his time to urinate.
« Ask the patient to contact the surgery immediately if complaints suggest acute urine retention.
« Medication has a limited effect on the complaints.
« Medication is limited to patients with troublesome complaints who derive insuffi cient benefi t from following their 
GP’s advice and are not eligible (or willing) to undergo invasive treatment.
« Choose alfl uzosine 10 mg once a day in the evening after meals or tamsulosine 0.4 mg  once a day in the morning 
after breakfast.
« In the case of slight-moderate liver function disturbances alfl uzosine 2.5 mg tablet 1-2 times per day after meals.
« Beware of orthostatic hypotension (especially during the initial period of use).
« If there is no improvement within 6 weeks: medication is stopped. In patients who derive benefi t: after 3 to 6 months 
medication is stopped to evaluate whether complaints recur. 
« Indications for invasive treatments as TURP: see referral.
« Global advantages and disadvantages vary with invasive treatment: 60 to 75% of improvement, 1-25% incontinence, 
1-10% erectile dysfunction and 4-61% ejaculation problems.
In the case of changes or deterioration in the complaints a check-up takes place and the diagnosis is reconsidered. The 
GP investigates whether there are:
- general malaise, new comorbidity or new medication.
- urine infection.
On certain indications, percussion of the bladder, digital rectal examination, abdominal ultrasound scanning and the 
creatinine level testing are performed (see Supplementary tests).
Check-ups related to the start of treatment with medication (in person or by telephone) take place
- after 6 weeks to evaluate the effect
- after 3-6 months to discuss with the patient whether the medication can be stopped 
Refer on the suspicion of a neurogenic bladder disorder, overfl ow bladder or urethral stricture. Refer for possible 
invasive treatment in case of:
- Request for invasive treatment due to perceived troublesomeness;
- Recurrent urinary tract infections or recurrent acute urine retention;
- Renal function disturbances and/or hydronephrosis.
Urinary diffi culty does not form a risk factor for prostate carcinoma
If at digital rectal examination a prostate carcinoma is suspected (without clinical indications of metastases) the following 
practical guidelines apply to the GP:
« Refer after patient education to a urologist for further diagnostics and evaluation of the therapeutic options.
« Discuss in patients with a life expectancy of less than 10 years (>72 years and <72 in whom comorbidity has a 
negative infl uence on life expectancy)  that a prostate carcinoma generally grows very slowly and quality of life will 
probably not improve much through medical intervention, whereas there is a considerable risk of side-effects.
« Discuss in patients with a life expectancy > 10 years (<72 without serious comorbidity) that they will possibly benefi t 
from a medical intervention.
If there are clinical indications of metastases (general malaise, weight loss, bone pain in the back/hip) refer to a urologist.
Screening for prostate carcinoma in a patient without complaints is not advisable. If a complaint-free patient still wishes to 
be screened for prostate cancer despite having received information, the GP performs digital rectal examination and PSA 
analysis.
- PSA>4ng/ml or abnormal digital rectal examination provide suspicion for prostate carcinoma (see above).
- PSA 4-10 ng/ml and normal digital rectal examination may have several causes, after discussing the matter with the 
patient repeat the PSA analysis at a later date.
SUSPECTED PROSTATE CARCINOMA
Treatment with medication
Invasive treatment
Check-ups
Referral
LOWER URINARY TRACT SYMPTOMS IN ELDERLY MEN  NHG-GUIDELINE (summary)  M42
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this increases with rising age.5;6 Post void residual urine may give lead to hydronephrosis 
and renal insufficiency, but the exact pathogenesis and what men are at risk is not clear.7 
Furthermore the characteristics of percussion of the bladder as a diagnostic test are 
insufficient to detect or exclude a post void residue in all patients. Percussion of the 
bladder may be valuable if there is a suspicion of reflex bladder, an overflow bladder or 
acute urinary retention, since in these cases clinical relevant post void residual urine will 
be more easily detected. If there is a strong suspicion of urinary retention and percussion 
appears to be normal; a trial of catheterisation of the bladder may be necessary.
Although the digital rectal examination is of limited diagnostic value in patients 
with lower urinary tract symptoms, the guideline development group has decided to 
recommend digital rectal examination in order to be be�er informed on local circumstances 
(e.g. constipation and rectal pathology), prostatitis as a possible cause of lower urinary 
tract symptoms and to meet patient expectations.
RECOMMENDATIONS FOR TREATMENT
Due to the benign nature of lower urinary tract symptoms and its variable course this 
revision of the guideline focuses on shared decision making on treatment possibilities. 
Although in general invasive treatment options result in a be�er symptom improvement 
in comparison to drug treatment, the risk of complications is higher as well. Therefore 
the treatment chosen will strongly depend on perceived bother and patient’s needs. 
A watchful waiting policy is realistic since an intervention is o�en not needed because of 
the variable course.
In pharmaceutical treatment α-receptor blocking agents are preferred (α-blockers). They 
decrease the outflow obstruction by altering the smooth muscle tone within the prostate 
and the urinary tract. Studies showed that all α-blockers appear to be practically similar 
effective and safe. Nevertheless, alfluzosine and tamsulosine are preferred, since patients 
tend to show less o�en treatment discontinuation due to side effects in these.8-11 Because 
of the variability in natural course of the symptoms it is sound to stop medication a�er a 
period of 3-6 months and evaluate whether symptoms will recur. 
In general practice there is no room for the use of 5-α-reductase inhibitors, since it lasts a 
considerable time until there is a clinical effect and this effect occurs in particular in larger 
prostates.12 
The guideline provides furthermore general information on (dis)advantages of surgical 
management. Traditional surgical interventions (e.g. transurethral resection of the 
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prostate) as well as less invasive treatment are briefly discussed.13 The general practitioner 
will refer to a urologist if a patient considers a surgical intervention. Other indications for 
referral are diagnostic doubts, or treatment failure on medication prescribed.
PROSTATE CARCINOMA IN RELATION TO THIS GUIDELINE
The understanding of lower urinary tract symptoms and prostate carcinoma being two 
separate entities as far as cause and incidence concerned is an important change to previous 
versions of the guideline. The literature shows that the presence of lower urinary tract 
symptoms appears to be no risk factor to prostate carcinoma: the prevalence of prostate 
carcinoma in an open population of men with lower urinary tract symptoms is equal to 
those without such symptoms.14;15 Testing for prostate carcinoma in all men with lower 
urinary tract symptoms visiting the surgery would mean screening, something that is 
still not proven sensible.16-19 Prostate carcinoma is yet incorporated in this guideline, since 
men with lower urinary tract symptoms and their (general) practitioners still relate these 
symptoms to prostate carcinoma. Moreover the suspicion of a prostate carcinoma may rise 
at the performance of a digital rectal examination, with a different clinical management as 
a consequence. Finally, questions on screening for a prostate carcinoma are o�en posed. 
To give appropriate advice specific knowledge is needed. It is expected that clarity on the 
management of (questions about) prostate carcinoma will improve the implementation of 
this guideline.
Patients suspected of prostate carcinoma will generally be referred to a urologist for 
further diagnosis and treatment. With regards to the prostate carcinoma some reflections 
can be offered: in general it grows slowly, it does not reveal itself, or only in a disseminated 
stage, by complaints and it has not (yet) been proven that treatment of prostate carcinoma 
increases survival, whereas there may be side-effects of diagnostics and treatments.
In particular this accounts for patients with a life expectancy of less then 10 years, where it is 
doubtful whether life expectancy and quality of life will improve substantially, while there 
are possible side effects to expect. These patients can chose for clinical management by the 
general practitioner, possibly a�er referral for only diagnosing the cancer. It is important 
that the general practitioner stays aware of possible metastases, since treatment is than 
sensible with regards to reductions of symptoms and prevention of complications.
In case of a suspect digital rectal examination a prostate carcinoma is diagnosed in half of 
the patients, in the assumption of a 2-5% prevalence.20 As a consequence a routine PSA-test 
in primary care does have no implications to clinical management: a normal PSA does not 
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rule out a prostate carcinoma and in case of an increased PSA always referral is needed for 
further evaluation. Moreover, the PSA-test is not disease specific and in its normal values 
age and prostate size dependent. 
Men without complaints requesting screening on prostate carcinoma have to be informed 
on absence of evidence for the benefit of the test. It has not been established that early 
detection and treatment of patients with an asymptomatic prostate carcinoma provides a 
decrease of suffering or prevent early death. On the other hand there is the burden of the 
diagnostic procedures and the complications of treatment. Although men with a familial 
occurrence of prostate carcinoma have an increased risk of obtaining it, the benefit of early 
detection is also not proven in this group. Nevertheless, the general practitioner can in 
some occasions allow screening, on the condition that the patient is well informed about 
all (dis)advantages.
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Abstract
Context
As guideline makers are supposed to have access to the same sources of research evidence, 
one would expect guidelines to be similar. Several studies showed that not all the guidelines 
gave the same recommendations on clinical management. In this study, we explored the use and 
interpretation of the evidence as a potential explanation for variation between guidelines, using 
lower urinary tract symptoms (LUTS) as an example. 
Methods
Electronic literature databases and web sites of institutions known to develop guidelines were 
searched for national guidelines on LUTS. Using the AGREE-instrument, these were systematically 
assessed in terms of quality. Recommendations with regard to the initial clinical management 
were subsequently identified and their citations were collected. The evidence used in ‘conflicting’ 
recommendations was explored in a qualitative manner. 
Results
Five guidelines met the inclusion criteria and were assessed. The Australian guideline scored highest 
on all AGREE domains. Of the 227 citations found in relation to initial clinical management, only 
11.9% were used in more than one guideline. There appeared to be a correlation between the 
country in which a guideline was developed and the number of references, from the same country, 
that was used. In general, diagnostic recommendations were more often ‘do’s’ or ‘don’ts’, rather 
than therapeutic recommendations that were more often ‘optional’. The NHMRC guideline had 
more ‘don’ts’ where clear evidence was lacking, compared to the AUA guideline, which was less 
restrictive and left some decisions ‘optional’.
Conclusions
The selection of evidence is less objective than is suggested within the concept of evidence-based 
medicine. For some selected topics, a certain bias in the use of evidence was found, as a few 
studies were the same but were used to underpin conflicting recommendations. Better worldwide 
collaboration is recommended between multi disciplinary developer groups. And guideline 
developers should report the methods for selecting the evidence explicitly.
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INTRODUCTION
During the last two decades, clinical practice guidelines have been developed for many 
clinical conditions to assist practitioners and patients in their decisions about appropriate 
health care.1 In general, guideline programmes intend to achieve optimal care for patients 
and sometimes cost containment as well.2 The purpose of evidence-based guidelines 
is to provide specific recommendations for practice, which are explicitly linked to the 
supporting evidence.3 Although guideline developers have access to the same sources 
of research evidence (e.g., MEDLINE, Cochrane Library) recommendations appeared to 
be conflicting, for instance in guidelines on breast cancer,4;5 low back pain,6;7 neck pain,8 
thyroid dysfunction,9 diabetes,10 atrial fibrillation,11 Chronic Obstructive Pulmonary 
Disease,12 uncomplicated cystitis13 and benign prostatic hyperplasia.14;15 We know li�le 
about the exact cause of such differences; inappropriate interpretation of research findings 
may have led to inadequate use of medical interventions. Experts in the guideline working 
group might have had conflicts of interests, which could have biased the interpretation of 
evidence.16 Cultural factors might also play a role.17 In this study, we explored the use and 
interpretation of the evidence as a potential explanation for variation between guidelines, 
using lower urinary tract symptoms (LUTS) as an example. 
LUTS is a common problem, especially in elderly men. The understanding of LUTS is 
changing and the causal role of benign prostatic hyperplasia is questioned since one third 
of the voiding problems are not related to urethral obstruction.18 As the population is aging, 
there is a growing demand for appropriate diagnosis and effective treatment of LUTS. 
The increasing availability of non-invasive treatments, such as new drugs, may suggest 
that voiding problems can be treated more easily than before.19 With the introduction 
of α-blocking medication, the management of LUTS has increasingly shi�ed from the 
specialist to the primary care physician in various countries.20-25 Therefore, there has been 
a need to develop guidelines in order to optimize the quality of care. In addition, public 
awareness is increasing, and LUTS are related to carcinoma of the prostate in the perception 
of many patients. They assume that PSA testing might help in preventing advanced 
disease, although this is still an issue of debate.26-29 Guidelines could solve this problem by 
providing clear and unambiguous recommendations based on the best available evidence. 
Recently, two studies compared international guidelines on benign prostatic hyperplasia. 
They found that most guidelines largely gave similar recommendations, although there 
were differences with respect to PSA testing and imaging of the urinary tract.14;15
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The aim of this study was to analyze in more detail the background of differences in 
recommendations by comparing and analyzing the citations in recent guidelines on LUTS, 
in particular those in support of conflicting recommendations.
METHODS
SEARCH STRATEGY
Guidelines of LUTS were identified by a computerized search of the database of MEDLINE, 
CINAHL and Current Contents from 1999 - 2003. Search in free text, and/or in MESH 
terms included the following terms: prostatic hyperplasia, urination-disorders, urethral 
obstruction, bladder-neck-obstruction, micturation problems, voiding problem, urinary 
problems, voiding disorders, micturation disorders, urinary disorders, LUTS, lower urinary 
tract symptoms, BPH, family practice (standards), family physicians (standards), urology 
(standards), guidelines, practice-guidelines, policies, standards, protocols. The detailed 
search strategy is presented in appendix A. In addition, an Internet search was performed 
in November 2003 by searching web sites of (inter)national institutes that were expected 
to be related with guideline making,2;15 supplemented with a search on www.Google.com 
using the following string: ‘clinical guideline’ OR ‘clinical protocol’ OR ‘practice guideline’ 
OR LUTS OR BPH OR ‘prostatic hyperplasia’.) (Appendix B). 
INCLUSION OF GUIDELINES
Only (inter)national guidelines wri�en (or translated) into English and published from 
1999 were included. Guidelines published before 1999 were considered to be out of date.30 
The guidelines covered diagnosis and/or management of lower urinary tract symptoms in 
older men and included recommendations concerning the initial management of patients 
with LUTS. Guidelines that did not link their individual recommendations to references 
were excluded.
ASSESSMENT OF THE QUALITY OF THE GUIDELINES
An assessment of a guideline is necessary before adopting it for use in clinical practice. 
High-quality guidelines account for potential biases in their development, for their 
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internal and external validity, and their feasibility in normal practice.31 The internationally 
validated and widely accepted Appraisal of Guidelines for Research & Evaluation 
(AGREE) Instrument was used to appraise the guidelines. The AGREE-instrument consists 
of 23 items grouped into six domains (scope and purpose, stake holder involvement, rigor 
of development, clarity and presentation, applicability, editorial independence) (Appendix D). 
Two appraisers (RW and JB) evaluated the selected guidelines independently and scored 
these using the AGREE instrument. Discrepancies were resolved by discussion or by 
adjudication of a third reviewer (MW) blinded to the previous reviews.
BIBLIOGRAPHIC ANALYSIS OF SCIENTIFIC EVIDENCE UNDERLYING THE RECOMMENDATIONS
We confined ourselves to the topics related to the initial care management of patients with 
LUTS. We identified the recommendations in the guidelines, which were defined as any 
statements which promote or advocate a particular course of action in clinical primary 
care (appendix E).
Subsequently, we compiled citations that were explicitly linked to the recommendations 
or listed at the end of relevant sections. We tabulated the year of publication, authors, the 
country of the first author as declared in MEDLINE and the abstract for each citation. Each 
citation was entered into a Reference Manager database (Version 10), adding a unique 
identifier code for each guideline. We used the Reference Manager search facility to 
quantify the numbers of citations shared with other guidelines and the country of the first 
author as a proxy for the country of origin of the cited study. 
QUALITATIVE ANALYSIS OF EVIDENCE
We defined the main topics that should be covered in the guideline. For each topic, 
the specific statements identified as recommendations were categorized as: positive 
recommendation (‘do it’), negative recommendation (‘don’t do it’), option (‘probably do 
it’ or ‘probably don’t do it’).32 If the guideline did not formulate specific statements with 
respect to the topic, then we distinguished two other categories: ‘mentioned’ (text available 
but no specific recommendations) and ‘not mentioned’ (no text available covering the 
topic). In case of conflicting recommendations (i.e. positive versus negative), the cited 
studies were compared and the content of the guideline was carefully examined for 
justification for the choices made. 
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RESULTS
SAMPLE OF GUIDELINES
Eighteen potential guidelines were identified. Twelve of these guidelines were found 
in MEDLINE33-44 and two of these were ‘duplicates’, as they were updated versions of 
another guideline in the sample.43;44 The databases of CINAHL and Current Contents did 
not provide extra guidelines. The Internet search yielded eight additional guidelines.45-52 
We excluded five guidelines that were published before 1999, nine that were not in English 
and one that did not have any references (Appendix C). Thus, based on our criteria, five 
of the eighteen guidelines were included: one from the United States of America, one 
from the United Kingdom, one from Finland, one from Australia and one (international) 
European guideline.47;49;53-55 (Table 1).
ASSESSMENT OF THE QUALITY OF THE GUIDELINES
The appraisal with the AGREE Instrument 31 showed that the guideline developed by the 
NHMRC 47 scored highest on all AGREE domains (Table 2). The guideline of the European 
Association of Urology 53 had the lowest score in all domains, except for clarity and 
presentation. The other three guidelines 49;54;55 scored intermediate.
According to the criteria for overall assessment in the AGREE Instrument Training 
Manual (www.g-i-n.net), the NHMRC guideline would be strongly recommended for 
use in practice, the SCHiN and AUA guideline would be recommended with provisos or 
alterations and the Duodecim and EAU guideline would not be recommended.
BIBLIOGRAPHIC ANALYSIS OF SCIENTIFIC EVIDENCE UNDERLYING THE RECOMMENDATIONS
The five guidelines comprised a total of 654 different references (range: 13-318 per 
guideline). Of these, 277 (42.4%) were linked to recommendations on initial care of patients 
with complaints of LUTS (Appendix E). Only 33 (11.9%) of these 277 references were used 
in more than one guideline (Table 3). No references were shared between four or all of the 
guidelines. Three references were used in three guidelines; these were the original Agency 
for Health Care Policy and Research (AHCPR) guideline on benign prostatic hyperplasia 
published in 1994 56 and two studies on treatment of LUTS: one studying the use of 
terasozin and finasteride 57 and the other comparing surgery with watchful waiting.58
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In most references, the first author originated from the United States of America. There 
appeared to be a clear correlation between the county of the guideline developers and the 
number of references used that originated from this country (Table 3).
Table 1: General characteristics of the included guidelines
Title Website-address
Organization (Year and country 
of publication)
The Management of Benign 
Prostatic Hyperplasia 
Guideline42;54
http://shop.auanet.org/timssnet/products/
clinical_guidelines/index.cfm
American Urological Association 
(2003, USA)
Treatment recommendation for 
benign prostatic hyperplasia 34;55
http://www.ebm-guidelines.com/
home.html (http://195.236.0.10/pls/ebmg/
ltk.koti?u=9010290&hakusana=)
Duodecim / Evidence-Based 
Medicine guidelines (2002, Finland)
European Association of 
Urology Guidelines on benign 
prostatic hyperplasia 39;53
http://www.uroweb.nl/files/uploaded_
files/guidelines/updateBPH.pdf
European Association of Urology 
(2002, Europe)
The management of 
uncomplicated lower urinary 
tract symptoms 47
http://www.nhmrc.gov.au/publications/
pdf/cp42.pdf
National Health and Medical 
Research Council (2000, Australia)
Benign hyperplasia prostate 49 http://www.prodigy.nhs.uk/guidance.asp?g
t=Prostate%20-%20benign%20hyperplasia
Sowerby Centre for Health 
informatics at Newcastle (SCHiN) 
for NHS (2003, UK)
Table 2: Standardized domain score according to AGREE
AGREE AUA54 Duodecim55 EAU53 NHMRC47 SCHiN49
Scope and purpose 56% 22% 11% 100% 100%
Stakeholder involvement 50% 50% 0% 83% 50%
Rigor of development 86% 48% 29% 95% 62%
Clarity and presentation 67% 50% 67% 100% 100%
Applicability 13% 13% 13% 75% 50%
Editorial independence 67% 33% 17% 100% 17%
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QUALITATIVE ANALYSIS OF EVIDENCE
The format of the guidelines strongly varied: where the UK 49 and the Finnish 
guideline 55 summed up the recommendations, the recommendations in the NHMRC,47 
EAU 53 and AUA54 guidelines were part of a narrative text. For most of the topics the 
recommendations showed no explicit inconsistency between the guidelines. In general, 
Table 3: Number of references used in five guidelines on LUTS and their country of origin
AUA54 Duodecim55 EAU53 NHMRC47 SCHiN49
No of references 
used related to initial 
care (reference set)
55 11 135 98 21
No of references 
used related to 
initial care shared 
with at least 1 other 
guideline
17 (30.9%) 2 (19.2%) 32 (23.7%) 20(20.4%) 5 (23.8%)
Origin of first 
author of references 
(countries 
contributing 
more than 5% are 
presented)
USA: 38 (69.1%)
UK: 3 (5.5%)
USA: 4 (36.3%)
UK, Italy,
New Zealand: 
each 2 (18.2%)
USA: 57 (42.2%)
UK:19 (14.1%)
Netherlands: 14 
(10.4%)
USA: 35 (35.7%)
UK: 14 (14.3%)
Australia: 6 (6%)
USA: 10 (47.6%)
UK: 4 (19.1%)
Table 4: Conflicting recommendations (complete table with references is presented in Appendix E)
AUA54 Duodecim55 EAU53 NHMRC47 SCHiN49
Laboratory examinations
Creatinine NR R R NR R
PSA O R R NR O
Additional Examinations
Residual volume O R R NR NM
Transrectal ultrasound prostate O M O NR M
Ultrasound upper urinary tract O M O NR M
Uroflowmetry O M O NR M
Urodynamic investigations O M O NR M
Counseling and treatment
α-blocking agents and 
5α-reductase inhibitors
O NM NR NM NR
Phytotherapy NR M M NR O
R: Recommended, O: Optional, NR: Not recommended, M: Mentioned in the text without giving a recommendation, NM: Not 
Mentioned in the guideline
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diagnostic recommendations were more o�en ‘do’s’ or ‘don’ts’, rather than therapeutic 
recommendations that were more o�en ‘optional’. The NHMRC guideline had more 
‘don’ts’ where clear evidence was lacking, compared to the AUA guideline, which was less 
restrictive and le� some decisions ‘optional’.
The recommendations on measurement of the residual volume, and the creatinine- and 
PSA-testing were conflicting (Table 4). ‘Conflicting’ recommendations and their references 
Box 1: Conflicting recommendations in the initial management of Lower Urinary Tract Symptoms
Creatinine testing
Conflicting recommendations of the NHMRC, which did not recommend creatinine testing, and the EAU which 
recommended it, were partly based on the same studies.56;59;60 Although both guidelines agreed that LUTS is 
rarely complicated with renal insufficiency, they came to different conclusions. The EAU guideline favored testing, 
because it assumed that measuring serum creatinine in all patients is cost effective and stated furthermore that 
creatinine testing was recommended in a 1997 urologists consensus conference.61 In the AUA guideline, the 
panel of experts decided that creatinine is not recommended without providing any literature. 
PSA testing
According to the NMHCR guideline, ‘‘it is not recommended to estimate serum PSA as part of the normal 
evaluation of a man with LUTS”. Without giving the precise criteria, the EAU and the AUA still recommended 
PSA measurement “when a diagnosis of prostatic carcinoma will change the decision that is to be made about which 
therapeutic option to use”. The AUA guideline explicitly stated that it should only be offered to patients with a 
life expectancy of more than 10 years. NHMRC and AUA guidelines emphasized that the patient should be fully 
informed about the consequences of a PSA test before ordering the test.
Three references linked to PSA occurred in more than one guideline.  A study among 6630 men on the validity 
of the combination of PSA and DRE in the diagnosis of prostate cancer 62 was used in NHMRC to support the 
absence of a relation between LUTS and prostate cancer; and in AUA to support that a combination of PSA and 
DRE is a relatively sensitive way to exclude prostate cancer as a diagnosis. AUA and EAU used the same two 
references to underline that PSA is not only related to prostate cancer, but that it is also related to prostate 
volume in men with BPH without evidence of prostate cancer,63 and a predictor of acute urinary retention.64
Measurement of the residual volume
Measurement of the post-void residual urine measurement was recommended by the EAU without any further 
explanation in the text. Because of the intra-individual variation and the absence of significant data on the 
relation with improved patient outcome it was not recommended by the NHMRC. The AUA panel considered 
the use of PVR measurements optional in men undergoing noninvasive therapy, because the safety of noninvasive 
therapy for patients with residual urine had not been documented. On the other hand, no level of residual urine 
mandates invasive therapy since natural course of many of these patients is uncomplicated. The only overlapping 
reference, concerning a randomized controlled trial comparing surgery to watchful waiting (556 men) that 
concluded that the level of bother, and not the residual volume, was the best predictor of success of surgery,58 
was used by the AUA and NHMRC to support this view.
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are presented in more detail in Box 1. This regards only those three guidelines that were 
explicit about the choices made (NHMRC,47 EAU 53 and AUA 54).
DISCUSSION
Our study examined the use of evidence in the development of clinical practice guidelines. 
We analyzed five recently published guidelines on LUTS with respect to recommendations 
on the initial management. The methodology assessed with the AGREE Instrument 
varied largely between the guidelines, which might explain the low proportion of shared 
evidence. Only 11.3% of the 227 references related to the initial care of the patient with 
LUTS were used in more than one guideline and some of these support conflicting 
recommendations. There also seemed to be a country-bias in the selection of references. 
Therefore, the selection of evidence is less objective than is suggested within the concept of 
evidence-based medicine. For some selected topics, we also found a certain bias in the use 
of evidence, because the same studies were used to underpin conflicting recommendations 
in some cases.
Both the AUA and NHMRC guideline have high scores in the AGREE domain of Rigor 
of development, which relates to the process used to gather and synthesize the evidence, 
the methods to formulate the recommendations and to update them.31 Nevertheless, 
they interpreted the evidence differently in some topics. It seems that the Australian 
NHMRC guideline is more directive and professional orientated leading to more ‘don’t 
recommendations’ compared to the AUA guidelines which contains more optional 
recommendations and leaves the final decision to the interaction between practitioner 
and patient. The AUA guideline could be considered as defensive medicine that might be 
explained by the US health care system, including free access to specialist care, competition 
between health care providers and autonomous patients with high expectations of medical 
care.65
In this study, we analyzed the quality as well as the clinical content of the guidelines. 
Conflicting recommendations were further analyzed by examining the references in order 
to explain the differences. Since the 1990s, the evidence collected in electronic databases 
is available to guideline developers all over the world. However, some variation in 
guidelines concerning the same subject cannot be excluded. This can be explained by 
context-specific factors such as the health care system, need for cost constraint, influence of 
patient preferences, and specific professional interests. In formulating recommendations 
these factors might even be as important as the evidence.16 We studied guidelines on 
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LUTS, in which the search was restricted to the last five years to minimize differences that 
could be explained by scientific progress with respect to LUTS or criteria for guideline 
development. A previous study showed that on average half of the guidelines become 
outdated a�er 5.8 years.30 One might ask whether our findings are transferable to 
guidelines in other disease areas. On the other hand, conflicting recommendations given 
were also found in guidelines on other topics as well.4-13 Variation was thought to be due 
to the methods used to formulate recommendations (consensus versus evidence based)5 
or in the methodological quality.7;8;11;12;15 Some authors suggested that cultural factors could 
explain different values of physicians as well as patients, which may result in different 
recommendations, even when the same evidence is used.4;13 
The five guidelines assessed in this study were developed by credible institutes producing 
guidelines on several subjects; the NHMRC, Duodecim and SCHiN also produce guidelines 
on non-urologic subjects.
All of the guidelines, except for the EAU guideline, were very explicit about the method of 
searching the literature in contrast to the guidelines analyzed by Irani, et al.15 Nevertheless 
only a small minority of the references were used in more than one guideline. This finding 
is consistent with other guideline studies on diabetes and cystitis.10;13 The low proportion 
of shared references suggests some bias in the selection of literature. Raine, et al. also 
suggested that evidence may be used to justify pre-existing opinions.66 On the other hand, 
guidelines should also be sensitive to local conditions and needs of medical care, which 
may account for some variations in recommendations. In that respect, it is remarkable 
that – despite the lack of overlap in references – the guidelines on LUTS provide similar 
recommendations on most topics covered by the guidelines. This might be explained by 
the international impact of the Agency for Health Care Policy and Research (AHCPR) 
guideline on Benign Prostatic Hyperplasia published in 1994.56 This comprehensive 
document was seen as a standard for many years and was used as a reference in three of 
the five guidelines in our study. In addition, international consensus conferences on the 
clinical management of benign prostatic hyperplasia may also contribute to international 
consensus.67
CONCLUSIONS
Although the evidence is available worldwide, there is only li�le overlap between the 
references used in guidelines. Evidence-based medicine suggests objectivity, but the 
selection and use of evidence is not neutral in practice. Be�er worldwide collaboration 
between guideline developers is recommended. Guideline development demands a 
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balanced judgment about applicability, consistency, and clinical impact of the evidence.68 
A balanced multi disciplinary guideline developing working group being explicit about 
potential conflicts of interests, is necessary to rule out strong personal biases.69 Explicit 
reporting of the methods used in selecting the evidence (i.e. search strategy, inclusion/
exclusion criteria) and formulating the recommendations should increase the transparency 
of a guideline.
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APPENDICES CHAPTER 2
Appendix A: Number of records found in the three literature databases used
Number of records
MEDLINE: 
1999 - 2003 
CINAHL
1999 - 2003
Current 
Contents
1999 - 2003
#1 ‘Prostatic-Hyperplasia’ / all subheadings in MIME,MJME 2497 - -
#2
‘Prostatic-Hypertrophy ‘ / all topical subheadings / all age 
subheadings in DE
- 196 -
#3 ‘Urination-Disorders’ / all subheadings in MIME,MJME 1118 122* -
#4 ‘Urethral-Obstruction’ / all subheadings in MIME,MJME 288 - -
#5 ‘Bladder-Neck-Obstruction’ / all subheadings in MIME,MJME 496 - -
#6 micturation adj problem* 1 1 2
#7 voiding adj problem* 44 6 38
#8 urinary adj problem* 48 13 39
#9 voiding adj disorder* 65 9 54
#10 micturation adj disorder* 1 0 1
#11 urinary adj disorder* 42 14 28
#12 luts 283 17 293
#13 lower adj urinary adj tract adj symptom* 684 95 595
#14 BPH 1349 108 1351
#15 Prostat* adj hyperplas* 2006 225 1707
#16 Prostat* adj hypertro* 229 43 163
#17 ‘Family-Practice’ / standards in MIME,MJME 1291 1515* -
#18 ‘Physicians-Family’ / standards in MIME,MJME 204 1272* -
#19 ‘Urology-’ / standards in MIME,MJME 57 - -
#20 ‘Physicians-’ / all topical subheadings / all subheadings in DE - 4974 -
#21
‘Urologic-Nursing’ /all topical subheadings/ all subheadings 
in DE
- 150 -
#22 ‘Guidelines-’ / all subheadings in MIME,MJME 7277 - -
#23 ‘Practice-Guidelines’ / all subheadings in MIME,MJME 15009 3937* -
#24 guideline* 42164 26902 30582
#25 protocol* 54328 9441 47021
#26
#1 or #2 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or 
#11 or #12 or #13 or #14 or #15 or #16 (when available/
appropriate)
4950 555 2789
#27
#17 or #18 or #19 or #20 or #23 or #24 or #25 (when 
available/appropriate)
95456 40854 76287
#28 #26 and #27 214 99 114
*: where ‘all subheadings in MIME,MJME’ it should be read ‘all topical subheadings / all age subheadings in DE’
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Appendix B: Health organisation sites searched for guidelines (countries in alphabetic order)
Australia: Singapore:
* http://www.health.act.gov.au/ * http://www.gov.sg/moh/mohinfo/prof-info.html
* http://www.health.gov.au/ Spain:
* http://www.health.nsw.gov.au/public-health/ * http://www.aatm.es/cgi-bin/frame.pl/ang/pu.html
* http://www.mja.com.au/public/guides/ Sweden:
Austria: * http://www.sbu.se/admin/index.asp
* http://www.oegam.at/ Switserland
Canada: * http://www.hin.ch/htbin/Hin-Homepage.pl
* http://dfcm19.med.utoronto.ca/ United Kingdom:
* http://mdm.ca/cpgsnew/cpgs/ * http://www.demon.co.uk/scarbpg/guides/
* http://www.albertadoctors.org/resources/guidelines.html * http://www.eguidelines.co.uk/
* http://www.ahfmr.ab.ca/ * http://www.equip.ac.uk/
* http://www.cancercare.on.ca/ccopgi * http://www.healthcentre.org.uk/hc/
* http://www.cma.ca/cpgs * http://www.leeds.ac.uk/nuffield/infoservices/UKCH/
* http://www.ccohta.ca/ * http://www.leeds.ac.uk/nuffield/infoservices/ECHHO/
* http://www.fhs.mcmaster.ca/fammed/ * http://www.ncl.ac.uk/chsr/
* http://www.gacguidelines.ca/ * http://www.nelh.nhs.uk/guidelinesfinder/
* http://www.hc-sc.gc.ca/pphb-dgspsp/ * http://www.nice.org.uk/
* http://www.hlth.gov.bc.ca/msp/protoguides/gps/ * http://www.prodigy.nhs.uk/ClinicalGuidance/
* http://www.ottawahospital.on.ca/library/ * http://www.rcgp.org.uk/index.asp
* http://www.smh.toronto.on.ca/ * http://www.sghms.ac.uk/depts/phs/hceu/
Denmark: * http://www.show.scot.nhs.uk/sign/guidelines/
* http://www.dsi.dk/ * http://www.sign.ac.uk
Finland: * http://www.york.ac.uk/inst/crd/
* http://www.duodecim.fi United States of America:
* http://www.ebm-guidelines.com/home.html * http://consensus.nih.gov
* http://www.stakes.fi/english/ * http://doctorpage.com/drpage/cpgdlines.htm
France: * http://hstat.nlm.nih.gov
* http://www.anaes.fr/ * http://medicine.ucsf.edu/resources/guidelines/
* http://www.upml.fr/andem/andem.htm * http://primarycare.medscape.com/
Germany: * http://shop.auanet.org/timssnet/products/
* http://www.degam.de/S5_leit_themen.html * http://text.nlm.nih.gov/ftrs/
* http://www.leitlinien.de/ * http://www.acponline.org/sci-policy/guidelines/
* http://www.uni-duesseldorf.de/WWW/AWMF/ * http://www.aafp.org
Greece: * http://www.ahcpr.gov
* http://147.102.33.1/helsqua/greece.htm * http://www.amda.com/info/cpg/
Israel: * http://www.coloradoguidelines.org/
* http://www.goldenhour.co.il/ * http://www.icsi.org/knowledge/
Netherlands: * http://www.guidelines.gov/index.asp
* www.artsen.net/nhg * http://www.humana.com/providers/guidelines/
* http://www.cbo.nl/ * http://www.kpcmi.org/
* http://www.landauer.net * http://www.medscape.com/
* http://www.paramedisch.org/ * http://www.medsurfer.com/pracguide.htm
New Zealand:
* http://nzhta.chmeds.ac.nz/
* http://www.nzgg.org.nz/library.cfm
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Appendix C: Excluded guidelines
Name
MED 
LINE
URL
Reason for 
exclusion
Benign prostatic hyperplasia: diagnosis and 
treatment. Clinical practice guideline (US of 
A, 1994) 1
-
http://hstat.nlm.nih.gov/hq/Hquest/db/
3103/screen/DocTitle/odas/1/s/52748
A
Benign Prostatic Hyperplasia: Treatment for 
Lower Urinary Tract Symptoms in Older 
Men (UK,1995) 2
- http://www.york.ac.uk/inst/crd/ehc22.pdf A
Guidelines on management of men with 
lower urinary tract symptoms suggesting 
bladder outflow obstruction (UK,1997) 3
-
http://www.rcseng.ac.uk/publications/
show_pub.asp?menu=publications&pub_
ID=12
A
NHG-standaard bemoeilijkte mictie bij 
oudere mannen (Netherlands,1997) 4
-
http://nhg.artsennet.nl/upload/104/
standaarden/M42/start.htm
A, B
Voor de praktijk. Benigne 
prostaathyperplasie; aanbevelingen voor 
transmurale zorg (Netherlands,1998) 5
-
http://nhg.artsennet.nl/upload/104/LTA/
lta5/start.htm
A, B
Hiperplasia benigna da prostata. Orientacoes 
e recomendacoes na pratica clinica urologica 
(Portugal,1999)6
+ NA B
Hiperplasia prostatica benigna y medicina 
basada en la evidencia: su aproximacion a la 
practica clinica (Spain, 2000)7
+ NA B
Hiperplasia benigna da prostata 
(Portugal,2001)8
+ NA B
[Clinical guideline for benign prostatic 
hyperplasia] (Japan, 2002)9
+ NA B
Prise en charge diagnostique et 
therapeutique de l’hypertrophie benigne de 
la prostate (France, 2003)10
-
http://www.anaes.fr/ANAES/framedef.nsf/
WebMasterparpage/71e60e94c17622aec1
25667f0023974b?OpenDocument
B
Leitlinien der Deutschen Urologen zur 
Diagnostik des BPH-Syndroms (Germany, 
2003)11;12
+
http://www.uni-duesseldorf.de/WWW/
AWMF/ll/urol-034.htm
B, C
Leitlinien der Deutschen Urologen zur 
Therapie des BPH-Syndroms (Germany, 
2003)13;14
+
http://www.uni-duesseldorf.de/WWW/
AWMF/ll/urol-035.htm
B, C
North Essex Guidelines for the Management 
of Benign Prostatic Hyperplasia (UK, ????) 15
- http://www.equip.ac.uk/ C
A: Guideline published before 1999, B: No translation available (PM: abstract suggested a guideline), C: Recommendation 
not directly linked to references or no references available
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Abstract
Objective
To determine associations among lower urinary tract symptoms (LUTS), symptom severity, 
subjective beliefs and social influences when seeking primary medical care in men aged ≥ 50 
years.
Subjects and methods
A population-based survey was conducted among 5052 men aged ≥ 50 years, using patient 
registers of 22 general practitioners (GPs) in the Netherlands from November 1999 to May 
2000. The questionnaire contained items concerning age, educational level, International Prostate 
Symptom Score (I-PSS), Bother Score (BS), and questions from the Health Belief Model on attitude 
and social influences. The study population comprised men with an I-PSS of > 7. The odds ratios 
(ORs) corrected for the I-PSS were calculated.
Results
In all, 3544 questionnaires (70.2%) were returned. Two groups of men with an I-PSS of > 7 were 
compared: those who consulted their GP in the previous 2 years because of voiding problems 
(268 cases) and the controls (272) who did not visit a GP for these symptoms. Cases more often 
thought a physician could improve their condition (OR 2.85), appeared to be more often advised 
by others to seek medical care (OR 6.36) and thought more often that this advice influenced 
their decision (OR 13.95). They also had more frequently received information from the media 
(OR 2.66) which affected their attendance (OR 12.52). In a multiple regression analysis, advice from 
others or information from the media were stronger predictors of seeking care than the influence 
of symptoms on daily life, the I-PSS or the BS.
Discussion
Social influences, i.e. advice from others or the media, were more important factors in the decision 
to seek medical care than symptom severity.
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INTRODUCTION 
The prevalence of LUTS is 200 - 300 per 1000 in middle aged and older men.1-5 LUTS can 
have a significant effect on men’s life in terms of the degree of bother, worry, interference 
with daily living and psychological well-being.6;7 Nevertheless, many men with LUTS do 
not consult a physician,4;8-17 so they lack the medical a�ention that could alleviate their 
symptoms and worries. Only if a patient perceives his symptoms as a problem he will 
consult a physician. Several studies explored the reasons why men with LUTS a�ended 
a physician;10-14;16;18 they showed that men with moderate to severe symptoms are more 
likely to seek medical care than men with mild symptoms. Increased a�endance to the GP 
was also related to a greater interference of symptoms with everyday life11;12 and greater 
age.10-12;18 However, many men with moderate to severe complaints do not seek medical 
care.
Different factors may be relevant in this process; it has been suggested that older men may 
accept chronic illness as part of ageing,19 which may also be true for LUTS 8 and urinary 
incontinence.20;21 Furthermore, men may experience a stigma associated with specific 
urinary symptoms such as dribbling and urgency, so it is difficult for them to discuss 
this with their doctor.8 Cunningham-Burley, et al.22 concluded from interviews that fear of 
cancer or surgery is yet another factor in a man’s decision to consult a doctor. The man’s 
perception of the care provider’s ability to give relevant information or effective treatment 
is important, as is the patient’s ability to cope with the LUTS.23 Finally, the social network 
and the media may influence the man in his decision to a�end a primary care physician.
An insight into the factors that determine consultation for LUTS is essential to devise 
advice and education focused on the needs and expectations of elderly men. In particular, 
this insight can help to induce those who will benefit the most from medical care, and 
where not a�ending is inappropriate, to consult their family doctor in time.
The present study aimed to determine which factors explain the decision to a�end a 
primary care physician for LUTS beyond the influence of symptom severity, and to explain 
the transition from the perception of LUTS to the presentation of LUTS to the GP.
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SUBJECTS AND METHODS 
A population-based case-control questionnaire study was conducted between November 
1999 and May 2000. Men consulting their GP because of LUTS in the previous 2 years were 
considered as ‘cases’; the controls were men with LUTS who never consulted their GP 
for the problem. The ethical commi�ee of the University Medical Centre Nĳmegen gave 
approval for the study. The study was based on the practice populations of 14 practices 
(22 GPs) in the eastern part of the Netherlands. The practices were equally distributed over 
urban and rural areas (four in cities, three in ‘urbanized’ areas and seven in rural areas). 
The aim was to recruit 198 men who had discussed their LUTS with the GP and 198 men 
who had not; this sample size would detect differences of 15% in dependent variables in the 
comparison between the groups (a = 0.05, power = 0.80, inter cluster correlation = 0.03). 
Most men with LUTS do not present these problems to a physician13;16;22 so we assumed 
that for each case at least one control would also be recruited. The prevalence of LUTS 
known to a GP is ≈ 50 per 1000 men in those men aged 50-69 years and 100 per 1000 in 
those aged ≥ 70 years.24 To recruit sufficiently many ‘middle-aged’ men we over-sampled 
those aged 50-69 years. With at least 100 men who visited their GP needed in each age 
group, this would require 2000 men aged 50-69 years and 1000 men aged ≥ 70 years to be 
recruited. Assuming a 60% response rate, at least 3333 men aged 50-69 years and 1667 men 
aged ≥ 70 years were sent the questionnaire (5000 men in all). 
GPs excluded patients with serious disease, terminal illness or limited cognitive capacity 
before taking a systematic random sample of 300 men (200 men aged 50- 69 years and 
100 aged ≥ 70 years) from the practice registers. Six GPs had insufficient patients in their 
practice list (the practice was too small or had a predominantly younger population) so 
all patients 50-69 years and ≥ 70 years were approached. Overall, this resulted in a mean 
(range) sample size of 230 (103-300) patients per GP. 
VARIABLES AND INSTRUMENTS 
Men were requested to complete the anonymous questionnaire within 10 days and to 
return it to the research institute in a pre-stamped envelope. A wri�en reminder was 
mailed to all men a�er 2 weeks. The questionnaires that remained uncompleted and those 
from men who stated they had a urinary stoma or a permanent catheter were excluded. 
The self-administered questionnaire was in three parts; the first contained 
socio-demographic questions (age and educational level), questions on the duration of 
voiding problems and on GP a�endance for these symptoms. The second part concerned 
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questions on urinary symptoms. The I-PSS was used to determine the symptom level of 
LUTS. The I-PSS is a validated seven-question score using a six-point answering scale (0, 
no complaints, to 5, many complaints). The scores of the questions were summed to give 
an I-PSS of 0-35. The Bother Score (BS) is a one-question score (‘If you were to spend the 
rest of your life with your urinary condition just the way it is now, how would you feel?), 
using a seven-point scale of 0-6 (‘delighted’ to ‘terrible’).25 Finally, this section contained 
three questions (on incontinence, adapting drinking habits and the experienced influence 
of complaints on everyday life) derived from the ICS-male instrument (Table 1).26 The 
third part of the questionnaire focused on the patients’ perceptions; 14 questions on 
a�itudes towards voiding problems and on cues to visit a GP, derived from the Health 
Belief Model,23 were included. These questions are also presented in Table 1. The questions 
used a three-point scale (not at all, somewhat, certainly), with two answering categories 
(yes/no) for ‘cues’. Men answering yes to one of these three questions were asked whether 
this factor influenced their decision to visit a GP (no influence, some influence or much 
influence). 
ANALYSIS 
In line with previous international publications25 we distinguished three symptom levels, 
i.e. minor (I-PSS 0-7), moderate (I-PSS 8-19) and severe complaints (I-PSS 20-35). Men were 
considered to have voiding problems if they had an I-PSS of > 7. Two sub samples were 
identified in this population: (i) controls, i.e. men with voiding problems who had never 
consulted their GP for these problems, and (ii) cases, i.e. men who consulted their GP in 
the previous 2 years for their voiding problems.
All variables were dichotomised, except for age (five categories) and education (three 
categories). Missing values were scored as ‘absence’ or ‘lowest possible value’ of the 
variables. For instance a missing value in the Health Belief Model items was scored as ‘no’ 
or ‘not at all’. 
As symptom severity is associated with the decision to consult a GP,4;8;10-13;15;16;18 all analyses 
of the Health Belief Model (Table 1) were corrected for the level of symptoms (the I-PSS as 
a continuous variable). Logistic regression analyses were used, using P < 0.05 to indicate 
statistical significance. All variables with significant bivariate associations in a binary 
correlation with ‘presenting LUTS’ were included, dichotomised in a multiple logistic 
regression model with a backward stepwise selection (I-PSS 8-19 and 20-35, age < 70 and 
≥ 70). The dependent variable was consulting a GP for LUTS (cases vs -controls). 
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RESULTS 
Of the 5052 questionnaires sent, 3602 were returned (71.3%); 46 questionnaires were 
incomplete and therefore excluded (21 questionnaires were sent to a wrong address, three 
men had died, four had language problems, four had cognitive problems, fi ve a serious 
illness, fi ve were absent for a long period, four other reasons). Twelve questionnaires were 
excluded because the responders had voiding problems other than LUTS (one spina bifi da, 
nine a urinary stoma, and two a permanent urinary catheter), leaving 3544 questionnaires 
(70.2%) (Figure 1) from men with a mean (SD, range) age of 63.2 (9.7, 50-96) years and an 
I-PSS of 5.4 (6.0, 0-35). 
In all, 689 men had an I-PSS of > 7 and self-perceived voiding problems; of these, 272 men 
with LUTS had never consulted their GP because of their voiding problems (controls) and 
they were compared with 268 similar men with LUTS who had consulted their GP in the 
previous 2 years (cases; Figure 1). 
Table 1 lists the diff erences in age and educational level between cases and controls. Cases 
were more likely to be older and to have more severe symptoms. Each I-PSS question had 
Figure 1: Sample characteristics of the population studied
5052 men mailed
909 men I-PSS
3602 questionaires 
returned
3544 questionares 
suitable for analysis
689 men percieved 
complaints
417 men presented 
their complaints to 
the GP
149 men with LUTS 
presenting to the GP 
more than 2 years 
ago
268 men with LUTS 
presenting to their 
GP in the last 2 years
CASES
272 men with LUTS 
not presenting to the 
GP
CONTROLS
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a significantly higher score in cases, except for the question: ‘Over the past month, how 
o�en have you found you stopped and started again several times when you urinated’. 
In a logistic regression analysis, with a�endance as the dependent variable, age and 
I-PSS were independent predictors. A�er correcting for the level of complaints (I-PSS) 
older men were still more likely to visit their GP for these voiding problems (P = 0.028, 
odds ratio, OR 1.237; 95% CI 1.024-1.495). A BS of ≥ 4 was also associated with a higher 
likelihood of consulting a GP. There was no significant difference in the mean duration of 
complaints between cases and controls (3.85 and 3.87 years, respectively; P = 0.969). Cases 
more o�en had incontinence, interference with their daily lives and modified their drinking 
pa�ern to prevent voiding problems. Although these three factors were significantly more 
common among cases, a substantial proportion of the controls also had these problems. 
More than half of the controls perceived their voiding problems to influence their lives; 
fewer said they were troubled with incontinence or prevented voiding problems by 
adapting drinking habits (Table 1). 
Table 1 shows that only a few men were convinced that their voiding problem was serious 
or related to a serious disease. Corrected for the I-PSS, there was no significant difference 
between cases and controls in these beliefs. Cases were more likely to know enough about 
their voiding problems, but half the men in both groups felt in need of information and 
there was, a�er correcting for the I-PSS, no significant difference in this need between the 
groups. About half the men in both groups were certain that they were able to cope well 
with their complaints. This feeling was not significantly different between the groups. The 
expected improvement in their condition a�er treatment by a GP or a specialist was more 
positive among the cases. The expectation that examination or treatment of their voiding 
problems would be unpleasant did not affect the decision to consult the doctor. Cases even 
seemed to have a more negative view of examinations and treatment (Table 1). 
A small majority of the cases said at least one of the three external cues (Table 1) was present 
before visiting the GP (54% of the cases vs 19.5% of the controls; P < 0.001, OR corrected for 
I-PSS 4.252, 95% CI 2.874 - 6.293). Cases were more o�en advised by their social network 
to seek medical care than were the controls. Cases more o�en thought that this advice 
influenced their decision than did the controls. Furthermore, cases more o�en remembered 
receiving information through the media (newspaper, television) about their voiding 
problems. Cases more o�en thought they were influenced by receiving information from 
the media in their decision to seek medical care. The cases also more o�en knew someone 
with voiding problems (Table 1). 
A�er multiple regression analysis in which all bivariate significant factors were included, 
the advice from the social network to a�end a physician was the strongest predictor of 
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GP a�endance. Information received from the media was also an important independent 
predictor. Furthermore, the expected improvement in their condition a�er treatment by a 
GP or a specialist, and the knowledge they perceived on voiding problems, appeared to 
be independent determinants of visiting a GP. Symptom- or complaint-related variables, 
e.g. bother, influence on daily life and incontinence, were also relevant, but their influence 
was less strong. Age, I-PSS, adaptation of drinking habits and an acquaintance with the 
same problem were no longer significant predictors (Table 2). 
DISCUSSION 
The advice of the social network and information from the media were clearly associated 
with the decision to seek primary medical care in men with LUTS; the relation was 
stronger than with symptom severity. Furthermore, specific beliefs were related to seeking 
medical care, e.g. the expectation that a physician can treat the voiding problems and the 
patients’ confidence in personal knowledge of voiding problems. Thus the decision to 
seek medical care in men with LUTS was associated with symptom severity and social 
influences. 
This study confirms that symptom severity and bother are important determinants 
inducing men to visit a doctor for voiding problems.4;8-18;22;27 However, the study also 
Table 2: Patient factors determining care seeking after multiple regression analysis
OR (CI:95%)
Others have advised me to visit the GP 5.547 (3.145-9.786)†
A GP or a specialist can treat my voiding problems well 2.707 (1.684-4.351)†
I have received information in the masse media on voiding problems 2.105 (1.260-3.517)‡
Examination and treatment of my voiding problems are unpleasant 1.998 (1.169-3.416)‡
Influence of voiding problems on daily life 1.913 (1.197-3.058)‡
I know enough about my voiding problems 1.788 (1.023-3.125)°
Bother Score ≥ 4 1.761 (1.100-2.820)°
Change clothes or wear pads when losing urine during the day 1.633 (1.044-2.553)°
Odds ratio: tested difference between the 2 groups: controls and cases, using multiple logistic regression analysis, method 
backward stepwise selection, all variables dichotomised. (°: P<0.05, ‡: P<0.01, †: P<0.001)
84
LUTS: SOCIAL INFLUENCE MORE IMPORTANT THAN SYMPTOMS IN SEEKING MEDICAL CARE
85
CHAPTER 3
suggests that influences in the social environment are stronger predictors of a�endance. 
A third of all the cases was advised by others to seek medical care. This is in concordance 
with MacFarlane, et al.,2 who further found that the social network was not always aware 
of a man having LUTS; moderate symptoms (I-PSS 7-18) were known to their spouses in 
only half of the cases. If the severity was known, three-quarters of the women advised their 
partner to visit a doctor.12 In studies of men with other medical conditions it was also found 
that the decision to consult a physician was more likely to be initiated by the spouse.28;29 
Apart from being advised by others, the present study also showed that information 
obtained from the media influenced men in deciding to consult a GP. In several other 
medical conditions, health education through the media is known to be change behaviour. 
The mass media were very effective in influencing the use of health services.30 
Information about LUTS was collected retrospectively, i.e. a�er the patient decided to 
consult his GP or not, and a�er this consultation occurred. Consequently the consultation 
may have biased the patient’s perception of symptoms in the cases. This potential recall 
bias should be considered when interpreting the findings, and is a problem encountered 
in other studies.10;11;13;14;16;18 A prospective approach, following patients from their first 
perception of LUTS, would have overcome this, but such a design was beyond the 
resources available for this study.
Many men do not consult their GP for their LUTS, but it is questionable to what extent 
this reluctance is a problem. The threat to the man’s health is limited and consequently the 
patient can and should be reassured that the existence of LUTS does not suggest that he 
has any condition which is likely to pose a significant health threat, now or in the future.31 
The natural history of LUTS has a very variable progression,8;32 but one in seven not 
a�ending a GP has serious symptoms (I-PSS = 20). In the last two decades many different 
medications and (more or less invasive) surgical interventions have been developed, so 
this group particularly may inappropriately resist medical care. Furthermore, the findings 
emphasize the need for the careful selection of patients with LUTS, to restrict medical care 
only to those who will benefit from it. 
The social network may have several motives for advising men to a�end a GP. The spouse 
or relative may be afraid of a serious disease or possible complications, or she may be 
confronted with inconvenience from the LUTS (the smell of urine, washing clothes, 
disturbance during the night). Possibly the communication with the social network made 
it more acceptable to visit the GP for LUTS; it might be important for GPs to explore not 
only the bother perceived by the patient, but also the bother for his social environment. 
Further research should be conducted to determine the motives of the social network. 
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The conclusion that the media are important in the decision to present with LUTS is 
ambiguous. It suggest possibilities for educating men with voiding problems, i.e. the media 
may be used to inform men about the causes and treatment possibilities of their condition. 
The media may also encourage behaviour to use health care services effectively.30 However, 
interest groups may misuse the mass media to raise unwanted health care demands. 
As symptom severity is not the only reason for men to seek medical care there is a need 
to inform patients adequately, to reassure those with minor symptoms and to encourage 
those with more severe symptoms with major effects on daily living to seek care. The 
present study indicates the possibility of involving the patients’ network in this task and 
in educating the patient. 
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Abstract
Objective 
To investigate associations between the level of shared care and the clinical management of patients 
with uncomplicated lower urinary tract symptoms (LUTS). 
Subjects and methods 
A cross-sectional survey study was conducted comprising all urologists and a random selection of 
general practitioners (GPs) in the Netherlands. Questionnaire responses were obtained from 182 
urologists (70%) and 261 GPs (55%). The first part of the questionnaire established the physicians’ 
characteristics and the second the level of familiarity with the national shared-care guidelines, 
arrangements between urologists and GPs, and the availability of a shared-care prostate clinic. The 
third part presented a written case of a 50-year-old man with clinical uncomplicated LUTS, and 
asked questions about diagnostic and therapeutic care. 
Results 
The clinical management of LUTS by GPs and urologists differed, particularly for diagnostic 
procedures. Only a minority of GPs (8%) and urologists (18%) had a shared-care clinic at their 
disposal. Such clinics were associated with an increase in tests ordered by the GP, e.g. creatinine 
levels (odds ratio, OR 3.83) and PSA levels (OR 5.93), and a decrease in choosing a watchful-waiting 
strategy for patients with mild symptoms (OR 0.24). Furthermore, urologists more often chose 
surgical intervention for moderate symptoms (OR 9.80).
Discussion 
A shared-care clinic may lead to a shift in primary care towards the working style of urologists. 
This health care may not be as cost-effective as expected by policy makers. Prospective studies are 
needed to provide better insight in the health outcomes and efficiency of shared-care clinics. 
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INTRODUCTION 
The number of men with LUTS seeking medical care is expected to rise in the future 
because of increasing life-expectancy and improving public awareness. Patients with 
LUTS are usually seen by GPs, and for selected cases by urologists.1 With the introduction 
of a-blocking medication it has become more feasible to treat LUTS in primary care. In 
several countries GPs are taking a more active role in the diagnosis and management of 
LUTS.2-5 If a patient is referred, specialists and primary care physicians both appreciate 
clear communication.6-8
Ten years ago reports were published on shared-care initiatives in the UK.9-11 Shared care 
was defined as the joint participation of hospital consultants and GPs in the planned 
delivery of care for patients with a chronic condition, informed by enhanced information 
exchange beyond routine discharge and referral le�ers;12 this was expected to streamline 
patient evaluation and help to enhance effective management.10 In the Netherlands, a 
commi�ee representing national associations of GPs and urologists published national 
recommendations for the shared care of LUTS.13 These evidence-based recommendations 
were intended to encourage urologists and GPs to make local arrangements for referral 
and shared-care prostate clinics. Making inter-professional arrangements was expected to 
contribute to the efficiency of health care.14
Previous studies have presented the effect of shared-care clinics on the daily practice of 
the urologist; effects of these clinics on the clinical management of the GP have not been 
reported. The aims of the present study were to describe the common clinical management 
of patients with uncomplicated LUTS, and to explore the effects of the level of shared care 
on the clinical management of both physician groups. 
SUBJECTS AND METHODS 
A cross-sectional survey study was conducted in 2000 using an anonymous questionnaire. 
The study sample comprised 306 urologists in the Netherlands and a random sample 
of 500 GPs. All urologists registered and working in clinical care with male elderly 
patients were included; paediatric-orientated urologists, and urologists still in training 
were excluded. The GPs had to be registered and active in primary medical care. All 
physicians were asked to complete the questionnaire within 10 days and to return it to the 
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research institute in a pre-stamped envelope. A wri�en reminder was mailed to those not 
responding at 3 and 6 weeks. 
The questionnaire consisted of three parts. The first part contained background questions 
to establish the physicians’ characteristics, i.e. gender, year of registration, practice se�ing, 
solo practice or shared (only for GPs), number of referral hospitals (only for GPs), special 
interest for urology (only for GPs), and size of the partnership (only for urologists). The 
second part focused on familiarity with the national shared-care guidelines published by the 
joint commi�ee of GPs and urologists,13 arrangements between urologists and GPs, and the 
availability of a shared-care prostate clinic. Three levels of shared care were distinguished: 
knowledge of the shared-care guideline, arrangement(s) in relation to shared care and an 
actual shared-care clinic. The third part concerned a wri�en case of a 50-year-old man with 
clinical uncomplicated LUTS, and questions were asked about the content of diagnostic 
and therapeutic care delivered under normal circumstances. The physicians could answer 
each question on a three-point scale (routine, sometimes, or never). Missing values were 
scored as ‘no/never’ or ‘lowest possible value’ of the variables. 
Within each professional group (GPs or urologists) the effect of shared care on the clinical 
management of the patient with uncomplicated LUTS was analysed. The unit of analysis 
was the physician. First, the consistency of the clinical management of the uncomplicated 
LUTS by the GP and the urologist was analysed, and second the effect of shared care on 
clinical management was explored. The consistency of the clinical management of the 
uncomplicated LUTS, by the GP and the urologist, was analysed by logistic regression, and 
differences between urologists and GPs expressed as odds ratios (ORs). Items concerning 
clinical management of the uncomplicated LUTS were considered as dependent variables, 
and were analysed bivariately for their association with each shared-care level. Physician 
characteristics and items related to the level of shared care were considered as independent 
variables. Items showing significant (P < 0.01) associations with the separate levels 
Table 1: Characteristics of physicians
Characteristic Urologists, n (%) GPs n (%)
N 182 261
Men 182 (100) 215 (82.2)
Registered for ≥ 15 years 109 (59.9) 105 (40.2)
Practice in a rural area - 57 (21.8)
Solo practice - 109 (41.8)
Normally referring to one hospital - 90 (34.5)
Special interest in urology - 35 (13.4)
Partnership of three urologists or less 68 (37.2) -
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were analysed in a multiple regression model (stepwise forward, conditional) for their 
association with the shared-care level, correcting for practice se�ing, gender and number 
of years registered as a urologist or GP. 
RESULTS 
Of the 306 questionnaires sent to urologists, 15 were returned blank because of wrong 
addresses, and another 29 addressees did not meet the inclusion criteria. Based on 
the corrected number of 262 questionnaires, 182 urologists (70%) responded. The GPs 
were effectively sent 478 questionnaires (corrections; 15 wrongly addressed, seven 
stopped working as a GP); of these 261 (55%) were returned. The distribution of the GP 
characteristics (Table 1) was not significantly different from national data on gender, age, 
number of years working as a GP, practice form (e.g. solo practice), or level of urbanization 
of the practice area. 
For symptom evaluation, the I-PSS was used regularly by half of the urologists, whilst 
only 20% of GPs used it (Table 2). Urologists routinely requested all diagnostic laboratory 
tests (except for serum glucose measurements) more o�en than GPs. Almost all urologists 
routinely used PSA testing and urine analysis; these tests were also requested by most GPs, 
but significantly less o�en. If referred to a urologist, most patients with uncomplicated 
LUTS would undergo uroflowmetry, and the volume of the post-void residual would be 
determined. Lifestyle advice on coping with LUTS was given by most physicians; urologists 
more o�en provided patients with information leaflets to support their explanation. 
Both urologists and GPs suggested medication for patients with moderate and surgery 
for patients with serious complaints. Alfuzosin and tamsulosin were prescribed most 
as first-choice medication in both groups; finasteride appeared to be the first choice of 
medication of 5% of GPs. 
The shared-care guideline published in 199813 was known to 68% of the urologists (123/182)
and 18% of GPs (47/261); 40% of GPs (103/261) and 43% of urologists (78/182) were aware 
of at least one specific arrangement in relation to shared care in their local se�ing. These 
arrangements o�en concerned information transfer, i.e. information provided in the le�er 
at discharge from specialist care (32%) or the referral le�er (25%). The policy on requesting 
a PSA test before referral (23%), indications for referral (22%), and conditions before 
discharge from specialist care (26%), were all commonly reported as other examples of 
arrangements made. 
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Only 8% of GPs (22/261) and 18% of urologists (32/182) said they had access to a 
shared-care clinic on prostate problems. These shared-care clinics were more common 
when urologists worked in hospitals with four urologists or more (24% vs 12%; OR 2.2). 
Fewer urologists in hospitals with small partnerships thought they needed this kind of 
facility than urologists in hospitals with larger partnerships (18% vs 33%; OR 2.3). There 
were no associations between shared-care clinics and GP characteristics. The association 
Table 2: Physician-reported clinical management of a hypothetical case of a 50-year-old man 
with uncomplicated LUTS (items which are always used)
Management Urologists, % GPs, % OR (95% CI)
  Symptom evaluation
I-PSS 51.1 19.5 4.30 (2.82-6.56)
Voiding list 25.0 3.4 8.66 (4.10-18.29)
   Laboratory investigations:
serum creatinine 75.4 43.7 3.70 (2.45-5.59)
serum PSA 92.9 65.1 6.96 (3.75-12.92)
serum glucose 17.8 30.4 0.50 (0.31-0.79)
urine analysis 95.6 79.7 5.51 (2.55-11.92)
urine culture 28.2 5.2 7.19 (3.60-14.37)
  Additional investigations* 
uroflowmetry* 84.6
determination of residue* 86.3
TRUS* 44.0
abdominal ultrasonography* 23.1
cystoscopy* 17.0
urodynamics* 4.4
IVU* 1.6
Counselling and treatment
  Providing information
Lifestyle advice given 92.9 90.4 1.38 (0.69-2.77)
Use of written patient information 82.4 39.5 7.19 (4.56-11.34)
  Treatment
Mild complaints and:
watchful waiting 88.7 93.8 0.52 (0.26-1.04)
medication 11.3 6.3
surgery 0 0
Moderate complaints and:
watchful waiting 1.1 14.6 0.35 (0.19-0.65)
medication 94.4 80.3
surgery 4.5 5.2
Severe complaints and:
watchful waiting 0 0.4 0.80 (0.49-1.32)
medication 16.9 19.4
surgery 83.1 80.2
First choice medication
Alfuzosin 21.4 36.4 0.48 (0.31-7.36)
Tamsulosin 48.4 39.1 1.46 (1.00-2.14)
Finasteride 0.5 5.4 0.10 (0.01-0.75)
*Additional investigations, urologists only.
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of the level of shared care with specific aspects of the clinical management was explored. 
GPs familiar with the shared-care guideline were more likely to use the I-PSS (OR 3.00) 
and voiding diary (OR 6.25), as recommended by the shared-care protocol. There were no 
associations between clinical management and familiarity with the shared-care protocol 
for urologists. 
A leaflet to support advice and information was more o�en provided by urologists 
who had made one or more arrangements (OR 2.93). GPs with at least one shared-care 
arrangement showed no differences in clinical management compared to GPs with no 
such arrangement. 
The GPs’ behaviour in the diagnostic and therapeutic approach to the patient was 
associated with an available shared-care clinic. The GPs more o�en used the I-PSS 
(OR 3.25), and more o�en requested laboratory tests (creatinine and PSA levels; OR 3.83 
and 5.93, respectively). For mild complaints, a watchful-waiting strategy was chosen 
less o�en by GPs with an available shared-care clinic than by GPs with no access (OR 
0.24). Urologists with shared-care clinic facilities used Trans Rectal Ultrasound (TRUS) 
more frequently (OR 3.70) and surgical intervention was more o�en chosen for moderate 
complaints (OR 9.80). 
DISCUSSION 
In the present study we compared the care routinely delivered by urologists and GPs 
to a hypothetical patient with uncomplicated LUTS. In the diagnostic phase, urologists 
were more exhaustive in the initial symptom evaluation and request for diagnostic tests. 
The treatment options chosen by the two professions were similar. Familiarity with the 
shared-care guideline and access to a shared-care clinic were associated with the clinical 
management. GPs familiar with the guideline were more likely to use instruments 
advocated by this guideline, e.g. the I-PSS and a voiding diary. Access to a shared-care 
clinic was only available to a minority of the physicians, and was associated with a more 
active approach to the patient; more laboratory tests were used and patients with similar 
symptom levels were treated more aggressively. 
The response rating among GPs to the questionnaire was relatively low (55%) so we cannot 
exclude selection bias in the results. However, response rates were similar to those in other 
studies in primary care urology,1-3;15-17 and the characteristics of the population studied 
showed no significant differences with demographic data of the overall GP population in 
the Netherlands. The questionnaire contained a standardized case of a 50-year-old man 
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with uncomplicated LUTS. This cannot reflect the tailor-made approach of daily practice, 
and results have to be judged with respect to this limitation. 
Most studies on variation of practice pa�erns have described the management of patients 
with complaints of LUTS/BPH by either urologists15;18-20 or primary care physicians.2;17;21 
We used the same questionnaire for both populations to compare care management. In 
general, compared with GPs, urologists were more o�en inclined to quantify the patient’s 
complaints by adopting scores, laboratory investigations or clinical measurement 
techniques. GPs more o�en took a ‘wait and see’ approach to a new patient. In their clinical 
management, GPs with a special interest in urology were no different from GPs that had 
no access to a shared-care clinic. This may reflect the composition of the patient population 
they manage, and their professional a�itude. The management of the diagnostic process 
as delivered by urologists and GPs in the present study is mostly consistent with studies 
on variation on practice pa�erns published previously.2;3;15-21 However, PSA tests were 
less o�en routinely requested by GPs in the present study (65%) than by primary care 
physicians in other countries (69-91%).2;3;16;21 This might be because the Dutch guideline 
for GPs advises against PSA testing, whereas national guidelines in most other countries 
suggest it as an option in the diagnostic process.22;23 
Several types of shared-care clinics for prostate problems have been described, each 
adapted to local needs and local se�ings.9-11;24 Audit reports on prostate-related shared care 
reported that 27-59% of the patients referred to shared-care clinics could be managed by 
watchful waiting or pharmacotherapy.9-11 In another study, a nurse-led prostate clinic was 
shown to be more cost-effective than all patients being seen in a urology clinic directly,24 
but there was no comparison to the situation where GPs managed these patients and no 
shared-care clinic was available. In the present study, GPs with access to a shared-care 
clinic less o�en chose a watchful-waiting policy for patients with mild symptoms, and 
urologists proposed surgery more o�en for patients with moderate symptoms. This raises 
the question whether these shared-care clinics are cost-effective. In a recent comment, 
Dunsmuir and Kirby4 concluded that it is unlikely that shared-care clinics imply more 
efficient health care. 
Among primary care physicians the availability of shared care seems to have led to a shi� 
of the primary care a�itude towards managing care as a specialist/urologist. Many policy 
makers expect shared care to be an efficient solution for (future) increases in health care 
needs. However, copying the specialist clinical management to primary care may not 
provide health care that is more cost-effective. Prospective studies are needed to provide a 
be�er insight into the health outcomes and the efficiency of shared-care clinics. Until then, 
a watchful-waiting approach for shared-care clinics is recommended to policy makers. 
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Abstract
Objective
Testing what the feasibility is of an open access facility to uroflowmetry in general practice.
Subject and methods
In a explorative study during a period of 14 months 19 general practitioners had open access 
to uroflowmetry as a tool in the diagnosis of lower urinary tract. After 14 months evaluative 
interviews were conducted. 
Results
A total of 12 men had actually performed uroflowmetry. Seven of the twelve men included had a 
Q
max 
≤ 10 ml/s (possible obstruction) and two had a Q
max 
≥ 15 ml/s (probably unobstructed). Except 
for two, in none of the patients the clinical management was influenced by the uroflowmetry 
and medication was prescribed for their complaints. In two cases a watchful waiting policy was 
chosen instead, after discussion of the results with the patient. None of the patients was referred 
to a urologist. From evaluative interviews at the end of the study we learned that all GPs were 
disappointed by the low incidence of patients with LUTS presenting at their surgery. The criteria 
for exclusion of the patients were thought of being too strict (notably excluding patients already 
treated for LUTS).
Discussion
With respect to the low number of included patients and the limited effect on clinical management 
uroflowmetry is not considered as very useful in general practice. Most GPs felt uroflowmetry 
would support a more objective indication and evaluation of treatment, and thought it could 
be a valuable, additional tool in general practice. They preferred uroflowmetry to be supported 
logistically by a diagnostic centre, to be used after request by the GP. In this centre the device should 
be distributed after the patient is instructed, and the resultant uroflowcurve should be interpreted 
by a specialist as well, since the respondents felt not able to do an adequate interpretation.
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INTRODUCTION
Several studies have indicated that, in an open population, 30% of men over 50 years of age 
have lower urinary tract symptoms (LUTS) that may be called bothersome.1-4 More men 
reaching high age and the reduced taboo on LUTS are expected to increase the number 
of men presenting with LUTS in future years: resulting in higher consumption of medical 
care. Although the general practitioner (GP) is able to get an idea of the bother related 
to LUTS the elderly patient is confronted with. Complaints concerning LUTS are o�en 
difficult to interpret on the basis of history taking alone.5-11 
Although the International Prostate Symptom Score (I-PSS) may clarify the subjective 
complaints of a patient,12 it was originally designed to evaluate the effects of treatment 
over time as a monitoring instrument and it was not intended to be a discriminative or 
predictive index.13;14 Without direct access to additional diagnostic tests a GP has to refer 
a patient with bothersome complaints to a urologist to get a be�er insight in the possible 
causes of the LUTS. A uroflowmetry is performed in 84.4% of all patients referred to a 
urological outpatient clinic making it the third most performed diagnostic procedure in 
referred patients (a�er digital rectal examination (97.7%) and blood and urine sampling 
(respectively 92.3 and 86.6%).15 The American Urological Association (AUA) guideline 
on LUTS recommends measurement of the flow rate in patients with a complex medical 
history or with a desire for invasive therapy.16 Although uroflowmetry has its limitations 
it may be helpful in differentiating BPH from non-BPH causes of the patients complaints 
(Box 1).
For a proper evaluation of LUTS with a uroflowmeter several measurements are needed, 
because of a variability between the measurements, the effect of circadian rhythms and 
artefacts in the measurements.9;17-26 Circumstances on the outpatient department are know 
to be problematic in obtaining a spontaneous, representative flow and volume.22;27 In recent 
years portable uroflowmetry devices have been developed and tested, delivering results 
comparable to traditional uroflowmeters.22;28;29 These portable devices potentially could 
cope with all problems mentioned above; allowing measurements at home and so giving 
a good insight into the voiding pa�erns and obtaining out of office time flows as well.11;21 
With these coming available, uroflowmetry in general practice has become more feasible 
as well, assisting to a more adequate referral. However, evaluations of its use in normal 
general practice is yet limited. The aim of the study was testing the clinical relevance of 
uroflowmetry in general practice.
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METHODS
DESIGN
Based on literature (Box 1) and discussions with experts in the field of urology (three 
urologists), general practice (two professors in general practice and the first author of the 
Dutch Guideline on LUTS) and on diagnostic procedures (two heads of laboratories and 
a medical technology assessment expert) a diagnostic protocol (Appendix Chapter 5) was 
worked out and an implementation plan was developed. A prospective observational pilot 
study was performed, testing the feasibility of the developed uroflowmetry protocol in 
general practices during 14 months (March 2001 through April 2002). The ethical commi�ee 
of the Radboud University Nĳmegen Medical Centre gave approval for the study.
THE INTERVENTION
THE UROFLOWMETRY DEVICE
The portable, ba�ery powered, Danica DaCapo Home Flowmeter is a weight transducer, 
measuring voided volume versus time and so calculating the flowrate.28 It is designed to 
record all voidings during a period of time in a single patient. The flowmeter is delivered 
in a small suitcase, and can easily be set up by the patient. Before voiding the flowmeter 
is activated by a foot switch; it switches of automatically a�er a fixed amount of time 
(Figure 1).
Figure 1: Uroflowmeter
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Box 1: Uroflowmetry, a more theoretical background
A pressure flow study (PFS) is considered to be the best method assessing bladder outflow obstruction 
according to several recent guidelines on LUTS.47-49 Since it is an expensive, time-consuming and 
rather unpleasant invasive procedure,50 it is advised to perform PFS only when invasive treatment 
is considered and not as a standard diagnostic procedure.37 Uroflowmetry, on the other hand, is 
a non-invasive test where the urinary flow is electronically recorded while voiding. It is very well 
able to differentiate between normal and abnormal voiding51 and can be used as a measurement to 
pre-select patients for further testing.52-54 Being a measure of the interplay between detrusor and 
urethra, uroflowmetry is not able to differentiate reliably between detrusor impairment and outflow 
obstruction, which is considered a disadvantage.51;52;55-60 However, when history is taken into account 
in an adequate way uroflowmetry can become a valuable tool.35;36
The uroflowmeter produces a flow-diagram from which several parameters can be obtained as: 
voiding time, maximum flow rate (Q
max, 
also known as Peak Flow Rate (PFR)), average flow rate (Q
ave
), 
and total voided volume(VV). The Q
max
 is the parameter with the highest reproducability61 and is 
better able to differentiate between normal and abnormal flows.62 The problem is the clinical relevant 
cut off point. A Q
max
 greater than 20 ml/s is unlikely to be associated with urodynamically-defined 
outflow obstruction.63 A Q
max
 of 15 ml/s or more appeared to be adequately diagnosed as not 
obstructed in 42% to 75% of the cases when pressure flow studies were considered as the golden 
standard.36;64;65 A Q
max
 < 15 ml/s has a sensitivity of 82 and a specificity of 38 for bladder outlet 
obstruction (at a Q
max
 < 10 ml/s there is sensitivity of 47 and a specificity of 70).35 The predictive 
value of Q
max
 on outcome after a transurethral resection of the prostate (TURP) was reported: 71% 
of those with a Q
max
 over 15 ml/s improved compared to 91% of those between 10 and 15 ml/s and 
92% for those less than 10 ml/s.65 However, this study found no difference between improvement in 
symptom scores between groups, and measured success as a subjective analysis of ‘much better’ or 
‘no change’. The numbers of patients involved when using these cut of points may be illustrated by 
open population studies of men aged 55-70 years where one in five had a Q
max
< 10 ml/s and a quarter 
a Q
max
 between 10 and 14.9 ml/s.66;67 Increasing age leads to a decrease in Q
max
; 60% of all men older 
then 80 years did not have obstruction despite a Q
max 
of 10 to 15 ml/s.68 Cut-of points of 15 and 
10 ml/s are generally accepted;59;69;70 where a Q
max
 value of greater than 15 millilitre per second is 
generally considered normal,48 and with a value below 10 ml/s obstruction is more probable.16;47 Apart 
from patho-physiological aspects, the flow appears to be subject to a number of external factors as 
(psychological) stress, abdominal straining, wagging and pinching the penis during voiding.9;28;58;59
Considerable debate exists on whether Q
max
 can be interpreted without considering the voided 
volume of urine. The reproducibility of the Q
max
 was higher in volumes more then 150 ml,61 although 
smaller voiding volumes may also give a reliable picture.21;35 Numerous nomograms have been 
developed to tackle this problem, but there is no universally accepted single volume correction 
technique and so the inaccuracy of flow rates with voided volumes of less than 125-150 ml should 
be recognised.71
It may be concluded that men with LUTS and normal Q
max
 are more likely to have a non-BPH-related 
cause of their symptoms. Men with a Q
max
 less than 10 ml/s are more likely to have urodynamic 
obstruction and are therefore more likely to improve with surgery. The Q
max
 correlated better with 
the degree of bladder outflow obstruction assessed by pressure flow studies than the I-PSS, in a 
population selected on the severity of complaints.36 Men with normal flow rates but significant urinary 
symptoms are more likely to have non-prostatic causes for those symptoms requiring more extensive 
investigation. Flow rates of the uroflowmetry are probably adequate for long term conservative 
treatment, such as watchful waiting and α-blockers.72.
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PRACTICE SETTING
The incidence of lower urinary tract symptoms is 1.2-4.5/1000 men/year30-32; so an average 
practice with the size of 2350 patients (men and women) would be able to recruit between 
1.4 and 5.2 new patients a year. Therefore the assumption was that an average GP will not 
be interested to do this kind of investments in a home flow meter (€ 2300.00, exclusive VAT 
and € 2.00 for disposable funnel and container (price level 2000)). So one apparatus had 
to be shared by a group of GPs. Two possible se�ings were studied: a surgery comprising 
5-6 GPs with one uroflowmeter at their disposal on site and a group of 15 GPs being 
able to refer a patient to a diagnostic centre/laboratory, where the uroflowmeter is made 
available.
If according to the protocol uroflowmetry is indicated and patient’s informed consent 
is obtained; the patient is instructed by a practice/laboratory assistant in operating the 
uroflowmeter. The device is taken home where the patient is requested to measure all 
voiding during 24 hours, this procedure is repeated at six weeks in accordance with the 
protocol. All flow curves obtained during these two measuring sessions will be at the 
disposal of the GP for interpretation. The GP obtained a compensation of € 20.— for 
each patient included. A wri�en reminder was sent to the participating GPs every two 
months. 
PARTICIPANTS
Within the city of Eindhoven 63 GPs were invited to take part in the study, of these 13 
GPs showed interest. Furthermore three surgeries containing 5-7 GPs were contacted 
and invited to take part as a whole, of these one surgery (comprising 6 GPs) agreed. 
All participating GPs were instructed in a 2-3 hours session in the diagnostic work-up 
of the patient with LUTS and the interpretation of the uroflow curve. Furthermore one 
practice-assistant (in the surgery participating) and two laboratory assistants were 
instructed in handling the uroflowmeter and instructing the patient how to operate the 
uroflowmeter at home. One uroflowmeter was placed in the surgery taking part, two 
others were situated in a diagnostic centre at disposal of the 13 GPs.
Men aged 50 years or older visiting their GP because of LUTS were invited to take part 
in the study. LUTS were defined as a lasting change of urination manifesting itself in 
hesitancy, a weak flow, dribbling, urge, feeling of retention or increased frequency of 
urination during day and night.33 Based on epidemiological data a total of 60 patients 
were expected to be recruited during the study. Excluded were patients already under 
medication for BPH, unable to perform the uroflowmetry (restricted cognitive abilities, 
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unable to urinate standing upright, depending on a urine catheter), with an indication 
for referral (carcinoma of the prostate, complicated LUTS) or in a terminal phase of a 
disease. 
OUTCOME
Main outcome measure was the feasibility of the protocol in the daily practice of the 
GP, measured as the number of patients participating and fulfilling the protocol. The 
GP kept record of each patient in the study of diagnostic tests, therapeutic actions and 
referrals performed. Six weeks a�er recruitment (a�er the second day of measurement) 
patients were asked to complete an evaluation questionnaire with questions on: physical 
complaints, present I-PSS and Bother Score, health care needs, evaluation of care as 
received from the GP and the diagnostic centre, and a�itude towards uroflowmetry.
At the end of the study a structured interview was held with participating GPs evaluating 
uroflowmetry as diagnostic procedure, the facilitators and barriers perceived and 
suggestions on improvement of the protocol for uroflowmetry in general practice.
RESULTS
The protocol was applied by 19 GPs during for 14 months; a total of 14 patients were 
included, of these 12 men have actually performed uroflowmetry (we were not able 
register the exact number of patients visiting the surgery because of LUTS). The average 
age of these patients was 62.5 years (range 50-81 years), with an average I-PPS of 14.4 
(range 5-29) and botherscore of 3.2 (range 2-4). There were no differences in the number 
of patients included between the se�ings tested. These 12 men produced a total of 263 
registered voidings during the two days of measurement: an average of 11.0 voidings per 
24 hours. Half of these were without artefacts and could be used in the interpretation. 
Seven men (58%) had a Qmax ≤ 10 ml/s and two (16%) had a Qmax ≥ 15 ml/s.
At all, except one, of the first consultations the GP provisionally diagnosed the complaints 
as LUTS based on a benign prostatic hyperplasia; this diagnosis was not altered because 
of the results obtained by uroflowmetry. For all of the first consultations the GP expected 
beforehand to prescribe medication for the patients complaints at the end of the protocol. 
In two cases this expectation was not met, instead a watchful waiting policy was chosen 
a�er discussion of the results with the patient; none of the patients was referred to a 
urologist.
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All patients evaluated the design used in the protocol as being without problems (three 
consultations at the surgery, installing and operating the uroflowmeter, delay in the 
diagnosis for more than six weeks).
EVALUATION INTERVIEWS WITH THE PARTICIPATING GPS
Seventeen GPs agreed to the interview evaluating the study (one withdraw because 
of illness, another preferred not to be approached any more). In general all GPs were 
disappointed by the low incidence of patients with complaints of LUTS presenting at 
their surgery. The criteria for exclusion of the patients were experienced as being too 
strict (specially previous treatment for BPH). They further felt a number of patients could 
not be considered as candidates for home-flowmetry because of restriction in cognitive 
of physical abilities (…the patient is not able to understand the device…, … that man was not 
able to void standing…), or patients did not agree to the conditions of the study. Most GPs 
felt uroflowmetry would give them the opportunity to indicate and evaluate treatment 
more objectively, and thought of uroflowmetry as a valuable, additional tool in general 
practice. They preferred uroflowmetry to be supported logistically by a diagnostic centre, 
where the device is distributed a�er request by the GP. In this centre the patient should be 
instructed, but also the uroflowcurve should be interpreted by a specialist: as due to the 
low incidence they felt not having enough routine for adequate interpretation. 
DISCUSSION
A protocol for uroflowmetry in general practice was tested for a year in the practices 
of nineteen GPs. During fourteen months twelve patients performed uroflowmetry 
according to the protocol. The uroflowmetry did not influence the diagnosis and treatment 
made at the initial consultation, except in two cases where GP and patient refrained from 
prescription of medication. Participating GPs and patients perceived uroflowmetry as a 
positive contribution to the diagnostic work up. With respect to the low number of included 
patients and the apparent absence of an effect on clinical management uroflowmetry is not 
considered as very useful in general practice.
Our study was a prospective study of the feasibility of uroflowmetry in general practice. 
The results we obtained can be seen as a pilot to future studies in this field. On the basis 
of national data of the incidence of LUTS one would expect a total of 50-60 new patients 
during the test period, but only 12 men (20%) were included. Even when inclusion criteria 
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would be extended to monitoring men already treated with medication we expect the 
number patients will not be high.
The quality of the curves was lower then found in previous studies. We found half of the 
uroflowcurves were having artefacts making them inaccessible to interpretation; this is 
much more then the 10-18% found in other studies with home-uroflowmetry.18;21;22 These 
differences may be due to the type of instrument used since in these studies the P-Flow, a 
hand held uroflowmeter, was used instead of the Da CapoHome Uroflowmeter.
Patients and GPs participating in the study were positive about uroflowmetry in 
general practice, although their (self-)selection may have biased them. Despite the 
limited consumption of uroflowmetry during the study, most of them saw a future for 
this diagnostic method in general practice. This future depended on the condition that 
logistic management was provided by a laboratory and that curves would be interpreted 
by a specialist. The la�er may be a problem; since interpretation of curves is not easy 
(experienced urologists were only able to predict the actual diagnosis in 36% of the cases, 
43% of the normal flows was considered as abnormal)34 and uroflowmetry only considered 
to be a valuable tool when patients history is taken adequately into account.35;36 
Home-uroflowmeter is a rather expensive diagnostic method for general practice when 
considered that the GP is only interested in the Qmax in his evaluation of the patient. Studies 
on simpler methods have shown to be reproducible as well: as a 5 second home flow 
rate,37;38 the ‘how many seconds for 100 ml’ test39;40 and the stream cup test41 in combination 
with a voiding dairy.42
This paper describes an a�empt of introducing a technique new to general practice. There 
are a number of techniques available to the GP in their own practice (e.g. spirometry)43;44 
or on an open access base in a hospital (e.g. endoscopy, ambulatory blood pressure 
measurement ).45;46 
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Appendix Chapter 5: The diagnostic protocol
The work up of a patient 50 years or older and complaints of lower urinary tract symptoms 
(Figure 1):
Since the problem often presents itself as a doorknob phenomenon it was advised to split the 
assessment of LUTS into two-three consultations (three in case of uroflowmetry):
1) The initial assessment (investigation of complaints, physical examination (Digital Rectal 
Examination). Explaining the I-PSS and voiding diary and handing one out to fill in at home, 
invite the patient to a next consultation when he has to bring a urine specimen. 
2) The next two consultations. The I-PSS and the urine specimen can be talked through.
At the end of the (second) consultation the further work up will be:
a) In case of uncomplicated LUTS and a I-PSS ≤ 7 and/or a quality of life index ≤ 3 ⇒ 
watchful waiting and re-assessment when complaints are increasing
b) In case of uncomplicated LUTS and a I-PSS ≤ 7 and a quality of life score ≥ 4 and in 
case of uncomplicated LUTS and a I-PSS ≥ 8 ⇒ uroflowmetry (Uroflowmetry will be 
performed twice with an interval of 6 weeks)
i) If the mean Q
max
 of 24 hours measuring is ≥ 10 ml/s and I-PSS 8-19 then the 
policy can be a shared decision in which the GP reassures the patient and 
suggests watchful waiting and reassessment of the complaints in case of 
increasing complaints.
ii) If the mean Q
max
 of 24 hours measuring is ≥ 10 ml/s and the I-PSS ≥ 20 or the 
flow ≤ 9 ml/s and the I-PSS 8-19 then the policy can be a shared decision in 
which the GP suggests medical treatment with an α-blocking agent and after 3 
months reassessment of the complaints
iii) If the mean Q
max
 of 24 hours measuring is ≤ 9 ml/s and the I-PSS ≥ 20 then policy 
can be a shared decision in which the GP suggests referral to a urologist
c) In case of complicated LUTS (as there are hematuria, acute urine retention, indications 
of prostate carcinoma, prostatitis, cystitis, indications of uretral strictures (transuretral 
instrumentation, sexually transmitted diseases), bladder dysfunction that may be due to 
diabetes, neurological conditions (as MS, parkinsonism)) patients are excluded from the 
study and should be dealt with in the proper way of treatment (antibiotics or referral 
to a specialist depending on diagnosis).
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  Man aged ≥ 50 years 
with LUTS
1st consultation:
 history taking and physical 
examination
After inclusion and 
informed consent
I-PSS,  voiding diary and 
making next appointment
Exclusion for study if:
1. Already treated BPH
2. Unable to perfom urofl owmetry:
- restricted cognitive abilities
- unable to urinate standing upright
3. Indication for referral: 
- suspicion of prostate carcinoma
- complicated LUTS
4. In a terminal fase of a disease
Home urofl owmetry 
during 24 hours
Twice with 6 week interval: 
next appointment 6 weeks 
later
Patient education, 
watchful waiting
I-PSS ≤ 7 and BS ≤ 3
2nd consultation
3rd consultation: dicussing test results and further treatment
I-PSS ≤ 19 I-PSS ≥ 20
Q
max
 ≥ 15 Patient education, watchful 
waiting
Consider referal to urologist 
or medication
Q
max
 ≤ 10 Consider referal to urologist 
or medication
Referral to urologist
I-PSS >7 or BS>3
Figure 1: Flow diagram of diagnostic work up
110
LOW FEASIBILITY OF UROFLOWMETRY IN GENERAL PRACTICE
111
CHAPTER 5
References
1. Wolfs GGMC, Knottnerus JA, Janknegt RA. Prevalence and detection of micturition problems among 2,734 
men. J Urol 1994;152 :1467-70.
2. Madersbacher S, Haidinger G, Temml C, Schmidbauer CP. Prevalence of lower urinary tract symptoms in 
Austria as assessed by an open survey of 2,096 men. Eur Urol 1998;34 :136-41.
3. Blanker MH, Groeneveld FPMJ, Prins A, Bernsen RMD, Bohnen AM, Bosch JLHR. Strong effects of definition 
and nonresponse bias on prevalence rates of clinical benign prostatic hyperplasia: the Krimpen study of male 
urogenital tract problems and general health status. BJU Int 2000;85:665-71.
4. Sonke GB, Kolman C, de la Rosette JJMCH, Donkers LHC, Boyle P, Kiemeney LALM. Prevalentie van 
lagere-urinewegsymptomen bij mannen en de invloed op hun kwaliteit van leven: het Boxmeer-onderzoek. 
Ned Tijdschr Geneeskd 2000;144 :2558-63.
5. Simpson RJ. Benign prostatic hyperplasia. Br J Gen Pract 1997;47:235-40.
6. Reynard JM, Abrams P. Bladder-outlet obstruction–assessment of symptoms. World J Urol 1995;13:3-8.
7. Grayhack JT. Benign Prostatic Hyperplasia. The scope of the problem. Cancer 1992;70 :275-9.
8. Abrams P. Managing lower urinary tract symptoms in older men. BMJ 1995;310 :1113-7.
9. Golomb J, Lindner A, Siegel Y, Korczak D. Variability and cicadian changes in home uroflowmetry in patients 
with benign prostatic hyperplasia compared to normal controls. J Urol 1992;147:1044-7.
10. Small DR, Lanigan DJ, Khan AB, Conn IG. Comparison of patients’ assessment of urinary flow strength with 
uroflowmetry. Eur Urol 1997;31:148-52.
11. Matzkin H, Greenstein A, Prager-Geller T, Sofer M, Braf Z. Do reported micturition symptoms on the 
American Urological Association Questionnaire correlate with 24-hour home uroflowmetry recordings? J 
Urol 1996;155:197-9.
12. Roehrborn CG. The American Urological Association Symptom Index, concerns and confirmation. J Urol 
1996;155:1975-6.
13. Lawrence K. Measurement properties of the AUA symptom score: a methodological clarification. Br J Urol 
1996;77:175-80.
14. Boyle P, Robertson C, Mazzetta C, et al. The prevalence of lower urinary tract symptoms in men and women 
in four centres. The UrEpik study. BJU Int 2003;92 :409-14.
15. Stoevelaar HJ, van de Beek C, Casparie AF, Nijs HGT, McDonnell J, Janknegt RA. Variatie in diagnostiek 
en behandeling van benigne prostaathyperplasie in de urologische praktijk. Ned Tijdschr Geneeskd 1996;140 :
837-42.
16. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment 
recommendations. J Urol 2003;170 :530-47.
17. Sonke GS, Robertson C, Verbeek AL, Witjes WP, de la Rosette JJ, Kiemeney LA. A method for estimating 
within-patient variability in maximal urinary flow rate adjusted for voided volume. Urology 2002;59:368-72.
18. Witjes WP, Wijkstra H, Debruyne FM, de la Rosette JJ. Quantitative assessment of uroflow: is there a circadian 
rhythm? Urology 1997;50 :221-8.
19. Feneley MR, Dunsmuir WD, Pearce J, Kirby RS. Reproducibility of uroflow measurement: experience during a 
double-blind, placebo-controlled study of doxazosin in benign prostatic hyperplasia. Urology 1996;47:658-63.
20. Reynard JM, Peters TJ, Lim C, Abrams P. The value of multiple free-flow studies in men with lower urinary 
tract symptoms. Br J Urol 1996;77:813-8.
21. Sonke GS, Kiemeney LA, Verbeek AL, Kortmann BB, Debruyne FM, de la Rosette JJ. Low reproducibility of 
maximum urinary flow rate determined by portable flowmetry. Neurourol Urodyn 1999;18 :183-91.
22. de la Rosette JJMCH, Witjes WPJ, Debruyne FMJ, Kersten PL, Wijkstra H. Improved reliability of uroflowmetry 
investigations: results of a portable home-based uroflowmetry study. Br J Urol 1996;78 :385-90.
23. Roehrborn CG, Andersen JT, Correa Jr R. Initial diagnostic evaluation of man with lower urinary tract 
symptoms. In Cockett ATK, Khoury S, Aso Y, et al. eds. Proceedings of the 3rd International Consultation of 
Benign Prostatic Hyperplasia: Monaco, Monaco: WHO, 1996.
110
LOW FEASIBILITY OF UROFLOWMETRY IN GENERAL PRACTICE
111
CHAPTER 5
24. Barry MJ, Girman CJ, O’Leary MP, et al. Using repeated measures of symptom score, uroflowmetry and 
prostate specific antigen in the clinical management of prostate disease. Benign Prostatic Hyperplasia 
Treatment Outcomes Study Group. J Urol 1995;153:99-103.
25. Jensen KM, Jorgensen JB, Mogensen P. Reproducibility of uroflowmetry variables in elderly males. Urol Res 
1985;13:237-9.
26. Poulsen EU, Kirkeby HJ. Home monitoring of uroflow in normal male adolescents: relation between flow-curve, 
voided volume and time of the day. Scan J Urol Nephrol 1988;58-62.
27. Ather MH, Memon A. Uroflowmetry and evaluation of voiding disorders. Tech Urol 1998;4 :111-7.
28. Jorgensen JB, Jacobsen HL, Bagi P, Hvarnes H, Colstrup H. Home uroflowmetry by means of the Da Capo 
home uroflowmeter. Eur Urol 1998;33:64-8.
29. Pel JJ, van Mastrigt R. Development of a low-cost flow meter to grade the maximum flow rate. Neurourol 
Urodyn 2002;21:48-54.
30. van der Velden J, de Bakker DH, Claessens AAMC, Schellevis FG. Een nationale studie naar ziekten in en 
verrichtingen in de huisartspraktijk. Basisrapport: morbiditeit in de huisartspraktijk. Utrecht: NIVEL, 1991.
31. van de Lisdonk EH, van den Bosch WJHM, Lagro-Janssen ALM. Ziekten in de huisartspraktijk. Utrecht: Bunge, 
1994.
32. Lamberts H. In het huis van de huisarts. Verslag van het transitieproject. Lelystad: Meditekst, 1994.
33. Klomp MLF, Gercama AJ, de Jong-Wubben JGM, et al. NHG-standaard bemoeilijkte mictie bij oudere mannen 
(eerste herziening). Huisarts Wet 1997;40 :114-24.
34. van de Beek C, Stoevelaar HJ, McDonnell J, Nijs HGT, Casparie AF, Janknegt RA. Interpretation of 
uroflowmetry curves by urologists. J Urol 1997;157:164-8.
35. Reynard JM, Yang Q, Donovan JL, et al. The ICS-‘BPH’ Study: uroflowmetry, lower urinary tract symptoms and 
bladder outlet obstruction. Br J Urol 1998;82 :619-23.
36. Homma Y, Gotoh M, Takei M, Kawabe K, Yamaguchi T. Predictability of conventional tests for the assessment 
of bladder outlet obstruction in benign prostatic hyperplasia. Int J Urol 1998;5:61-6.
37. Schwartz BF, Soderdahl DW, Thrasher JB. Home flow rates in evaluation of lower urinary tract symptoms in 
men. Tech Urol 1998;4 :15-7.
38. Bloom DA, Foster WD, McLeod DG, Mittemeyer BT, Stutzman RE. Cost-effective uroflowmetry in men. J Urol 
1985;133:421-4.
39. Hansen MV, Zdanowski A. The use of a simple home flow test as a quality indicator for male patients treated 
for lower urinary tract symptoms suggestive of bladder outlet obstruction. Eur Urol 1997;32 :34-8.
40. Folkestad B, Spangberg A. Timed micturation and maximum urinary flow rate in randomly selected 
symptom-free males. Scan J Urol Nephrol 2004;38 :136-42.
41. Currie RJ. The streamtest cup: a new uroflow device. Urology 1998;52 :1118-21.
42. Blanker MH, Groeneveld FP, Bohnen AM, et al. Voided volumes: Normal values and relation to lower urinary 
tract symptoms in elderly men, a community based study. Urology 2001;57:1093-9.
43. Chavannes N, Schermer T, Akkermans R, et al. Impact of spirometry on GPs’ diagnostic differentiation and 
decision-making. Respir Med 2004;98 :1124-30.
44. Corrigan SP, Cecillon DL, Sin DD, et al. The costs of implementing the 1999 Canadian Asthma Consensus 
Guidelines recommendation of asthma education and spirometry for the family physician. Can Respir J 2004;11:
349-53.
45. Charles RJ, Cooper GS, Wong RC, Sivak M-VJ, Chak A. Effectiveness of open-access endoscopy in routine 
primary care practice. Gastrointest Endosc 2003;57:183-6.
46. Lorgelly P, Siatis I, Brooks A, et al. Is ambulatory blood pressure monitoring cost-effective in the routine 
surveillance of treated hypertensive patients in primary care? Br J Gen Pract 2003;53:794-6.
47. de la Rosette JJ, Alivizatos G, Madersbacher S, et al. EAU Guidelines on benign prostatic hyperplasia (BPH). 
Eur Urol 2001;40 :256-63.
48. National Health and Medical Reseach Council. The management of uncomplicated lower urinary tract 
symptoms. http://www.nhmrc.gov.au/publications/pdf/cp42.pdf . 1-5-2000. Canberra, Australian Govt. Pub. 
Service. Clinical practice guidelines. 
112
LOW FEASIBILITY OF UROFLOWMETRY IN GENERAL PRACTICE
49. The Management of Benign Prostatic Hyperplasia Guideline. http://shop.auanet.org/timssnet/products/
clinical_guidelines/index.cfm . 2003. Baltimore, American Urological Association Education and Research. 
50. Shaw C, Williams K, Assassa PR, Jackson C. Patient satisfaction with urodynamics: a qualitative study. J Adv 
Nurs 2000;32 :1356-63.
51. Janknegt RA, Rollema HJ, van de Beek C. Urodynamisch onderzoek noodzakelijk voor correcte diagnostiek bij 
prostatisme. Ned Tijdschr Geneeskd 1994;138 :1751-6.
52. van Mastrigt R, Pel JJM. Towards a noninvasive urodynamic diagnosis of infravesical obstruction. Br J Urol 
1999;84 :195-203.
53. Rosier PF, de Wildt MJ, Wijkstra H, Debruyne FF, de la Rosette JJ. Clinical diagnosis of bladder outlet 
obstruction in patients with benign prostatic enlargement and lower urinary tract symptoms: development 
and urodynamic validation of a clinical prostate score for the objective diagnosis of bladder outlet obstruction. 
J Urol 1996;155:1649-54.
54. Madersbacher S, Klingler HC, Djavan B, et al. Is obstruction predictable by clinical evaluation in patients with 
lower urinary tract symptoms? Br J Urol 1997;80 :72-7.
55. Benign prostatic hyperplasia: diagnosis and treatment. Clinical practice guideline, number 8. http:
//hstat.nlm.nih.gov/hq/Hquest/db/3103/screen/DocTitle/odas/1/s/52748 . 1994. Maryland, Department of 
health and public services. 
56. Chancellor MB, Blaivas JG, Kaplan SA, Axelrod S. Bladder outlet obstruction versus impaired detrusor 
contractility: the role of outflow. J Urol 1991;145:810-2.
57. Poulsen AL, Schou J, Puggaard L, Torp Pedersen S, Nordling J. Prostatic enlargement, symptomatology 
and pressure/flow evaluation: interrelations in patients with symptomatic BPH. Scan J Urol Nephrol 
1994;157(Suppl).
58. Kaplan SA, Te AE. Uroflowmetry and urodynamics. Urol Clin North Am 1995;22 :309-20.
59. Jensen KM. Uroflowmetry in elderly men. World J Urol 1995;13:21-3.
60. van Maastrigt R, Pel JJM. Towards a noninvasive urodynamic diagnosis of infravesical obstruction. Br J Urol 
1999;84 :195-203.
61. Homma Y, Imajo C, Kawabe K. Maximum flow rate: the single uroflowmetric parameter in clinical trials for 
benign prostatic hyperplasia? Int J Urol 1995;2 :322-5.
62. Layton TN, Drach GW. Selectivity of peak versus average male urinary flow rates. J Urol 1981;125:839-41.
63. Abrams PH, Griffiths DJ. The assessment of prostatic obstruction from urodynamic measurements and from 
residual urine. Br J Urol 1979;51:129-34.
64. Nielsen KK, Nordling J, Hald T. Critical review of the diagnosis of prostatic obstruction. Neurourol Urodyn 
1994;13:201-17.
65. Jensen KM, Jorgensen JB, Mogensen P. Urodynamics in prostatism. I. Prognostic value of uroflowmetry. Scand 
J Urol Nephrol 1988;114(Suppl):63-71.
66. Overland GB, Vatten L, Rhodes T, et al. Lower urinary tract symptoms, prostate volume and uroflow in 
norwegian community men. Eur Urol 2001;39:36-41.
67. Girman CJ, Panser LA, Chute CG, et al. Natural history of prostatism: Urinary flow rates in a community-based 
study. J Urol 1993;150 :887-92.
68. Madersbacher S, Klingler HC, Schatzl G, Stulnig T, Schmidbauer CP, Marberger M. Age related urodynamic 
changes in patients with benign prostatic hyperplasia. J Urol 1996;156 :1662-7.
69. Ball AJ, Smith PJ. The long-term effects of prostatectomy: a uroflowmetric analysis. J Urol 1982;128 :538-40.
70. Schacterle RS, Sullivan MP, Yalla SV. Combinations of maximum urinary flow rate and American Urological 
Association symptom index that are more specific for identifying obstructive and non-obstructive prostatism. 
Neurourol Urodyn 1996;15:459-70.
71. McConnell JD. Why pressure-flow studies should be optional and not mandatory studies for evaluating men 
with benign prostatic hyperplasia. Urology 1994;44 :156-8.
72. Abrams P. Objective evaluation of bladder outlet obstruction. Br J Urol 1995;76 :5-10.
112
LOW FEASIBILITY OF UROFLOWMETRY IN GENERAL PRACTICE
SECTION III
The implementation of clinical guidelines
 

CHAPTER 6
Effects of distance learning on clinical management of 
LUTS in primary care: a randomised trial 
René Wolters
Michel Wensing
Maarten Klomp
Toine Lagro-Jansen
Chris van Weel
Richard Grol
Patient Education and Counseling (in press)
116
IMPLEMENTATION: EFFECTS ON CLINICAL MANAGEMENT IN GENERAL PRACTICE
117
CHAPTER 6
Abstract 
Objective
To determine the effect of a distance learning programme on general practice management of men 
with lower urinary tract symptoms (LUTS).
Subjects and methods
A cluster randomised controlled trial was performed. General practitioners (GPs) were randomised 
to a distance learning programme accompanied with educational materials or to a control 
group only receiving mailed clinical guidelines on LUTS. Clinical management was considered as 
outcome.
Results
Sixty-three GPs registered care management of 187 patients older than 50 years attending the 
practice because of LUTS. The intervention group showed a lower referral rate to a urologist 
(OR 0.08 (95% CI: 0.02-0.40)), but no effect on PSA testing or prescription of medication. PSA 
testing tended to be requested more frequently by intervention group GPs. Secondary analysis 
showed patients in the intervention group received more educational materials (OR 75.6 
(95% CI:  3.60-419.90)).
Conclusions
The educational programme had impact on clinical management without changing PSA testing. 
Distance learning is an promising method for continuing education. Practice implications: 
Activating distance learning packages are a potentially effective method for improving professional 
performance. Emotional matters as PSA testing probably need a more complex approach.
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INTRODUCTION 
In order to optimise clinical care several countries developed guidelines on LUTS.1;2 
Guidelines developed by the Dutch College of General Practitioners recommend 
detailed history taking, without using symptoms scores or voiding dairies. Digital rectal 
examination (DRE), percussion of the bladder and urine analysis are considered as good 
clinical practice. A serum creatinine is limited to patients with suspicion of renal failure 
and PSA testing is restricted to few conditions (family history of prostate carcinoma, 
inconclusive DRE, start of medication for LUTS and a life expectancy of more than 10 
years). In patients with bothersome symptoms who are not able or willing to have surgical 
treatment the medication of choice is an a-blocking agent, where 5α-reductase blockers 
are reserved for specialist care. Referral should be considered in men with complicated 
LUTS.3;4 
With an ageing population and a rising public awareness of the prostate there is a growing 
demand for care of LUTS. The introduction of a-blocking medication created a shi� of the 
diagnosis and management of LUTS from the specialist to the primary care physician in 
various countries.5-10 Although there is no relation between LUTS and prostate cancer,11 
LUTS are in the perception of many patients related to the carcinoma of the prostate, 
leading to patient requests for PSA testing in primary care, notwithstanding the benefits 
of PSA are still an item of debate.12-15 Despite the guideline a study in a non random sample 
of GPs showed that PSA was tested in 64.9% of all patients with voiding problems and 
this number is rising.16;17 Sorum recently found three factors predicting the likelihood of 
ordering a PSA: possible regret over not ordering a PSA for a patient subsequently found 
to have advanced cancer, interpretation of guideline recommendations and diagnostic 
uncertainty.18 Preparatory interviews with 20 GPs on possible facilitators and barriers 
for changing routines suggested that fear of prostate cancer by patient and GP was an 
important factor associated with PSA testing. PSA testing is presented in the media as a 
valid screening test and informing the patient on its true nature is time consuming. 
From these interviews we extracted targets for behavioural change (for instance fear of 
cancer was addressed by information on absence of the relation between LUTS and prostate 
cancer). Given the relative low priority of the subject for GPs, we needed a simple, relevant, 
easy to participate, educational programme aimed at encouraging physicians to inform 
patients and facilitate shared decision making.3;19;20 Just sending recommendations showed 
conflicting results,21 so we developed a comprehensive distance learning programme based 
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on the package for individual learning (PIL) which comprises the core of implementation 
activities of the Dutch College of General Practitioners. Recently published trials on the 
eff ect of distance learning22 and consultation supporting materials19;23;24 have shown eff ects 
on self rated competence and care delivered, respectively. 
A study was performed to determine the eff ect of this distance learning programme on 
general practice care for LUTS patients older than 50 years.
SUBJECTS AND METHODS 
We performed a cluster randomised trial, which was approved by the research ethics 
commi� ee. Allocation of the GPs to the intervention or control group was done by an 
independent statistician who delivered computer-generated random numbers. The 
intervention group of GPs received the educational programme with distance learning 
and the control group received a standard set of guidelines on LUTS (which is available to 
all Dutch GPs3;4). Both groups were blinded for the intervention in the other group. Patients 
were also blinded for the intervention. A� er fulfi lling the intervention (April 2001) GPs 
were instructed to recruit patients until June 2002.
  142 GPs showed interest and were randomly allocated
72 GPs control group
Figure 1: Flow chart
70 GPs intervention group
GP guideline and shared care guideline: 4 
points of special relevance in the guideline 
were noted and returned to the research 
institute
31 GPs in control group recruited 
92 patients
44 GPs control group returned notes
32 GPs in intervention group recruited
 95 patients
GP guideline, shared care guideline with PIL 
(fi lled in PIL was asked to return to research 
institute), decision tree, I-PSS, BS, voiding diary, 
patient information leafl ets 
45 GPs intervention group returned PIL
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SUBJECTS 
One hundred forty two GPs showed interest and were allocated to one of the two groups: 
70 to the intervention group and 72 to the control group (Figure 1). All LUTS patients of 
older than 50 years visiting the GP were considered (note that voiding problems not a 
request for PSA testing defi ned our population). Exclusion criteria were: terminal phase 
of a disease, cognitive problems, known prostate carcinoma, a ureterostomy or bladder 
catheterisation. All others were invited and those giving informed consent formed the 
research group. 
LUTS were defi ned according the guideline for GPs: persistent change in urination 
manifesting itself as diffi  culty in starting urination, weak fl ow, dribbling, urge, feeling of 
retention and/or increased frequency of urination during the day and night.4
INTERVENTION 
All materials were sent by mail. The distance learning programme comprised (1) a package 
for individual learning (PIL) developed by the Dutch College of General Practitioners, (2) 
consultation supporting materials: a voiding diary, the international prostate symptom 
score (I-PSS) and Bother score (BS), (3) the guideline summarised into two decision trees 
(one on clinical management of LUTS and one on PSA testing (Figure 2)) and a brief 
  Man with LUTS
Aged between 
50 and 70 years
Figure 2: Decision tree on PSA testing
PSA not 
recommended
Normal DRE
Prostate 
carcinoma within 
1st or 2nd line of kin
PSA not 
recommended
Consider: 
PSA-testing and/
or referral to a 
urologist
Annually DRE 
and PSA-testing
PSA-testing
Considering 
medication for 
LUTS 
YESYES
YES YES
NO
NO NO
NO
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explanation and (4) two information leaflets for patients (on PSA testing and on treatment 
for LUTS). The PIL booklet consisted of a guideline based,4 interactive knowledge test 
(duration < 2 hours); answers to questions on key issues were sent to a central institute and 
a standard set of correct answers were returned to as feedback (Box 1). 
The control group of GPs received the existing national guidelines on LUTS. They were 
asked to study these documents, note down four points they found especially relevant and 
send them to the research institute in an envelope provided. 
MEASURES 
Primary outcomes were the number of PSA requests, medication prescribed and the 
referral rate to a urologist. Secondary outcome measures were: use of symptom scores, 
physical examination, laboratory tests, life style advice given, distribution of patient 
information leaflets and duration of the consultation. 
Clinical management was evaluated by prospective recording of patient data and 
management immediately a�er consultation with an eligible patient.25 A structured 
form was designed to document GP management and contained items on history taking 
(15 possible items), physical examinations (DRE, percussion of the bladder), additional 
Box 1: Contence of the Distance Learning Programme
Enhancement of knowledge:
• Two documents as background information (‘Benign prostatic hyperplasia; recommendations for 
transmural care’3 and ‘Dutch College of General Practitioners guidelines on Lower urinary Tract 
Symptoms’4)
• Package for Individual Learning (PIL): (Small booklet , 28 pages, 2 hours work)
o Eight open questions reflecting on a recent male patient attending surgery with LUTS
o Fourteen open questions on the clinical management of hypothetical 4 cases
o Eight true/false statements on clinical management of LUTS
o Six open questions on statements about (fear of) prostate cancer
o Six open questions reflecting possible barriers around bladder catheterisation in case of acute urinary retention
Consultation supporting materials:
• Dutch College of General Practitioners guidelines on Lower urinary Tract Symptoms summarised on an A5 
format card.
• The guideline summarized in two decision trees:
o Clinical management of a patient with LUTS
o Indications for PSA testing
• International Prostate Symptom Score (I-PSS)
• Bother Score (BS)
• Voiding dairy
Patient information leaflets (each about 900 words):
• On causes of LUTS and treatment options
• On prostate carcinoma in relation to LUTS and the limitations of PSA-testing
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testing (creatinine, PSA, urine sample, voiding list), information provided (life style advice, 
information leaflets, discussion of therapy options) and therapy (medication, referral to a 
urologist). 
A�er the consultation, patients filled in a questionnaire to obtain data on age, educational 
level, duration of complaints and symptom level (I-PSS, BS). They returned the 
questionnaire in a pre-stamped envelope to the research institute. 
POWER 
The trial was designed to detect a 20% difference in adherence to the guidelines, particularly 
a decrease in PSA requests from 80 to 60% (α = 0.05, power = 0.80, icc = 0.05). A total of 180 
patients from 60 GPs were needed, assuming that they would be able to recruit an average 
of three patients each. Anticipating a loss to follow up of 30%, the aim was to include 86 
GPs. 
ANALYSIS 
The unit of analysis was the patient. Age, duration of symptoms, I-PSS and BS were 
handled as continuous variables, while all others were dichotomous. Missing data 
were considered to be a negative answer (‘not performed’ or ‘not present’). The analysis 
compared intervention and control group with respect to outcome measures. Odds ratios 
were calculated with logistic regression analysis, with P< 0.05 as the level of statistical 
significance. Separate analyses were performed for a number of dependent variables 
reflecting professional performance (Table 3). Independent variables in these models 
were group allocation, I-PSS, BS and age. For data analysis we used SPSS (version 10.0). 
Cluster effects due to randomisation were corrected for by a multi level analysis in SAS 
(version 6.12) with the GLIMMIX MACRO procedure. 
RESULTS 
The educational programme was completed by 89 of the GPs; 63 GPs (31 GPs in the 
intervention group and 32 GPs in the control group) were able to recruit patients (Figure 1). 
GPs in both groups studied were comparable (Table 1). A non-response analysis was 
performed on the 79 GPs who did not complete the educational programme or recruit 
patients. No differences were found (regarding age, gender, practice se�ing (practice size, 
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Table 1: Characteristics of the GPs (absolute numbers and percentages between brackets; OR = odds ratio)
Total
(n = 63)
Intervention
(n = 31)
Control
(n = 32)
OR (95% CI)
Mean age (SD) 47.4 (6.5) 47.7 (7.2) 47.1 (5.8) 0.98 (0.91-1.06)
< 45 years of age 18 (28.6) 9 (28.1) 9 (29.0) 1.05 (0.35-3.12)
< 15 years working as GP 28 (45.0) 14 (46.7) 13 (43.3) 0.93 (0.35-2.52)
Male 47 (74.6) 25 (78.1) 22 (71.0) 0.68 (0.22-2.14)
GP trainer 22 (35.5) 12 (37.5) 10 (32.3) 1.26 (0.45-3.56)
Solo practice 18 (28.6) 8 (25.0) 10 (32.3) 0.70 (0.23-2.10)
(Urbanised) rural area 29 (46.8) 16 (50.0) 13 (43.4) 0.77 (0.28-2.08)
>1 Hospital to refer to 36 (58.1) 22 (68.8) 14 (46.7) 2.51 (0.89-7.09)
Table 2: Charateristics of the patients included in the study (absolute numbers and percentages between 
brackets; OR = odds ratio)
Total
(n = 151)
Intervention 
(n = 75)
Control 
(n = 76)
OR (95% CI)
Mean age (years) (SD) 66.3 (9.0) 66.2 (8.6) 66.4 (9.4) 1.00 (0.96-1.03)
Age in categories
50-59 years (%) 39 (25.8) 17 (22.7) 22 (28.9) 1.05 (0.74-1.49)
60-69 years (%) 58 (38.4) 31 (41.3) 27 (35.5)
70-79 years (%) 43 (28.5) 22 (29.3) 21 (27.6)
≥ 80 years (%) 11 (7.3) 5 (6.7) 6 (7.9)
Education
Lower (%) 58 (38.5) 25 (33.3) 33 (43.4) 125 (0.89-1.75)
Secondary (%) 47 (31.1) 25 (33.3) 22 (28.9)
Higher (%) 35 (23.2) 18 (24.0) 17 (22.4)
Unknown (%) 11 (7.3) 7 (9.3) 4 (5.3)
Symptoms
Duration >1 year (%) 80 (54.8) 40 (57.1) 40 (52.6) 1.03 (0.54-1.95)
Mean I-PSS (SD) 14.9 (7.5) 14.3 (7.8) 15.5 (7.2) 0.98 (0.94-1.02)
Mean Bother Score (SD) 3.1 (1.1) 3.0 (1.0) 3.2 (1.2) 0.84 (0.63-1.13)
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urbanisation, computerisation, GP-trainership) and a�itude towards (LUTS) guidelines). 
During the study 187 patients were recruited; 151 returned their questionnaire (Table 2).
DIAGNOSTIC PROCEDURES 
No differences were found in history taking and diagnostic procedures (Table 3). A 
symptom score was used in about one out of five consultations despite distribution of the 
I-PSS in the intervention group. The voiding list, distributed as part of the intervention, 
was used in one out of eight consultations in the intervention group. 
The GPs performed a digital rectal examination (DRE) in 82.4%, percussion of the 
bladder in 29.4% and PSA testing was requested in 50.3% of the consultations. Although 
the PIL intended to increase GP’s and patient’s awareness of the implications of PSA 
testing, PSA tests were requested 17.6% more o�en in the intervention group (Table 3). A 
considerable portion of the patients (33.9%) in the intervention group influenced the GP’s 
Table 3: Clinical management of voiding problems in the study period (absolute numbers and 
percentages between brackets; OR = odds ratio corrected for clustering)
Total
(n = 187)
Intervention
(n = 95)
Control
(n = 92)
OR (95% CI)
Diagnostic procedures
I-PSS measured 38 (20.3) 22 (8.6) 16 (17.4) 2.92 (0.53-16.04)
Voiding list used 16 (8.6) 12 (12.6) 4 (4.39) 5.68 (0.61-53.27)
DRE 154 (82.4) 75 (78.9) 79 (85.9) 0.61 (0.21-1.75)
Percussion of the bladder 55 (29.4) 26 (27.4) 29 (31.5) 0.76 (0.27-2.14)
Serum PSA 94 (50.3) 56 (58.9) 38 (41.3) 2.04 (0.87-4.77)
Serum creatinine 64 (34.2) 37 (38.7) 27 (29.3) 1.43 (0.51-4.01)
Urine analysis 119 (63.6) 54 (56.8) 65 (70.7) 0.55 (0.30-1.00)
Counseling and treatment
Lifestyle advice given 110 (58.8) 58 (61.1) 52 (56.5) 1.32 (0.48-3.63)
Consultation >15 minutes 15 (8.0) 11(11.6) 4 (4.3) 3.14 (0.52-18.86)
Wait and see policy 115 (61.5) 61 (64.2) 54 (58.7) 1.47 (0.66-3.28)
α-blocking medication 57 (30.5) 30 (31.6) 27 (29.3) 0.92 (0.35-2.41)
Finasteride 5 (2.7) 3 (3.2) 2 (2.2) 1.47 (0.24-8.99)
Referral to urologist 15 (8.1) 2 (2.1) 13 (14.1) 0.08 (0.02-0.40)
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decision and the GP seemed to perceive patient’s fear of cancer more o�en (32.1%) as a 
motivating factor (Table 4). 
According to guidelines PSA testing should be limited to certain indications.3;4 In our 
study the indications to test PSA were met by 69 patients (intervention = 39, control = 30): 
85.6% were considered to have a life expectancy of at least 10 years; 6.3% of these patients 
had a positive family history; 13.8% an inconclusive DRE and 28.1% were receiving 
medication. The PSA test was ordered in 26 patients of the intervention group (66.7% of 
the patients with an indication) and in 15 of the controls (50.0% of the patients with an 
indication) (χ2: P = 0.16). In total 118 patients in our study had, according to the guideline, 
no indication; in 44.9% of these patients a PSA test was requested (intervention: 53.6%, 
control: 37.1% (χ2: P = 0.07)). 
COUNSELLING AND TREATMENT 
The intervention decreased the number of referrals (OR 0.08) and had no other significant 
effects (Table 3). Life style advice was given in about 58.8% of the visits. Consultations 
longer than 15 minutes tended to occur more frequently in the intervention group 
(P = 0.066). A future consultation was planned in two thirds of the visits in both groups. 
In the intervention group, patient education leaflets were used in 51.6% of the contacts, 
compared to 7.6% in the control group (OR 75.5). 
In 61.5% of the patients a watchful waiting policy was followed. Medication was prescribed 
to a third of the patients; the majority received an α-blocker. Plausible indications for referral 
mentioned in the guidelines include: bothersome LUTS and the patient’s wish for surgery, 
Table 4: Reasons for PSA request as stated by the GP (absolute numbers and percentages between brackets; 
OR = odds ratio)
PSA requests recorded
Total
(n = 94)
Intervention
(n = 56)
Control
(n = 38)
OR (95%CI)
PSA request influenced by 
the patient
23 (24.7) 19 (33.9) 4 (10.8) 2.98 (0.78-11.44)
Reason for PSA testing
As a routine 26 (27.7) 15 (26.8) 11 (28.9) 1.02 (0.32-3.25)
Inconclusive DRE 21 (22.3) 11 (19.6) 10 (26.3) 0.66 (0.17-2.58)
GP is anxious about cancer 26 (25.0) 14 (25.0) 12 (31.6) 0.97 (0.20-4.75)
Patient is anxious about 
cancer
24 (25.2) 18 (32.1) 6 (15.8) 2.24 (0.60-8.42)
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or complicated LUTS. One or more of these factors were present in 44 patients in our study 
group (18 patients in the intervention group and 26 in the control group, P =  0.133). 
DISCUSSION
Our simple distance learning educational programme, aimed to change GP management 
of men with LUTS, effectively decreased the number of patients referred to a urologist and 
increased the number of patients provided with educational materials. We also intended 
enhance evidence based decision on PSA testing by providing the GP with tools to inform 
the patient about the (dis)advantages of this test. Although not significant, there were some 
indications of an unintended increase in the number of test requests. Also, the consultation 
time tended to increase. Other aspects of LUTS management did not change. 
The few randomised trials which have been conducted using distance learning 
programmes did not measure effects on daily patient management.22;23 Our study was a 
cluster randomised trial on GPs, not being part of a research network, delivering daily 
care to unselected patients during more than a year. This care was recorded with a method 
reflecting actual care.25 The intervention itself was simple, flexible, not time consuming 
and considered pleasant by participating GPs. It did not require changes in practice 
infrastructure. 
The study was limited since a prospective pre-intervention measurement was not 
feasible considering the low incidence of LUTS in general practice. Another limitation 
is the fact that we were able to collect data on 63 GPs of the original 142 we intended to 
educate. Fi�y-three GPs terminated their participation to the study, this may be due to 
the collectively experienced workload of the Dutch GPs and their conflicts with health 
insurance companies during the study period. Our strategy registering normal daily care 
caused a further loss to evaluation of 26 participating GPs, who where motivated, but not 
able to include patients during the study. Furthermore, some clinical relevant outcomes 
(consultation time and PSA request) did just not reach significance which may be caused 
by the sample size. 
Fear of prostate cancer in patients with LUTS is a motivating factor to visit the GP26;27 and 
patients believe PSA testing offers health benefits.28 Amongst GPs possible regret over not 
ordering a PSA and diagnostic uncertainty factors appeared to predict the likelihood of 
ordering a PSA.18 Our distance learning intervention provided the patient and GP with 
information to make a balanced choice. Earlier published data showed that this positively 
influenced patient evaluation of care and improved patients coping with LUTS.29 GPs 
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in our intervention group tended to request more o�en PSA testing; suggesting that the 
intervention did not reduce the fear of missing prostate carcinoma by not performing 
PSA testing. Chapple found many patients were only told the implications of PSA testing 
a�er a positive result and underlined the importance of making an informed decision.28 
Another study with self selected patients showed that a decision aid on PSA increased 
knowledge, but did not decrease the number of tests.30 Studies on unselected populations 
without LUTS showed a decreasing effect of decision aids on PSA testing.31;32 A paper on a 
qualitative analyses of patient rational showed that underlying believes and prior testing 
influenced intentions towards testing more than weighing of communicated risks and 
benefits.33 So in our study, having prostate related complaints, patients may have already 
made up their minds before a�ending surgery and the information received on PSA 
testing reinforced their decision. 
Without significant differences in the distribution of possible indications for referral, fewer 
patients in the intervention group were referred to a urologist; suggesting GPs in the 
intervention group were more confident about managing patients with LUTS themselves. 
This may explain the trend towards a longer consultation time. A recent study on a 
computerised multimedia decision aid to educate patients with LUTS about treatment 
choices has shown an increase in patient participation in the decision process, without 
changing the number of specialist consultations.19 Alternatives for educating the GP like 
providing computerised support for a GP’s decision appeared to involve many barriers for 
daily practice.34 
Our intervention showed changed GP management in terms of a decrease in the 
number of referrals and an increase in the provision of educational materials to patients. 
Implementing rational PSA testing appears to be a complex and emotional subject with 
regard to fear of (missing) cancer and may need a different approach. 
Although wri�en educational materials have limited effects,35 distance learning is 
particularly useful for GPs who live in remote or rural areas.36 Even in a densely populated 
area such as The Netherlands, it can also serve a useful purpose, because of its flexible 
use in time. In general practice, various disorders are thought of as being ‘small’ (low 
incidence/low priority); in these cases self-education could play a role as the method is 
known to be effective. Just sending materials does not alter the emotions of the patient or 
the doctor. Although, Dutch guidelines on PSA testing are evidence based, they might be 
too strict for application in daily care. Guidelines in other countries emphasize the need 
for well informed decision making, rather than whether or not PSA is actually tested. 
Postponing or even refraining from referral to a urology specialist may mean greater cost 
efficiency. 
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Abstract 
Objective
To determine whether a distance-learning programme on LUTS provided to the general practitioner 
(GP) affected patient self-management
Subjects and methods
A randomised trial was performed to examine the effects of the distance-learning programme 
(an educational package for the GP and a patient information leaflet) compared with written 
guidelines on LUTS mailed to the GP. In 63 general practices (32 intervention and 31 control) 
across the Netherlands all patients older than 50 years presenting LUTS for the first time were 
invited to participate. Main outcome measures were patient evaluation of quality of care received 
and perceptions of enablement
Results
A total of 151 patients was included. The intervention increased patient enablement regarding 
maintenance of independence (OR 3.14) and coping with illness (OR 2.21). Overall enablement 
scores were not changed. Patients in the intervention group had more positive evaluations of 
general practice care received (OR 2.28 to 3.95). An explorative analysis suggested that the effects 
of the intervention were mediated in particular by handing out of patient information leaflets.
Discussion
A distance-learning programme on LUTS for GPs had positive effects on patient self-management. 
Handing out leaflets appeared to be a crucial mediating factor.
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INTRODUCTION 
Lower Urinary Tract Symptoms (LUTS) are bothersome, but generally not life-threatening. 
This chronic condition is common among men in the age group of 50 years and older. 
The clinical management of these complaints can be difficult.1 A fear of carcinoma of the 
prostate and whether or not to test for prostate specific antigen (PSA) have to be dealt 
with.2;3 In the management of patients with LUTS it is considered to be important to involve 
the patient in making decisions based on his own preferences and needs.4 Consequently, 
patient education and shared decision-making based on the available research evidence 
are crucial for the adequate management of LUTS and for helping patients to cope with 
their illness. 
A patient’s decision to seek medical care for LUTS is, apart from the severity of his 
complaints, also driven by factors such as advice from people in his environment and 
information from the media.5 Those who seek medical advice have specific expectations 
about the provision of information on their complaint and its management.6 Patients are 
increasingly involved in the management of their illness and health care providers should 
support them in this role.7 This implies that patients should be educated in problem 
solving skills in order to promote self-management.8 Patient enablement reflects patient 
reported effectiveness of the practitioners’ efforts to enhance self-management.9;10 
Recently published trials on the effects of distance learning11 and consultation support 
materials12-15 have found effects on the self-rated competence of the primary care 
physician and the care delivered, respectively. We developed a comprehensive, activating 
distance-learning programme that aimed to encourage primary care physicians not only to 
improve their knowledge on LUTS, but also to change their professional performance and 
support communication with the patient about the subject. This study aimed to examine 
its effects on patient outcomes, particularly patient enablement and patient evaluation of 
care.
SUBJECTS AND METHODS 
In a cluster randomised trial one group of GPs received the multifaceted distance-learning 
programme (the intervention group) and the other group received a standard set of 
guidelines on LUTS16;17 (control group) by mail. A�er the intervention was delivered 
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(April 2001), GPs were instructed to recruit prospectively patients presenting at their 
surgery for the fi rst time with LUTS over a period of 15 months. The GPs were blinded 
for the intervention in the other group and patients were not aware of the content of 
the intervention. Allocation of the GP to an intervention or control group was done by 
computer generated random numbers provided by an independent statistician. The 
project received approval from the research ethics commi� ee. 
SUBJECTS 
Across the Netherlands 142 GPs were randomly allocated to one of the two groups 
(Figure 1). All patients visiting the GP’s regular surgery hours with complaints of LUTS and 
older than 50 years were considered (note that voiding problems and not a request for PSA 
testing defi ned our population). Patients were excluded if they were: in a terminal phase 
of a disease, unable to complete a questionnaire because of cognitive problems, known to 
have a prostate carcinoma, a ureterostomy or depending on bladder catheterisation. All 
others were invited and those giving informed consent comprised the study group.
  142 GPs showed interest and were randomly allocated
72 GPs control group
Figure 1: Flow chart
70 GPs intervention group
GP guideline and shared care guideline: 4 
points of special relevance in the guideline 
were noted and returned to the research 
institute
31 GPs in control group recruited 
92 patients
44 GPs control group returned notes
32 GPs in intervention group recruited
 95 patients
GP guideline, shared care guideline with PIL 
(fi lled in PIL was asked to return to research 
institute), decision tree, I-PSS, BS, voiding diary, 
patient information leafl ets 
45 GPs intervention group returned PIL
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INTERVENTION 
The distance-learning programme comprised (a) a Package for Individual Learning 
(PIL) developed by the Dutch College of General Practitioners (NHG), as well as (b) 
consultation support materials: a voiding diary, the International Prostate Symptom Score 
(I-PSS) and Bother Score (BS), (c) LUTS guideline16 converted into a decision tree with a 
brief explanation and (d) two patient information leaflets (one on PSA testing and one 
on treatment for LUTS). The PIL consists of an interactive knowledge test based on the 
LUTS guideline.16 GPs were asked to go through all the questions as presented in the PIL; 
questions on key issues of LUTS had to be send to a central institute; the correct answers 
were then sent to the respondents as feedback. The control group was provided with the 
existing national guidelines16;17 on LUTS only. They were asked to read these documents 
and write down four points that they had found particularly relevant and send them to the 
research institute in the envelope provided. All materials were directed to the physicians 
and it was le� up to the physician whether or not materials were used. 
MEASURES 
Outcome was measured on patient level. Patients were asked to fill in a questionnaire 
a�er the consultation and send it in a pre-stamped envelop to the research institute. 
Patient’s evaluation of the care received and experience of being enabled to cope with the 
complaints were the main focus of the study. A validated patient questionnaire was used 
to measure patient’s evaluations of care.18 Questions were related to communication and 
patient involvement (3 items), support (2 items), medical care (2 items) and information 
(3 items) (Table 2). An adapted version of a six-item patient enablement instrument was 
used to measure the level to which patients were able to cope with their symptoms 
(Table 3).19 Additional measures were patients’ perception of their complaints (‘Bother 
Score’ (BS)) and their preferences a�er the consultation regarding additional diagnostic 
procedures and surgery. 
Patient variables (age, educational level, duration of complaints, symptom level 
(International Prostate Symptom Score (I-PSS)) and management received) were recorded 
as well by the patient questionnaire. Factual information on the care delivered (diagnostic 
procedures (DRE, PSA), counselling and treatment (lifestyle advice, information leaflets, 
medication and referral)) was obtained from the GPs’ records of their management. 
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POWER 
A medium effect, which was expected to be clinically relevant,20;21 regarding patient 
enablement or evaluation of care required a total of 138 patients from 46 GPs (α = 0.05, 
power = 0.80, icc = 0.05). 
ANALYSIS 
The unit of analysis was the patient. All variables (except for age, duration of complaints 
and I-PSS) were dichotomised. Where possible, missing items were accounted for as a 
negative answer (‘not applicable’). Missing answers to the separate items of the patient 
evaluation of care questionnaire and the adapted patient enablement instrument were 
excluded from the analysis. Patient evaluation of care scores were obtained by adding all 
the items assigned the score ‘good’. Scores could range from 1 to 10. The enablement scores 
were calculated by adding the separate items (‘be�er/more’ scored as 1, ‘much be�er/much 
more’ as 2). Scores could range from 0 to 12.19 Patients who filled in less than half of the 
items were excluded from calculating scores. 
The effect of the intervention on patient evaluation of care and patient enablement were 
the primary outcome measures. Analysis of the effectiveness of the intervention, corrected 
for a cluster effect by multi level analysis, was done in SAS (version 8.0) with the GLIMMIX 
MACRO procedure (dichotomous variables) and the PROC MIXED procedure (continuous 
variables). In this analysis, corrections were made for other possible prognostic factors, 
such as age, I-PSS and BS (older patients tend to be more positive about their care provider, 
while patients with a poorer health status tend to be more negative;22 age was found also 
to affect the enablement instrument)19 (Tables 2 and 3). The effect of the intervention on the 
degree to which the patients perceived their complaints as bothersome and their wishes 
regarding additional tests and surgery were also corrected for cluster effects. 
On data at baseline significance was calculated with Students t-test and χ2-test analysis 
using SPSS (version 10.0). P< 0.05 was taken as the level of statistical significance. 
Finally, we performed explorative analyse (GLIMMIX MACRO and PROC MIXED) to 
identify factors which may have affected the study outcomes. Factors considered in the 
analyses included the intervention (PIL), patient factors (age, I-PSS, BS), PSA testing, 
patient education (use of information leaflets, lifestyle advice) and treatment chosen 
(prescription of medication, referral to a urologist). 
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RESULTS 
POPULATION CHARACTERISTICS 
A total of 89 physicians actually participated in the study, 63 of those (32 in the intervention 
group and 31 in the control group) were able to recruit patients (Figure 1). A non-response 
analysis was performed on the physicians who did not complete the educational programme 
or recruit any patients. No differences were found (regarding age, gender, practice se�ing 
(e.g. number of GPs at the practice, urbanisation, computerisation, GP trainership) and 
a�itude towards (LUTS) guidelines). The physicians recruited 187 patients; 151 (81%) of 
them returned their questionnaires. 
The patients in the two groups were comparable at baseline, with an average age of 
65 years, equal variation in educational level and a mean I-PSS of 15. About half of the 
patients had experienced LUTS for more than a year (Table 1). In the physicians records of 
their management no significant differences were found between the two patient groups, 
except for a higher number of information leaflets handed out (OR 11.5) and a lower 
number of referrals to a urologist a�er the initial consultation (OR 0.09) in the intervention 
group. 
Table 1: Baseline charateristics of the patients included in the study
Total
(n = 151)
Intervention
(n = 75)
Control
(n = 76)
Mean age [SD] 65.2 [8.7] 65.2 [8.6] 65.2 [8.8] P = 0.98 a
Education
Lower education (%) 58 (38.5) 25 (33.3) 33 (43.4) P = 0.55 b
Secondary education (%) 47 (31.1) 25 (33.3) 22 (28.9)
Higher education (%) 35 (23.2) 18 (24.0) 17 (22.4)
Unknown (%) 11 (7.3) 7 (9.3) 4 (5.3)
Complaints
Duration >1 year (%) 80 (54.8) 40 (57.1) 40 (52.6) P = 0.93 a
Mean I-PSS [SD] 14.9 [7.5] 14.3 [7.8] 15.5 [7.2] P = 0.33 a
a Student’s t-test b χ2-test
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PATIENT EVALUATION OF CARE 
The total score on the patient evaluation questionnaire showed that the patients in the 
intervention group (mean score = 5.48; SD = 3.13) were more satisfied than the controls 
(mean score 4.01; SD = 3.22) (size of effect: 1.47 (95% CI: 0.39- 2.55)). Significant differences 
were found between the patients in the two groups on four out of the ten items in the 
patient evaluation instrument. Patients in the intervention group more o�en felt they had 
been involved in thinking about their complaints (OR 2.28). They were more satisfied 
about the information given on the management of their complaints (the physician had 
communicated his intentions (OR 3.48) and clearly explained the treatment (OR 2.57)). 
They were convinced more that the treatment they received helped to decrease their 
complaints (OR 3.95) (Table 2). 
PATIENT ENABLEMENT 
More patients in the intervention group felt that they were able to cope with their illness 
(OR 2.21) and maintain their independence (OR 3.14). There were no significant differences 
in the other items in the patient enablement instrument between the two groups, or in the 
total sum score (mean score = 2.32; SD = 2.50) of the instrument. A�er the consultation half 
of the patients felt confident about their health and thought they were able to understand 
their illness (Table 3). 
OTHER PATIENT OUTCOMES 
Fewer patients in the intervention group expressed the wish for additional tests compared 
to the control group (OR 0.46 (95% CI: 0.21-0.98)). The mean Bother Score in the total 
population was 3.1 and there were no differences between the two groups. About one in 
every seven patients wanted surgery; there were no differences between the two groups. 
EXPLORATIVE ANALYSIS 
We explored whether patient education or other aspects of professional routines influenced 
the patient outcomes. Handing out information leaflets appeared to have a significant 
positive effect on patient evaluation of care and enablement. Patients who were advised 
on their lifestyle were satisfied with the way the physician had tried to reassure them, but 
despite this, they were less confident about their health than the patients who had not been 
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Table 3: Separate items of the patient enablement score filled in directly after the consultation
Patient enablement Total
Intervention 
group
Control 
group
OR corrected for 
age, I-PSS and BS
As a result of your visit to the doctor today 
do you feel you are
…able to maintain your independence 
(n = 129) a
36 (27.9) 24 (36.9) 12 (18.8) 3.14 (1.26-7.83)
…able to cope with your illness 
(n = 132) a
48 (36.4) 29 (44.6) 19 (28.4) 2.21 (1.03-4.75)
…able to help yourself (n = 130) a 27 (20.8) 17 (26.2) 10 (15.4) 2.11 (0.86-5.16)
…confident about your health 
(n = 137) a
68 (49.6) 40 (57.1) 28 (41.8) 1.92 (0.85-4.33)
…able to understand your illness 
(n = 136) a
72 (52.9) 37 (55.2) 35 (50.7) 1.21 (0.60-2.43)
…able to cope with life (n = 135) a 47 (34.8) 25 (36.8) 22 (32.8) 1.18 (0.58-2.41)
Odds ratios are calculated by multi level analysis. (men that answered with better/much better or more/much more were 
counted).  a Number of patients that answered the question.
Table 2: Separate items of the evaluation of care score filled in directly after the consultation
Evaluation of care Total
Intervention 
group 
Control 
group 
OR corrected for 
age, I-PSS and BS
To what extent did the GP
…treat your complaints in order to 
decrease them (n = 104)a
43 (41.3) 29 (58.0) 14 (25.9) 3.95 (1.70-9.15)
…tell you what he intends to do 
(n = 127)a
83 (65.4) 48 (78.7) 35 (53.0) 3.48 (1.53-7.95)
…explain the treatment in a clear 
way (n = 128)a
86 (67.2) 46 (78.0) 40 (58.0) 2.57 (1.20-5.90)
…involve you in thinking about your 
complaints (n = 122) a
63 (51.6) 37 (61.7) 26 (41.9) 2.28 (1.09-4.80)
…endeavour to decrease your 
complaints (n = 129) a
63 (48.8) 36 (55.4) 27 (42.2) 1.77 (0.86-3.64)
…reassure you about the complaints 
(n = 131)a
63 (48.1) 36 (55.4) 27 (40.9) 1.76 (0.88-3.53)
…convince you about the importance 
of following the advice (n = 131) a
75 (57.3) 41 (62.1) 34 (52.3) 1.49 (0.73-3.03)
…let you decide on the treatment 
(n = 88)a
42 (47.7) 24 (51.1) 18 (43.9) 1.34 (0.55-3.29)
…discuss treatment options with you 
(n = 126) a
65 (51.6) 33 (55.0) 32 (48.5) 1.28 (0.63-2.60)
…make you feel at ease (n = 114) a 53 (46.1) 28 (50.0) 25 (43.1) 1.20 (0.53-2.70)
Odds ratio calculated by multi level analysis (men that answered with ‘good’ were counted). 
aNumber of patients who answered the question.
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Table 4: Explorative analyses of whole population on factors affecting patient outcome
Determinants/predictors
Odds Ratio
(95% CI)
Got leaflet
Evaluation of care: To what extent did the GP
…tell you what he intends to do (n = 127)a OR: 3.97 (1.51-10.46)
…involve you in thinking about your complaints (n = 122) a OR: 3.92 (1.69-9.10)
…endeavour to decrease your complaints (n = 129) a OR: 2.46 (1.10-5.50)
…reassure you about the complaints (n = 131)a OR: 2.29 (1.03-5.07)
…make you feel at ease (n = 114) a OR: 2.82 (1.19-6.72)
Patient enablement: As a result of your visit to the doctor today do 
you feel you are
…able to cope with your illness (n = 132) a OR: 2.61 (1.20-5.70)
Got lifestyle advice
Evaluation of care: To what extent did the GP
…reassure you about the complaints (n = 131)a OR: 2.91 (1.39-6.11)
Patient enablement: As a result of your visit to the doctor today do 
you feel you are
…confident about your health (n = 137) a OR: 0.42 (0.19-0.93)
Got medication
Evaluation of care: To what extent did the GP
…discuss treatment options with you (n = 126) a OR: 0.40 (0.18-0.86)
…make you feel at ease (n = 114) a OR: 0.34 (0.14-0.82)
Got referral
Patient enablement: As a result of your visit to the doctor today do 
you feel you are
…confident about your health (n = 137) a OR: 0.17 (0.03-0.94)
Only significant (P<0.05) results are presented. a Number of patients that answered the question
advised on their lifestyle. Patients who received prescriptions for medication were less 
satisfied about the treatment options discussed during the consultation (Table 4). There 
was no relation between PSA testing and any of the outcome measures. Higher Bother 
Scores were related with a greater need for additional diagnostic procedures and greater 
preference for surgical treatment. 
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DISCUSSION 
The distance-learning educational programme that aimed to improve communication 
effectively enhanced patient self-management. Patients felt more able to cope with their 
illness and to maintain their independence. The explorative analysis suggested that the 
positive effects on patient evaluation of care and enablement were associated with the 
provision of patient leaflets in the initial consultation. Thus the intervention appeared to 
be mediated by handing out more patient education leaflets. 
Very few randomised trials have been conducted regarding distance-learning programmes. 
Available studies measured the effects on physicians (knowledge of the subject or 
management of virtual patients as outcome measures)11;12 rather than on patients. Our 
study was a cluster-randomised trial on GPs who were not in an existing research 
network. Patients were recruited prospectively for more than a year. The intervention was 
friendly (flexible, not very time-consuming (less than 2 hours) and considered pleasant by 
the participating physicians). It was multifaceted, did not require any changes in practice 
infrastructure and could be used in rural areas or by physicians with li�le time. The study 
had some limitations. A�er the intervention 26 GPs were unable to recruit any patients 
during the time of the study. And although there was a prospective inclusion of patients; 
no pre-intervention measurement was performed because of the low incidence of LUTS in 
general practice. The evaluation of complex interventions like our study may be difficult 
because of problems of identifying and reproducing the intervention.23 So whether or not 
the interactive learning as such played a role cannot be evaluated in our design of the 
study. On the other hand the handing out of patient education leaflets appeared to be a 
significant factor a�er the explorative multi level analysis. 
Few similar studies have been performed. Many previous studies on LUTS were done in a 
hospital se�ing and focused on decision making regarding (surgical) treatment of prostate 
cancer24-27 or BPH.28-30 Some studies were done in open populations or in the level of the 
initial consultation and focused specifically on PSA testing,31-36 clarifying symptoms35;37 or 
initial treatment choices.14;38 
An interactive multimedia computer programme seemed to increase patient’s participation 
and knowledge, and decreasing the decisional conflict.14 Our study tested a more complex 
intervention by providing supporting materials combined with educating the physician, 
leading to a be�er patient evaluation of care (specially on information transfer related 
items) and the feeling of being be�er enabled to maintain independence and to cope with 
their illness, without affecting their complaint level. The results of our study suggested 
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that these decision aids also work in the daily care delivered and not only in the optimal 
conditions of a clinical trial. 
The patient education leaflet as part of the intervention led to greater satisfaction in 
the evaluation of items on the transfer of information and gave patients the feeling that 
they could cope with their illness. Provision of information appeared to meet patient’s 
expectations of care and enable him to cope with his complaints. The explorative analysis 
was not able to correct for actual events during the consultation. As these leaflets may 
very well only have been used in combination with verbal patient education, giving not 
enough credit to the physician. Patients who have been prescribed medication more 
o�en stated they were feeling less at ease and were less positive about the way treatment 
options were discussed. This indicates that prescription of medication may have given 
patients the feeling of not being taken seriously. It may give an explanation to the recently 
reported rapid discontinuation of medication in newly diagnosed LUTS patients.39 Further 
research is needed to identify the exact causal mechanisms, but of the nine factors used in 
the explorative analysis PSA testing did not have any effect on the outcome measures used 
in this study. We expected items like reassurance on complaints or confidence in health 
to be related with PSA testing, since Wolf found men less confident about their health 
were more interested in having their PSA tested.34;40 But requesting a PSA test showed no 
significant relation with any of the items of the enablement, evaluation of care or the wish 
for additional diagnostic procedures. 
We conclude that the distance-learning package for GPs improved patients’ satisfaction 
with care and some aspects of their enablement. The physician can achieve optimal 
management of LUTS by being well-informed him/herself and by providing the patient 
with material that he can study for himself, whether it is a simple leaflet or an advanced 
interactive computer programme. This study showed that a combination of evidence 
based information for physicians and patients contributes to improved patient outcomes. 
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Abstract
Objective
Guidelines for primary care management of lower urinary tract symptoms in older men recommend 
shared decision making regarding the choice of treatment. This study aimed to determine the 
costs and patient outcomes of an implementation strategy to enhance uptake of these guidelines. 
The intervention comprised a distance learning programme for general practitioners, comprising 
evidence-based information, assessment of learning needs, a knowledge test, and patient education 
materials. The control group only received the written guidelines.
Material and Methods
A cluster randomised trial in 187 older, male patients compared costs and outcomes in the 
two study groups. A health care perspective was taken in the economic evaluation with a three 
month time horizon. The primary health outcome was the patient reported urinary symptoms at 
three months. Costs related to the distance learning package and the health care provided were 
considered, using undiscounted standardised prices.
Results
Patient-reported urinary symptoms at three months did not differ between the study groups. The 
mean costs per patient were € 42.71 lower in the intervention group compared to the control 
group, mainly because of a lower number of referrals to the urologist, but the 95% confidence 
intervals of the group means overlapped.
Discussion
The distance learning programme did not significantly change costs or outcomes compared to 
written guidelines, although there was a trend towards lowered costs. Studies with a longer 
follow-up period are needed.
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INTRODUCTION
The population prevalence of lower urinary tract symptoms (LUTS) in middle aged to 
elderly men is 20-30%.1 In several countries, guidelines have been developed for these 
bothersome, but not life-threatening, symptoms and pursue by large similar diagnostic 
and therapeutic care.2-6 This study is based on the Dutch guidelines on LUTS.5;7 These 
recommend PSA testing only in a few conditions, although GPs in various countries 
request PSA testing in most men with LUTS.8;9 Medication should be restricted to patients 
with bothersome symptoms who are not able or not willing to have surgical treatment. 
Referral should be considered in men with complicated LUTS. Overall, the guidelines 
recommend to involve patients in decisions on the management of the symptoms.
To implement these guidelines we used a distance learning programme for general 
practitioners (GPs), which emphasised counselling and shared decision making 
with the patient. Recently published trials on the effect of distance learning10 and 
consultation-supporting materials11;12 have shown effects on self-rated competence and 
care provision. We have reported that our distance learning programme reduced the 
referral rate to a urologist, but did not change PSA testing or prescription of medication.13 
Patient perceptions of enablement and patient evaluation of quality of care received 
improved, but effects on patient reported symptoms were not yet studied.14 The study 
presented here aimed to determine the costs and patient outcomes of the distance learning 
programme on LUTS.
MATERIAL AND METHODS
DESIGN
A cluster randomised trial was performed in which one group of GPs received the distance 
learning programme (the intervention group) and the other group received a standard 
set of guidelines on LUTS (control group). Details of the study have been reported 
elsewhere.13;14 A�er the intervention GPs were instructed to recruit patients over a period 
of 15 months. The project received approval from the research ethics commi�ee. 
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SUBJECTS
A random sample of 1500 GPs was invited by le� er to take part in the study. A total 
of 142 GPs showed interest and were allocated to one of the two groups: 70 to the 
intervention group and 72 to the control group (Figure 1). All LUTS patients of older 
than 50 years visiting the GP were considered. Exclusion criteria were: terminal phase 
of a disease, unable to complete a questionnaire because of cognitive problems, known 
prostate carcinoma, a ureterostomy or bladder catheterisation. All others were invited and 
those giving informed consent formed the research group. LUTS were defi ned according 
to the national guideline on LUTS for GPs: a persistent change in urination manifesting 
itself as diffi  culty in starting urination, a weak fl ow, dribbling, urge, feeling of retention 
and/or increased frequency of urination during the day and night.5
The trial was designed to detect a 20% diff erence in adherence to the guidelines, 
particularly a decrease in PSA requests from 80% to 60% (α = 0.05, power = 0.80, icc = 0.05). 
A total of 180 patients from 60 GPs were needed, assuming that they would be able to 
recruit an average of three patients each. Anticipating a loss to follow-up of 30%, the aim 
was to include 86 GPs.
  142 GPs showed interest and were randomly allocated
72 GPs control group
Figure 1: Flow chart
70 GPs intervention group
GP guideline and shared care guideline: 4 
points of special relevance in the guideline 
were noted and returned to the research 
institute
31 GPs in control group recruited 
92 patients
44 GPs control group returned notes
32 GPs in intervention group recruited
 95 patients
GP guideline, shared care guideline with PIL 
(fi lled in PIL was asked to return to research 
institute), decision tree, I-PSS, BS, voiding diary, 
patient information leafl ets 
45 GPs intervention group returned PIL
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INTERVENTION
The distance learning programme comprised a Package for Individual Learning (PIL) 
developed by the Dutch College of General Practitioners (NHG) with additional materials: 
(1) consultation-supporting materials: a voiding diary, the International Prostate Symptom 
Score (I-PSS) and Bother Score (BS), (2) the guideline summarised into a decision tree and 
a brief explanation and (3) two information leaflets for patients (one on PSA testing and 
the other on treatment for LUTS). The PIL booklet contains an interactive knowledge test 
based on the guideline;5 answers to questions on key issues of LUTS are sent to a central 
institute and the correct answers are returned to the sender as feedback. The control group 
of GPs received the existing national guidelines on LUTS. They were asked to study these 
documents, note down four points they found especially relevant and send them to the 
research institute in the envelope provided.
OUTCOMES AND INSTRUMENTS
Primary outcome in this study was patient reported symptom level, using the I-PSS, a 
validated instrument for urinary symptoms.16 A�er the consultation and three months 
later, patients filled in a questionnaire to obtain data on age, educational level, duration 
of complaints and symptom level. They returned the completed questionnaire in a 
pre-stamped envelope to the research institute. Clinical management was evaluated by 
prospective recording of patient data and management by practitioners immediately a�er 
consultation with an eligible patient. A structured form was designed to document GP 
management and contained items on history taking, physical examinations, additional 
testing, information provided and therapy. 
ANALYSIS
For data analysis we used the Statistical Package for the Social Sciences (SPSS) and 
Microso� Excell. The unit of analysis was the patient. The effectiveness was examined 
with t-test to compare patient-reported symptoms three months a�er the intervention, 
considering P-values of 0.05 as significant. The economic evaluation aimed to determine 
the incremental costs of the distance learning programme compared to wri�en guidelines 
for GPs in terms of patient reported symptoms. A health care perspective was taken, as 
non-medical costs (such as patient costs related to visits to the GP and absence from work) 
were assumed to be absent or minimal in this elderly population. Costs and benefits were 
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related to a three-months period a�er the initial consultation of the patient with the GP, 
which was similar to the observation period in the randomised controlled trial. It was 
planned to perform a cost-effectiveness analysis, if the intervention was effective, and a 
cost analysis, if there was no effect. 
Costs considered included material costs and GP time related to the distant learning 
programme or reading of the guidelines (both were fixed per patient), initial consultations 
(fixed on the basis of the design of the study), and costs of health care received (variable 
costs per patient). The costs of the development of the clinical guideline and educational 
programme were not included, as both had been developed for the total population of 
GPs in the Netherlands. Data on GP time and health care were based on physician reports. 
Prices referring to the year 2002 were used, based on available guidelines17-19 (see Table 4 
for a detailed description of the calculations). Discounting was not performed because of 
the short time period. The reliability of variable costs was examined with 95% confidence 
intervals, based on the observed use of resources.
RESULTS
The educational programme was completed by 89 out of the 142 GPs who showed interest 
in participating in the study while 63 GPs (31 in the intervention group and 32 in the 
control group) were also able to recruit patients (Figure 1). These GPs were comparable 
with the original sample of 1500, except for a lower number of solo practices in the study 
sample (43.1% vs 30.2%, one-way ANOVA: P = 0.034). The GPs recruited 187 patients 
during the study; 151 of them returned their questionnaires, which showed that they were 
comparable at baseline (Table 1). 
Table 2 shows the urinary symptoms at inclusion and three months. The distribution of 
scores in the population did not differ between the intervention group and the control 
group before or a�er the intervention, indicating the absence of an effect on health 
outcomes. In both groups the urinary symptoms decreased significantly. Four individuals 
developed serious symptoms between baseline and post-intervention measurement: one 
in the intervention group and three in the control group. The remaining individuals with 
serious urinary symptoms at three months a�er their initial consultation already reported 
these at baseline.
Table 3 provides an overview of the volumes and costs associated with the intervention 
and the health care provision. The mean fixed costs were higher in the intervention group 
compared to the control group (€ 51.62 versus € 44.00), mainly because of the material 
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costs related to the distance learning package. Remarkably, the GP reported time spent 
on self-study was similar in both study conditions: a total of 79.5 minutes per GP in the 
intervention group and 70.0 minutes in the control group (€ 33.47 and € 32.31 per patient, 
respectively). Health care provision was also similar between the two groups. The only item 
of health care provision, which showed significantly different volumes between the study 
groups, was the number of referrals to the urologist: this was lower in the intervention 
group. The mean costs related to health care provision was lower in the intervention 
Table 2: Patient reported lower urinary tract symptoms
Intervention Control
At inclusion (n = 151)
Minor (I-PSS: 0-7) 10 (13%) 9 (12%)
Moderate (I-PSS: 8-19) 49 (65%) 48 (63%)
Severe (I-PSS: 20-35) 16 (21%) 19 (25%)
At three months (n = 122)
Minor (I-PSS: 0-7) 15 (27%) 19 (29%)
Moderate (I-PSS: 8-19) 37 (66%) 40 (61%)
Severe (I-PSS: 20-35) 4 (7%) 7 (11%)
Note: Differences between groups were not significant (P<0.05) at baseline or at three months. An analysis of the original 
continuous scores showed the same results.
Table 1: Characteristics of the patients at baseline (absolute numbers and percentages between brackets)
Total
(n = 151)
Intervention
(n = 75)
Control
(n = 76)
Mean age (years) [SD] 66.3 [9.0] 66.2 [8.6] 66.4 [9.4]
Age in categories 
50-59 years (%) 39 (25.8) 17 (22.7) 22 (28.9)
60-69 years (%) 58 (38.4) 31 (41.3) 27 (35.5)
70-79 years (%) 43 (28.5) 22 (29.3) 21 (27.6)
≥ 80 years (%) 11 (7.3) 5 (6.7) 6 (7.9)
Education
Lower (%) 58 (38.5) 25 (33.3) 33 (43.4)
Secondary (%) 47 (31.1) 25 (33.3) 22 (28.9)
Higher (%) 35 (23.2) 18 (24.0) 17 (22.4)
Unknown (%) 11 (7.3) 7 (9.3) 4 (5.3)
Symptoms
Duration >1 year (%) 80 (54.8) 40 (57.1) 40 (52.6)
Mean I-PSS [SD] 14.92 [7.48] 14.32 [7.77] 15.51 [7.17]
Mean BS (Bother Score) [SD] 3.07[1.11] 2.96 [0.99] 3.17 [1.20]
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 Table 3: Cost analysis
Mean number of units per 
patient
Mean costs per patient (€)
Intervention 
(n=95 patients)
Control
(n=91 patients)
Intervention
 (n=95 patients)
Control
(n=91 patients)
Fixed costs
Distance learning package € 18.75 (*1) 0.42 - 7.89 -
Written guidelines € 2.50 (*1) - 0.46 - 1.15
GP self-study (minutes) € 0.75 ( *2) 33.47 32.31 25.11 24.23
Initial consultations € 18.62 (*3) 1.0 1.0 18.62 18.62
Subtotal fixed costs 51.62 44.00
Variable costs
Diagnostic tests (* 4) 
Serum PSA € 7.90
Serum creatinine € 1.35
Urine sediment € 1.35
Qualitative urine screening € 1.79
Urine culture € 2.69
0.58
0.39
0.45
0.21
0.03
0.41
0.29
0.53
0.36
0.07
4.58
0.53
0.61
0.38
0.08
3.24
0.39
0.72
0.64
0.19
Additional consultations € 18.62 (*3) 1.22 1.31 22.75 24.43
Alpha-receptor blocker € 69.65 (*5) 0.31 0.29 21.50 20.11
Finasteride € 87.32 (*5 ) 0.03 0.02 2.62 1.75
Referral to urologist € 305.50 (*6) 0.02 0.14 6.11 42.77
Subtotal variable costs 
59.15 
(34.55-88.76)
94.24
(56.90 - 131.58)
Mean total costs per patient
103.15
(78.55 -132.76)
145.86
(108.52 - 183.20)
Incremental costs per patient - -42.71
Legend:
*1 Costs of distance learning package based on price charged by the Dutch College of General Practitioners (including packaging and mailing). 
Costs of written guidelines refer to copying, packing and mailing of the guideline text. Breakdown of costs over patients based on 40 
packages in intervention group and 42 packages in control group.
*2 Volumes were based on GP reports. Answering categories: <1 hours, 1-2 hours, 2-3 hours, and >3 hours (calculations based on resp. 30, 90, 
150 en 210 minutes). Four GPs reported they have spent 2-3 hours or >3 hours. Meaningfull standard error of measurement could not 
be determined. It was assumed that GPs did not reduce the number of consultations because of the self-study and we used 40% of the 
consultation price (€ 18.62, see *3) to estimate the costs of this non-consultation time.
*3 Each included patient had an initial consultation. GPs reports on the consultation time showed that this was on average 11.1 minutes in 
the intervention group and 10.7 minutes in the control group (based on item with answering categories 0-5, 5-10.10-15, >20 min). Fifteen 
consultations were 15 minutes or longer. Follow-up consultations were based on patient reports at 3 months after the initial consultation 
(n = 116 responders). Non-responders were assumed to have had no contacts. The price per consultation was based on guideline prices 
from 1999 (Oostenbrink 2000), extrapolated to 2002 (4% inflation per year, 1 € = 2.21 guilders).
*4 Volumes were based on GP report at initial consultation. Prices were based on Diagnostisch Kompas 2000, extrapolated to 2002 
(4% inflation per year).
*5 Volumes based on GP report and prices per month were based on Farmacotherapeutisch Kompas 2001 (extrapolated to 2002 with 4% 
inflation rate). The mean costs of alpha-receptor inhibitors was estimated on the basis of patients reports on medication use at 3 months, 
which comprised 52 patients who reported on alpha-receptor inhibitors: 5 had received prazosine (€ 8.54 per month), 19 alfuzosine 
(€ 26.55), and 28 tamsolusine (€ 27.83). This resulted in a mean price of € 25.51 per month (= 4.5 weeks). It was assumed that all 
initial prescriptions were for 6 weeks, as recommended in the guideline, and that 25% discontinued drug treatment, as found in a previous 
study,21 resulting in an overall mean of 11.25 weeks. This implied overall means of € 63.78 for alpha-receptor blockers and € 81.45 for 
finasteride per treated patient. Pharmacy costs (€ 5.87) were included for initial prescriptions.
*6 Volumes were based on GP reports at initial consultation and prices on Diagnostisch Kompas 2000, extrapolated to 2002 (4% inflation 
per year). Based on clinical experience it was determined that urological care included, as a minimum, two consultations with the urologist 
and ordering of a PSA test (€ 7.90), serum creatinine (€ 1.35), uroflow test (€ 125.41) and rectal ultrasound (€ 68.62). The costs of an 
outpatient consultation was based on guideline prices from 1999 (Oostenbrink 2000) and extrapolated as in *3, resulting in a price of 
€ 45.81.
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group, but the 95% confidence intervals of the two group means overlapped. Likewise, 
the mean total costs seemed to be € 42.71 lower in the intervention group compared to 
the control group at three months a�er the initial consultation, but the 95% confidence 
intervals showed overlap.
DISCUSSION
The distance learning programme had no observable effect on patient reported urinary 
symptoms at three months a�er the initial consultation (the symptoms improved in both 
groups), while the costs per patient in the first three months tended to be lower. However, 
this reduction was not significant, so we conclude that the intervention did not change 
costs or health outcomes. 
Distance learning is a promising approach, because it seems feasible for the participants 
and involve li�le costs, but few randomised trials have been conducted to test its 
cost-effectiveness. Available studies did not measure the effects on real patients, but on 
GPs’ knowledge or management of virtual patients as outcome measures.12;13;20 Our study 
showed that the distance learning programme reduced the referral rate and tended to 
increase the number of PSA tests.13 Although ordering a PSA test is not consistent with the 
guideline, it may be psychologically necessary for not referring the patient. 
A limitation of this study was the short follow-up period. The effectiveness of treatment 
by the urologist is not measured, because of waiting times for seeing the urologist and 
delays in treatment effects (e.g. a�er surgery). On the other hand, the effect of surgery 
or medication on urinary symptoms may be limited. Also, it might be possible that some 
non-referred patients may be referred to an urologist in the near future if the symptoms 
recur. This may be acceptable, given the non-life threatening character of the urinary 
symptoms. Patients with recurring episodes were also included in our sample, so this 
factor has already reduced the intervention effect. In the total population the average 
level of symptoms improved, which suggests that many patients will not be referred. 
Nevertheless, we cannot rule out the possibility that referral to the urologist is more 
efficient in the long run for some patients. Larger trials with longer follow-up are needed 
to examine this issue.
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This thesis presented several studies related to evidence to and the implementation of 
the 1997 revision of the guideline on lower urinary tract symptoms in general practice in 
the Netherlands.1;2 The guideline development, the clinical management of LUTS and an 
implementation strategy were examined. 
This chapter summarises the most important findings and provides answers to the 
questions as formulated in the introduction. Subsequently the findings relating to other 
existing literature and main methodological issues are discussed. Finally the implications 
of the results for guideline developers, clinical practice and for policy makers are talked 
through.
MAJOR FINDINGS AND CONCLUSIONS:
THE EVIDENCE: CLINICAL GUIDELINES
According to evidence recently found in international literature the major part of the 1997 
guideline on lower urinary tract symptoms in general practice in the Netherlands was 
still appropriate. The most important change that was made in this latest revision was the 
more distinct separation of lower urinary tract symptoms from prostate carcinoma; since 
LUTS was no longer considered to increase the risk of prostate cancer. Prostate carcinoma 
was still discussed to improve the guideline’s applicability. Other changes were: the 
limited relevance to recommend bladder percussion to detect post-void urinary residue, if 
medication is considered alfuzosine and tamsulosine are preferred in general practice and 
a clearer focus on shared decision making.
In the systematic search five recently published national guidelines on LUTS were found 
and assessed for their methodological quality according to the criteria for good guideline 
development in the AGREE Instrument.3 The National Health and Medical Research 
Council (NHMRC, Australia)4 guidelines were strongly recommended for use in practice, 
the Sowerby Centre for Health Informatics at Newcastle (SCHiN, UK)5 and American 
Urologist Association (AUA)6 guidelines were recommended with provisos or alterations 
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and the Duodecim (Finland)7 and European Association of Urology (EAU)8 guidelines 
were not recommended.
The guidelines we found showed conflicting recommendations with regards to the 
diagnostic process (creatinine, prostate specific antigen and post-void residual volume). 
Diagnostic recommendations were more o�en formulated in ‘do’s’ or ‘don’ts’ than 
therapeutic recommendations. The NHMRC guideline had more ‘don’ts’ where clear 
evidence was lacking, compared to the AUA guideline, which le� some decisions ‘optional’. 
Only 11.3% of the 227 references in all guidelines occurred in more than one, and the few 
overlapping studies were partly used to underpin conflicting recommendations.
CLINICAL MANAGEMENT OF LUTS: EXPLORATION OF THE PROBLEM 
The decision to consult a general practitioner (GP) for lower urinary tract symptoms 
was explained only partly by the severity of complaints. Advice from the social network 
appeared to be the strongest predictor of GP consultations, followed by information received 
from the media. The expected improvement in the patients’ condition a�er treatment by a 
GP or a specialist, and the knowledge they perceived on voiding problems, also appeared 
to be determinants. Half of the men felt they were in need of more information about their 
condition and only a few men were convinced that their voiding problem was serious or 
related to a serious disease, regardless of whether they had a�ended the GP or not.
The clinical management of a hypothetical patient with uncomplicated LUTS by GPs and 
urologists differed in the diagnostic work up; urologists reported to order tests routinely 
as opposed to GPs. In symptom management urologist and GPs were more comparable. 
Urologists more o�en provided patients with information leaflets to support their 
explanation.
The shared-care guideline2 was be�er known to urologists than to GPs. A minority of both 
groups said to have access to a shared-care clinic on prostate problems. The availability of 
shared care seems to shi� GPs towards care management similar to a urologist: an increase 
in using I-PSS and requesting tests (creatinine and PSA), and for mild complaints a 
watchful-waiting strategy was chosen less o�en. Urologists with shared-care clinic 
facilities showed an increase in trans rectal ultrasound use and surgical interventions for 
moderate complaints.
The feasibility of uroflowmetry was tested in the daily care of 19 GPs, where 12 men with 
LUTS were recruited during 14 months. Except for two, in none of the patients the clinical 
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care was influenced by the uroflowmetry. With respect to the low number of included 
patients and the apparent absence of an effect on clinical management uroflowmetry was 
not considered as very useful in general practice.
In evaluative interviews GPs were disappointed by the low incidence of patients with 
LUTS presenting at their surgery and exclusion criteria of the patients were regarded too 
strict. GPs preferred uroflowmetry to be supported logistically by a diagnostic centre and 
the uroflowcurve should be interpreted by a specialist, since the respondents felt unable 
to an adequate interpretation. 
THE IMPLEMENTATION OF CLINICAL GUIDELINES
A�er randomisation GPs were sent either national guidelines (controls), or a distant 
learning package (comprising a package for individual learning, consultation supporting 
materials, decision trees and patient information leaflets) (intervention).
The intervention did not change history taking and diagnostic procedures. Although not 
significant, the intervention group requested 18% more o�en PSA-tests and tended to 
longer consultations. On the other hand the GPs in the intervention group decreased their 
number of referrals to the urologist because of LUTS and their patients were more o�en 
provided with wri�en educational materials.
Urinary symptoms decreased significantly in patients of both groups and the symptoms 
between the groups did not differ at inclusion and three months, indicating the absence of 
an intervention effect on health outcomes. Patients in the intervention group were more 
o�en satisfied with their consultation (were more o�en involved in thinking about their 
complaints, were more satisfied about communication on intentions and treatment and, 
were more convinced of treatment effects). Furthermore, they were be�er able to cope 
with their illness and maintain their independence. Handing out patient information 
leaflets appeared to be a crucial mediating factor in the positive effects on patient 
self-management. 
Because of the material costs related to the distance learning package the mean fixed costs 
were higher in the intervention group. The GPs reported that time spent on self-study was 
similar in both study conditions. Health care provision was also similar between the two 
groups except for the lower number of referrals to the urologist in the intervention group. 
The mean total costs seemed to be lower in the intervention group compared to the control 
group at three months a�er the initial consultation, but the difference was not statistically 
significant.
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INTERPRETATION OF FINDINGS
THE EVIDENCE: CLINICAL GUIDELINES
The latest revision of the guideline on lower urinary tract symptoms of the Dutch College 
of General Practitioners was already six years old at the time a new working group was 
composed. A revision was needed since in common opinion guidelines should be updated 
on a regular base and provide recommendations based on the best available evidence.3;9 
The update of a general practice focused guideline was in particular relevant as literature 
indicated that with the introduction of α-blocking medication, the management of LUTS 
has increasingly shi�ed from the specialist to the GP,10 and GPs require guidelines taking 
notice of a population that is different from the patients a�ending hospitals.11;12 In addition, 
public awareness on the carcinoma of the prostate is high, and in the perception of many 
patients LUTS is related to this. Among patients expectations towards the PSA test in 
preventing advanced disease are high, although this is still an issue of debate.13;14 Although 
prostate carcinoma and LUTS are not causally related, the subject of prostate carcinoma 
is still discussed in the guideline in order to improve the guideline’s acceptability and 
credibility and so increasing its effectiveness in daily practice.15
Comparative studies on guidelines until now concluded that variation was a consequence 
of the methods used to formulate recommendations (consensus versus evidence based),16;17 
cultural factors,18-20 or of the methodological quality.17;21-24 Variation in methodological 
quality were caused by more or less systematic review of the literature,17;22;23 proper 
external reviewing in the development process,21;22 a�ention to organizational barriers 
and cost implications,21;22 information on independency of developers,21 and presence of 
strategies for dissemination and implementation.17;22 The five guidelines in our study also 
showed a variability in the selection of evidence, which appeared to be less objective than 
is suggested within the concept of evidence-based medicine. Since for some selected topics, 
a certain bias in the use of evidence was found, and a few identical studies were used to 
underpin conflicting recommendations. Elements as: need for cost constraints, influence 
of patient preferences, specific professional interests and variation between health care 
systems might be as important as the evidence in formulating recommendations.15;20;25
Where Irani, et al.24 found in their study that most guidelines lacked to be explicit on 
their methods used in collecting literature; all the guidelines we found, except for one, 
accounted for their systematic search. Nevertheless only a small minority of the references 
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were used in more than one guideline. This finding is consistent with guideline studies on 
diabetes and cystitis.18;26 In that respect, it is remarkable that – despite the lack of overlap 
in references – the guidelines on LUTS provide similar recommendations on most topics 
covered by the guidelines. This might be explained by the international impact of the 
Agency for Health Care Policy and Research (AHCPR) guideline on Benign Prostatic 
Hyperplasia published in 1994,27 and the international consensus conferences on the 
clinical management of benign prostatic hyperplasia.28
GUIDELINE ADHERENCE: EXPLORATION OF THE PROBLEM 
Many men with LUTS in our survey sample were not consulting a physician because of 
their complaints. Shame and fear were already mentioned as possible explanations to non 
a�endance.29 
On the other hand non a�endance may not be beforehand a problem since LUTS are not 
life threatening. It is known that most of the symptoms reported in the open population are 
not presented to a physician.12 Patients confronted with chronic disease have a tendency 
to accommodate to their illness by changing internal standards, values and the concept of 
quality of life.30 And so, many men will also accept LUTS as a part of their ageing,31 and 
as long as there is no grave impairment of their quality of life there is no need to mobilise 
these patients.
In general, the patient who visited the GP’s surgery had more severe complaints and a 
higher interference of symptoms with everyday life and higher age.29;32-36 However, our 
study suggested that influences of the social environment were even stronger predictors 
of GP consultation than symptom severity: as a third of all the cases were advised by 
others to seek medical care. The role of the spouse was already identified as being of great 
importance in this decision,32;37 but one can also think of children and other (professional) 
caretakers.38 The media also influenced men in searching medical care. A Cochrane review 
found the mass media to be very effectively in influencing the utilisation of health services 
although studies in this field are difficult to perform.39 A recent Danish study questioned 
these effects and concluded that health items brought in the mass media were not 
remembered more o�en by patients visiting the GP compared to patients who did not.40
Most studies on variation of practice pa�erns described the management of care to 
patients with complaints of LUTS/BPH of either urologists 41-43 or GPs.44;45 We used an 
identical questionnaire in a survey among GPs and urologists and compared the clinical 
management in both populations. From the results of this study one could question 
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whether guidelines on the management of LUTS were followed by GPs in the Netherlands, 
as was also discussed in similar studies performed in other countries.41;44
It has been reported that GPs in recent years take a more active role in the diagnosis and 
management of lower urinary tract symptoms.10 Shared care as the joint participation of 
hospital consultants and GPs in the planned delivery of care for patients with LUTS is 
expected to streamline the patient evaluation and help to enhance effective management. 
Most studies published on shared care in urology were audit reports and present the effect 
of a variety of shared care clinics on the daily practice of the urologist.46-49 Regre�ably 
there were no studies comparing shared care clinics to a situation were GPs handle these 
patients. In our study we found indications that patients who run into a shared care se�ing 
risk a more ‘aggressive’ management since their GPs less o�en chose a watchful waiting 
policy in patients with mild symptoms and refer to urologists who propose surgery more 
o�en to patients with a moderate symptom level. This may support the earlier doubts of 
the efficiency of shared care clinics.50 Thomas recently published data from a randomized 
trial of an open access urological clinic and found a reduction in waiting times and an 
increase in clinical management plans at the end of the initial hospital visit. No effects 
were found in costs, symptom outcomes, psychological well being and quality of life of 
the patients.51 
Earlier studies performed with portable uroflowmeters have shown it to be a valuable 
test allowing representative flow and volume measurements at home and so giving a 
good insight into the voiding pa�erns.52;53 No studies were found reporting the use of 
uroflowmetry in daily care of the GP.
Patients and GPs participating in the study were positive about uroflowmetry in general 
practice, although their (self-)selection may have biased them. Despite the limited use of 
uroflowmetry during the study, most of them saw a future for this diagnostic method in 
general practice. This future depended on the condition that logistic management was 
provided by a laboratory and that curves would be interpreted by a specialist. The la�er 
may be a problem; since interpretation of curves is not easy (experienced urologists were 
only able to predict the actual diagnosis in a third of the cases, almost half of the normal 
flows was considered as abnormal)54 and uroflowmetry is only considered to be a valuable 
tool when patients history is taken adequately into account.55 Furthermore we found only 
half of the uroflowcurves were accessible to interpretation, which is rather low compared 
to the 82-90% found in other studies with home-uroflowmetry.52;53 These differences 
may be due to the type of instrument used since in these studies the P-Flow, a hand held 
uroflowmeter, was used instead of the Da CapoHome Uroflowmeter.
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Home-uroflowmetry is a rather expensive diagnostic method for general practice when 
considered that the GP is only interested in the Qmax in his evaluation of the patient. Studies 
on simpler methods have shown to be reproducible as well: as a 5 second home flow rate56 
and the ‘how many seconds for 100 ml. test’ 57 in combination with a voiding dairy.58
An a�empt has been made to introduce a technique new to general practice. There are a 
number of techniques available to GPs in their own practice (e.g. spirometry59;60) or on an 
open access base in a hospital (e.g. endoscopy,61 ambulatory blood pressure measurement62) 
which proved to be successful and applicable.
THE IMPLEMENTATION OF CLINICAL GUIDELINES
There are only few randomised trials that tested distance learning programmes. Effects 
on daily patient management were usually not measured; they have shown effects on self 
rated competence, knowledge of the subject or management of virtual patients as outcome 
measures.63;64 In our study we observed the effects of a distant learning programme and 
consultation supporting materials on actual clinical performance by the GP and quality of 
care perceived by the patient under normal practice conditions. An alternative approach 
– like providing computerised support for the GP’s decision – was still to be confronted 
with many obstacles in daily practice,65 but this may change in the future. 
Our most importance change in the intervention group was a decrease in the number of 
patients referred to the urologist. Other aspects of LUTS management did not change, 
although there was a trend of an increase in consultation time and number of PSA-tests 
requested. While we observed a decrease in referrals, a recent study with a computerised 
multimedia decision aid, educating men with LUTS about treatment choices, has shown 
an increase in patient participation in the decision process, but without changing the 
number of specialist consultations.66
We also intended to enhance evidence based decision making on PSA testing by providing 
the GP with tools to inform the patient about the (dis)advantages of this test. GPs in 
our intervention group tended to request more o�en PSA testing; suggesting that the 
intervention did not reduce the fear of missing prostate carcinoma by not performing PSA 
testing. Fear of prostate cancer in patients with LUTS is a motivating factor to visit the 
GP 29 and patients believe that PSA testing can offer health benefits.67 This leads to patient 
requests for PSA testing, notwithstanding the fact that the benefits of this test are still an 
item of debate.13;14 Amongst GPs possible regret over not ordering a PSA and diagnostic 
uncertainty factors appeared to predict the likelihood of ordering a PSA.68 Studies on 
unselected populations without LUTS showed a decreasing effect of decision aids on 
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PSA testing69;70 and a study with self-selected patients showed that a decision aid on 
PSA increased knowledge, but did not decrease the number of tests.71 Men less confident 
about their health were found to be more interested in having their PSA tested70 and 
underlying patients’ believes and prior testing influenced intentions towards testing more 
than weighing of communicated risks and benefits.72 In our study patients where already 
having complaints and were in a sense also a self-selected population. Moreover, the GPs 
were stimulated to provide the patient with information on PSA testing and it seems that 
this increased the number of requested tests since the information received on PSA testing 
reinforced the patient’s decision to do the test.
In our study we found limited effects of our intervention on clinical outcome, but 
patients seemed to be more enabled and more satisfied with the care they received. 
In the management of patients with LUTS it is considered to be important to involve 
the patient in making decisions based on his own preferences and needs.73 Patients are 
known to have specific expectations about the provision of information on their complaint 
and its management.74 In our patient survey we found that half of the men with LUTS 
were in search for information on their condition. Providing patients with adequate 
information is important as can also be seen in hospital studies on (surgical) treatment of 
prostate cancer75-78 or BPH.79-81 The explorative analysis suggested that the positive effects 
on patient evaluation of care and enablement were associated with the provision of more 
information (by patient leaflets) in the initial consultation. 
METHODOLOGICAL CONSIDERATIONS
A variety of research methods was used to answer the research questions posed in this 
thesis. The methods used were roughly related to the sections as presented in this thesis.
In chapter 1 results are dependent on literature available in the databases (e.g. MEDLINE, 
PubMed, Embase). Not all the questions formulated could be adequately answered due 
to absence of well performed and documented studies and many data were reflecting 
hospital populations. In concordance with the concept of guidelines made by GPs for 
GPs,11 except for one, all members of the working group were GP. A ‘professional bias’ 
was prevented by processing comments made by a patient representative and referees in 
relevant professions (3 urologists, 2 pharmacists, 1 sexologist).
In the study that compared national guidelines on LUTS we confined ourselves to 
guidelines recently published in English. Not all the relevant guidelines may have 
been identified this way. Some might have been published in ‘secondary’ literature and 
most will not be published in English or within the period searched. Our decision to 
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limit the language and time window of guideline publication was to minimize effects 
due to translation, literature available to the working groups and a current standard of 
guideline development. Recommendations were assessed on their content in relation to 
the initial management to decrease potential conflicts due to differences in point of view, 
in clinical responsibility and clinical se�ing of GP or specialist. The assessment using the 
AGREE instrument3 is depending on the quality of reporting of (the development of) the 
guideline. Current opinion is that it is important that groups presenting evidence should 
be transparent about how they reached judgements in the first place.82 
The patient survey on health care seeking behaviour in relation to LUTS in chapter 3 data 
was collected retrospectively with a 2 year horizon with the risk of a recall bias in relation 
to the cues for visiting the GP. Furthermore, registering symptoms at the time of the 
questionnaire might have caused a possible underestimation of its effect in the group who 
visited the GP, since at least some of them will have obtained treatment. A prospective 
approach, following patients from their first perception of LUTS, would have overcome 
this, but such a design was beyond the resources available for this study and we would 
have to cope with the problem that the questionnaire might have had altered patient 
behaviour.
The wri�en vigne�e used in chapter 5 can only be an abstract of the tailor-made approach 
of daily practice and results have to be judged with respect to this limitation. The response 
among GPs (55%) could evoke suspect on bias in the results, but the population studied 
showed no significant differences with data on the Dutch GP population. A possible over 
representation of GPs with special interest in urology could have caused an overestimation 
of the GPs being acquainted with shared care protocols or prostate clinics, but conclusions 
on these protocols effecting their management would probably persist.
Although the feasibility study of uroflowmetry in general practice was only carried out in 
Eindhoven this probably will not have negatively influenced study outcome; since this city 
has a relative long tradition of a diagnostic centre providing to GPs ambulatory diagnostics 
otherwise hospital based. In evaluative interviews a less strict inclusion of patients was 
suggested by the participating GPs. This would probably increase the number of patients, 
giving a be�er founded answer to the acceptability to the patient but not to it’s value as a 
diagnostic tool in general practice.
The cluster randomised controlled trial presented in the last three chapters was performed 
without pre-intervention measurement so it was not possible to document change in 
behaviour of the individual GP. In retrospect this would have given more information 
on changes in requests for PSA. Of the 142 GPs who were randomised 52 did fulfil the 
requirements for participation and another 26 GPs were not able to include patients 
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during the time of the study. We think this loss will not have influenced the results since 
the GPs were randomised and loss was similar in both groups. 
Clinical management was evaluated by the GP using self-reporting techniques immediately 
a�er consultation with an eligible patient. This technique has been used before and showed 
to be valid and alternative methods as going through the medical record can only provide 
information on a very limited set of clinical decisions.83 However, this approach may have 
influenced their performance, but this was the case in both groups.
A further point of consideration was the short follow-up period and it might be possible 
that some non-referred patients may have been referred later to a urologist a�er recurrence 
of the symptoms. In the total population the average level of symptoms improved, which 
suggests that many patients will not be referred. Nevertheless, we cannot rule out the 
possibility that referral to the urologist is more efficient in the long run for some patients. 
IMPLICATIONS AND RECOMMENDATIONS
ON GUIDELINE DEVELOPMENT
Although the evidence is available worldwide, there is only li�le overlap between the 
references used in guidelines. Evidence-based medicine suggests objectivity, but the 
selection and use of evidence is mostly not neutral. Be�er worldwide collaboration between 
guideline developers is recommended. This could be achieved by developing clinical 
subject related evidence based reviews and these could be used as a basis for guidelines 
developed on a local level and adapted to local circumstances. These guidelines should 
be developed balancing applicability, consistency, and clinical impact of the evidence by 
a multi disciplinary working group. In an a�achment to the guideline methods used in 
selecting the evidence (i.e. search strategy, inclusion/exclusion criteria) and formulating 
the recommendations should be explicitly reported.
Current indicators on working according the guidelines are based on registering actions 
and ignore that these actions are the resultant of a shared decision process that might 
well be guided by recommendations. Observational techniques that might be used to 
obtain information on these processes are too complex and too laborious to be used on 
a wide scale and are subject to problems of interpretation. And using patients surveys to 
get a be�er insight into their satisfaction or perception of quality of care will also provide 
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information on one facet and a happy patient may not always be an adequately treated 
patient. More research is needed to tackle this problem.
ON PRACTICE MANAGEMENT
It is known that the majority of the health problems that patients are confronted with 
are solved without seeking professional medical care and the mechanisms regulating 
this should be appreciated. Only part of the patients are driven by the severity of their 
symptoms when visiting the GP, and this should trigger the GP not only to enquire about 
symptoms but to ask also for other motives. We found that half of the patients were in need 
of information and only few thought of the problems as being serious. The aim should 
be to reassure those with minor symptoms and to encourage those with symptoms that 
have major impact on daily living to seek care. And a man who is sent by his spouse may 
very well not always be helped with prescribing medication, but should also be provided 
with content that meets the spouses needs. The patient’s environment should be included 
in the information on the complaints and its treatment possibilities; providing patient 
information leaflets that can be read at home might help in this. It seems to be important 
for doctors to explore not only the bother perceived by the patient, but also the bother for 
his environment. More research is needed on the motives of the social network advising 
patients to a�end the GP’s practice. In studying this: nuisance (smell of urine, cleaning 
clothes/furniture, broken nights because of frequent voiding), fear of cancer and sexual 
problems should be included as potential factors.
Among GPs the availability of shared care seems to have led to a shi� of the primary care 
a�itude towards managing care as a specialist/urologist. Many (policy makers) expect 
shared care to be an efficient solution for (future) increased health care needs. But copying 
the specialist clinical management to general practice is unlikely to be more (cost) effective 
health care. Prospective studies are needed to provide be�er insight in the health outcomes 
and the efficiency of shared care clinics. And research is needed to study open access 
alternatives that promote sharing of care and knowledge between GPs and urologists 
without medicalizing the patient. For now, a watchful waiting approach regarding shared 
care clinics should be recommended to policy makers.
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ON MEDICAL EDUCATION AND QUALITY IMPROVEMENT
Although wri�en educational materials have limited effects, distance learning is 
particularly useful for GPs who live in remote or rural areas. In a dense populated area 
as the Netherlands this type of medical education may also be suitable to GPs in need 
for flexible continuous education as there are part-timers, young parents and GPs not 
yet se�led. In general practice, various disorders are thought of as being ‘small’ (low 
incidence/low priority); in these cases self-education and distant learning could also play 
a role as the method is known to be effective.84
In such a complex problem as PSA testing, where the GP requests an inadequate test in 
order to minimize his own as well as the patients fear for (missing) a prostate carcinoma, 
just sending educational materials is probably not enough. In this case fear as well as 
a�itude has to be changed and this requires probably a more intensive approach. A se�ing 
where a�er being provided with the evidence on PSA testing in the open population, the 
GP is enabled to test and discuss his opinions in a safe group of colleges and subsequently 
provided with proper patient education, could be more effective. This may be a strategy 
tested in future research. 
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SUMMARY
This thesis dealt with the clinical management of Lower Urinary Tract Symptoms (LUTS) 
in the Dutch general practice. The evidence to the management of LUTS as found in 
international literature was studied, as well as recent national guidelines on LUTS 
published in other countries. Furthermore, the behaviour of patient, general practitioner 
(GP) and medical specialist with regards to these complaints was explored. Finally, the 
effectiveness of an implementation strategy to the 1997 revision of the clinical guidelines 
on LUTS was evaluated. 
In the Introduction the subject of LUTS and the problems in relation to it’s clinical 
management were discussed. Literature and data on the patients’ and GPs’ perspective 
with regard to LUTS are presented. Questions for further research were identified that 
formed the basis of this thesis.
THE EVIDENCE: CLINICAL GUIDELINES
Chapter 1 presented the work of the guideline development group assigned by the Dutch 
College of General Practitioners (NHG). During a year the group regularly discussed the 
literature found in a systematic search for its evidence and relevance to daily practice in 
general practice. A�er processing comments by reviewers it was authorised by the Dutch 
college.
The major part of the 1997 guideline on lower urinary tract symptoms proved to be at 
this time still appropriate for the clinical management of lower urinary tract symptoms 
in general practice in the Netherlands. The most important change was the more explicit 
separation of lower urinary tract symptoms from the prostate carcinoma, since LUTS 
was no longer considered to be associated with an increased risk of prostate cancer. 
Nevertheless prostate carcinoma was included in this guideline to clarify underlying 
issues and in order to improve its practical use. 
Because of the limited clinical importance of a bladder residue, the recommendation to 
perform a percussion of the bladder was limited to men with suspicion of acute urinary 
retention, a reflex bladder or an overflow bladder. When in doubt in these cases: a trial of 
catheterisation of the bladder might even be necessary. 
174
IMPROVING MANAGEMENT OF ELDERLY MEN WITH LOWER URINARY TRACT SYMPTOMS IN GENERAL PRACTICE
175
SUMMARY / SAMENVATTING
This revision of the guideline focused on shared decision making on treatment possibilities 
because lower urinary tract symptoms have a benign nature with a variable course in 
most cases, and without a clear treatment imperative in itself. Watchful waiting and 
prescription of α-blocking medication remained the main treatment modalities for the GP. 
Alfuzosine and tamsulosine were the two drugs of preference because of their acceptance 
by the patients. If other treatments were preferred the patient should be referred to the 
urologist.
In Chapter 2 electronic literature data bases and web sites of institutions known to develop 
guidelines were searched for national guidelines on LUTS. Those found were systematically 
assessed in terms of quality using the AGREE-instrument. Recommendations with 
regard to the initial clinical management were subsequently identified and their citations 
were collected. The evidence used in ‘conflicting’ recommendations was explored in a 
qualitative manner. 
We found five recently published national guidelines developed by the American Urologist 
Association (AUA), Sowerby Centre for Health Informatics at Newcastle (SCHiN, UK), 
Duodecim (Finland), the National Health and Medical Research Council (NHMRC, 
Australia) and the European Association of Urology (EAU). According to the criteria for 
good guideline development in the AGREE Instrument, the NHMRC guideline would 
be strongly recommended for use in practice, the SCHiN and AUA guideline would be 
recommended with provisos or alterations and the Duodecim and EAU guideline would 
not be recommended.
In the guidelines studied recommendations were notably conflicting with respect to the 
diagnostic process. This was most remarkable in the recommendations on testing for 
creatinine and prostate specific antigen (PSA) and in the measurement of the post-void 
residual volume. Only 11.3% of the 227 references in all guidelines were used in more 
than one guideline to support the recommendation with respect to the initial care of the 
patient with LUTS. For some topics identical studies were used to underpin conflicting 
recommendations. Therefore, the use of evidence seemed less self-evident and objective 
than aimed for within evidence-based medicine. Both the AUA and NHMRC guideline 
had high scores in the AGREE domain of Rigor of development, which related to the 
process used to gather and synthesize the evidence, the methods to formulate the 
recommendations and to update them. Nevertheless, the NHMRC guideline was more 
directive and professional oriented leading to more ‘don’t recommendations’, compared 
to the AUA guidelines which contained more optional recommendations and le� the final 
decision to the interaction between practitioner and patient.
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CLINICAL MANAGEMENT OF LUTS: EXPLORATION OF THE PROBLEM 
A population-based survey was conducted in Chapter 3 among 5052 men aged ≥ 50 years. 
The study population comprised men with an I-PSS of > 7 and those visiting the GP 
because of LUTS were compared those who did not. 
One in every five men above the age of 50 years appeared to have moderate to severe LUTS 
and only 60% of the men with symptoms consulted the surgery of their GP because of their 
complaints. The severity of complaints was related to visiting their GP, but this was not 
influenced by symptom severity alone. The advice from the social network to consult their 
GP appeared to be the strongest independent predictor of GP a�endance, followed by 
information received from the media. The expected improvement in their condition a�er 
treatment by a GP or a specialist, and the knowledge they perceived on voiding problems, 
also appeared to be determinants of visiting a GP. Half of the men felt they were in need 
of more information about their condition and only a few men were convinced that their 
voiding problem was serious or related to a serious disease, regardless of whether they 
a�ended the GP or not.
Chapter 4 reports of a cross-sectional survey study among urologists and GPs. 
Questionnaire responses were obtained from 182 urologists (70%) and 261 GPs (55%). 
The level of familiarity with the national shared-care guidelines was explored as well as 
arrangements between urologists and GPs and the availability of a shared-care prostate 
clinic. This was related to the clinical care of a wri�en case of a 50-year-old man with 
clinical uncomplicated LUTS.
We found that the shared-care guideline on LUTS, developed by urologists and GPs and 
published in 1998 was be�er known to urologists than to GPs. Given a hypothetical patient 
with uncomplicated LUTS, urologists reported to order tests routinely as opposed to GPs. 
As far as symptom management was concerned, lifestyle advice on coping with LUTS 
was given by most physicians in both groups, although urologists more o�en provided 
patients with information leaflets to support their explanation. Urologists and GPs showed 
comparable a�itudes towards treatment choices for patients with moderate (medication) 
and with serious complaints (surgery). 
A minority of GPs and urologists said to have access to a shared-care clinic on prostate 
problems. The association of the level of shared care with specific aspects of the clinical 
management was explored. Among GPs the availability of shared care seems to have led 
to a shi� towards similar care management as a specialist/urologist. We found GPs, having 
a shared-care clinic at their disposal, more o�en used the I-PSS (a symptom score), and 
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requested more o�en laboratory tests (creatinine and PSA levels). For mild complaints 
a watchful-waiting strategy was chosen less o�en. Urologists with shared-care clinic 
facilities used the trans rectal ultrasound more frequently and chose more o�en a surgical 
intervention for moderate complaints.
In Chapter 5 a third explorative study was presented where during a period of 14 months 
19 GPs had open access to uroflowmetry as a tool in the diagnosis of lower urinary tract. 
A total of 12 men had actually performed uroflowmetry.
Seven of the twelve men included had a Qmax ≤ 10 ml/s (possible obstruction) and two had 
a Qmax ≥ 15 ml/s (probably unobstructed). Except for two, in none of the patients the clinical 
management was influenced by the uroflowmetry and medication was prescribed for their 
complaints. In two cases a watchful waiting policy was chosen instead, a�er discussion of 
the results with the patient. None of the patients was referred to a urologist. With respect 
to the low number of included patients and the limited effect on clinical management 
uroflowmetry is not considered as very useful in general practice.
From evaluative interviews at the end of the study we learned that all GPs were 
disappointed by the low incidence of patients with LUTS presenting at their surgery. The 
criteria for exclusion of the patients were thought of being too strict (notably excluding 
patients already treated for LUTS). Most GPs felt uroflowmetry would support a more 
objective indication and evaluation of treatment, and thought it could be a valuable, 
additional tool in general practice. They preferred uroflowmetry to be supported 
logistically by a diagnostic centre, to be used a�er request by the GP. In this centre the 
device should be distributed a�er the patient is instructed, and the resultant uroflowcurve 
should be interpreted by a specialist as well, since the respondents felt not able to do an 
adequate interpretation.
THE IMPLEMENTATION OF CLINICAL GUIDELINES
The last three chapters reported of a cluster randomised controlled trial. A total 142 GPs 
were randomised to a distant learning package (comprising a package for individual 
learning (PIL), consultation supporting materials (voiding diary, I-PSS and BS), two 
decision trees (on clinical management of LUTS and on PSA testing) and two information 
leaflets for patients) (intervention), or were sent national guidelines (controls). In 63 general 
practices (32 intervention and 31 control) across the Netherlands 187 patients older than 50 
years presenting LUTS for the first time were included. 
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In Chapter 6 the clinical management of the GP was considered as an outcome. From 
their registrations no differences were found in history taking and diagnostic procedures. 
Although the PIL intended to increase GP’s and patient’s awareness of the implications of 
PSA testing, PSA-tests were requested even 17.6% more o�en in the intervention group 
(although not significant). The intervention decreased the number of referrals to the 
urologist because of LUTS (OR 0.08 (95% CI: 0.02-0.40)). There were no other effects found 
to be significantly changed in the intervention group, although there was a trend towards 
longer consultations in the intervention group. The patients in the intervention group 
were more o�en provided with wri�en educational materials (52% versus 8%).
Chapter 7 had patient evaluation of quality of care received and perceptions of enablement 
as main outcome measures. Patients in the intervention group were more o�en satisfied 
with their consultation than controls. In particular they felt more involved in thinking 
about their complaints and were more satisfied about the way the GP communicated 
his intentions and explained the treatment and they were more convinced the treatment 
they received helped to decrease their complaints. In addition patients in the intervention 
group felt more able to cope with their illness and maintain their independence.
It may be concluded that the distance-learning programme on LUTS for GPs had some 
positive effects on patient self-management. Handing out leaflets appeared to be a crucial 
mediating factor. Patient who were advised on their lifestyle were satisfied with the way 
the GP had tried to reassure them, but despite this, they were less confident about their 
health than the patients who had not been advised on their lifestyle. Patients who received 
prescriptions for medication were less satisfied about the treatment options discussed 
during the consultation. There was no relation between PSA testing and any of the 
outcome measures. Higher Bother Scores were related with a greater need for additional 
diagnostic procedures and greater preference for surgical treatment. 
A health care perspective was taken in Chapter 8 reporting the economic evaluation with a 
three months time horizon. The primary health outcome was the patient reported urinary 
symptoms at three months. Costs related to the distance learning package and the health 
care provided were considered, using undiscounted standardised prices.
Patients in both groups compared reported a significant decrease of urinary symptoms. The 
urinary symptoms at inclusion and three months did not differ between the intervention 
group and the control group before or a�er the intervention, indicating the absence of an 
effect on health outcomes. 
178
IMPROVING MANAGEMENT OF ELDERLY MEN WITH LOWER URINARY TRACT SYMPTOMS IN GENERAL PRACTICE
179
SUMMARY / SAMENVATTING
The mean fixed costs were higher in the intervention group compared to the control 
group (€ 51.62 versus € 44.00), mainly because of the material costs related to the distance 
learning package. Remarkably, the GP reported time spent on self-study was similar 
in both study conditions: a total of 79.5 minutes per GP in the intervention group and 
70.0 minutes in the control group (€ 33.47 and € 32.31 per patient, respectively). Health 
care provision was also similar between the two groups except for the number of referrals 
to the urologist: this was lower in the intervention group. The mean total costs seemed to 
be lower in the intervention group compared to the control group at three months a�er the 
initial consultation, but the 95% confidence intervals showed overlap.
In the general discussion main conclusions are presented and their relation to other 
literature as well as the methodological considerations of the studies performed.
The text of the second revision of the guideline on LUTS of the Dutch College of General 
Practitioners (NHG) was added as an appendix to this thesis. 
178
IMPROVING MANAGEMENT OF ELDERLY MEN WITH LOWER URINARY TRACT SYMPTOMS IN GENERAL PRACTICE
179
SUMMARY / SAMENVATTING
SAMENVATTING
Dit proefschri� gaat over het klinisch handelen bĳ bemoeilĳkte mictie (= plasklachten) 
bĳ oudere mannen (ook wel Lower Urinary Tract Symptoms of LUTS genoemd) in 
de Nederlandse huisartsenpraktĳk. De wetenschappelĳke onderbouwing van het 
behandelen van bemoeilĳkte mictie, zoals gevonden in de internationale literatuur, werd 
kritisch beoordeeld en er is gekeken naar recente, in andere landen verschenen nationale 
richtlĳnen met betrekking tot bemoeilĳkte mictie. Verder vond een onderzoek plaats naar 
het gedrag van patiënt, huisarts en specialist met betrekking tot deze klachten. Tot slot 
werd een implementatiestrategie voor de richtlĳn ‘Bemoeilĳkte mictie bĳ oudere mannen’ 
zoals deze in 1997 gepubliceerd is door het Nederlands Huisartsen Genootschap (NHG) 
geëvalueerd.
In de inleiding werd het fenomeen van bemoeilĳkte mictie bĳ oudere mannen kort 
uiteengezet evenals de problemen die bestaan met betrekking tot het beleid bĳ deze 
klachten. Gegevens over de houding van de patiënt en de arts met betrekking tot dit 
klachtencomplex werden besproken. Vervolgens werden de onderzoeksvragen die de 
basis van dit proefschri� vormen geformuleerd.
DE ONDERBOUWING: MEDISCHE RICHTLIJNEN
In Hoofdstuk 1 werden de bevindingen van de werkgroep die door het NHG was 
samengesteld om de richtlĳn ‘Bemoeilĳkte mictie bĳ oudere mannen’ te herzien, 
gepresenteerd. Gedurende een jaar werd er door deze groep literatuur, die via 
systematisch zoeken verkregen was, beoordeeld op de wetenschappelĳke waarde en de 
relevantie voor de dagelĳkse huisartsgeneeskundige praktĳk. Na het verwerken van de 
commentaren van referenten uit gerelateerde disciplines werd de uiteindelĳke versie 
door de autorisatiecommissie geaccepteerd. 
Het grootste deel van de eerdere herziening uit 1997 bleek nog steeds van toepassing 
te zĳn op de dagelĳkse behandeling van bemoeilĳkte mictie in de huisartsenpraktĳk 
in Nederland. De belangrĳkste verandering betrof een explicietere scheiding tussen 
bemoeilĳkte mictie klachten en het prostaatcarcinoom. Bemoeilĳkte mictie werd namelĳk 
niet langer verondersteld gerelateerd te zĳn met een verhoogde kans op prostaat 
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carcinoom. Desalnie�emin werd het prostaatcarcinoom in deze NHG-Standaard wel 
behandeld om zo gerelateerde zaken nader toe te kunnen lichten en het gebruik voor de 
dagelĳkse praktĳk te verbeteren.
Door de beperkte klinische relevantie van het bestaan van een residu in de blaas na de 
mictie werd de aanbeveling om de blaas te percuteren beperkt tot die mannen waarbĳ 
een verdenking op een acute blaasretentie of de aanwezigheid van een reflex of een 
overloopblaas bestaat. Mocht er toch twĳfel blĳven bestaan dan kan een proefcatherisatie 
overwogen worden.
Deze herziening van de richtlĳn stelde de gezamenlĳke besluitvorming centraal bĳ te 
volgen beleid rondom behandelingsmogelĳkheden. Bemoeilĳkte mictie bĳ oudere mannen 
is namelĳk goedaardig met een wisselend klachtenbeloop in de meeste gevallen en zonder 
een duidelĳk obligate behandelingsstrategie. Een afwachtend beleid en het voorschrĳven 
van een zogenaamde α-blokker zĳn de behandelingsmogelĳkheden die de huisarts ter 
beschikking staan. Alfluzosine en tramsulosine werden aangeduid als medicamenten 
van voorkeur, omdat deze goed door patiënten verdragen werden. Als andere 
behandelmogelĳkheden dan afwachten of behandeling met een α-blokker de voorkeur 
zouden genieten dan werd geadviseerd de patiënt naar een uroloog te verwĳzen.
In Hoofdstuk 2 werden elektronische literatuurbestanden en de webpagina’s van instituten 
die richtlĳnen ontwikkelen doorzocht op de aanwezigheid van nationale richtlĳnen 
met betrekking tot bemoeilĳkte mictie. De gevonden richtlĳnen werden systematisch 
beoordeeld met behulp van de AGREE-scorelĳst. Met name aanbevelingen ten aanzien 
van het eerste medisch handelen bĳ een nieuwe patiënt werden geïdentificeerd en de 
bĳbehorende literatuurverwĳzingen verzameld. Daar waar de aanbevelingen ‘strĳdig’ 
waren werd de gebruikte literatuur op een kwalitatieve manier bekeken. 
Er werden vĳf recent gepubliceerde nationale richtlĳnen gevonden. Deze waren ontwikkeld 
door de American Urologist Association (AUA), Sowerby Centre for Health Informatics in 
Newcastle (SCHiN, UK), Duodecim (Finland), the National Health and Medical Research 
Council (NHMRC, Australia) en de European Association of Urology (EAU). Volgens de 
criteria voor goede richtlĳnontwikkeling zoals geformuleerd in het AGREE-instrument 
zou de NHMRC richtlĳn sterke aanbeveling verdienen voor gebruik in de praktĳk. De 
richtlĳnen ontwikkeld door SCHiN en de AUA zouden onder voorbehoud aanbevolen 
worden en de Duodecim en de EAU richtlĳnen zouden niet aanbevolen worden.
In de onderzochte richtlĳnen werden met name verschillen gevonden in de aanbevelingen 
die betrekking hadden op het diagnostisch handelen. Dit was het meest uitgesproken 
voor de aanbevelingen ten aanzien van het bepalen van het serum kreatinine, het Prostaat 
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Specifiek Antigeen en het meten van het blaasresidu na de mictie. Slechts 11,3% van de 
227 gevonden literatuurverwĳzingen werd in meer dan één richtlĳn gebruikt als argument 
voor een aanbeveling. Voor enkele onderwerpen werd dezelfde referentie gebruikt om 
strĳdige aanbevelingen te onderbouwen. Het gebruik van evidence was dan ook minder 
vanzelfsprekend en objectief dan verondersteld werd binnen het concept van evidence-based 
medicine. Zowel de richtlĳn van de AUA als die van de NHMRC had hoge scores in het 
AGREE domein ‘Methodologie’. In dit domein werden het proces van verzamelen 
en bundelen van de gegevens, alsmede de methodes gebruikt om aanbevelingen te 
formuleren en te zĳner tĳd weer te herzien, beschreven. Desalnie�emin was de NHMRC 
richtlĳn directiever en ‘professional georiënteerd’ en waren de aanbevelingen vaker 
negatief ten aanzien van het verrichten van diagnostiek of beleid in vergelĳking met de 
AUA richtlĳn. Die beva�e vaker optionele aanbevelingen en liet de uiteindelĳke keuze 
over aan de samenspraak tussen arts en patiënt.
HET KLINISCH HANDELEN BIJ BEMOEILIJKTE MICTIE: VERKENNING VAN HET PROBLEEM
In Hoofdstuk 3 werden de resultaten gepresenteerd van een enquêtestudie die werd 
verricht onder een open populatie van 5052 mannen van 50 jaar of ouder. De studie betrof 
de mannen die een score hoger dan 7 hadden met de Internationale Prostaat Symptoom 
Score (I-PSS); in deze groep werden de mannen die wel de huisarts hadden bezocht voor 
deze klachten vergeleken met zĳ die dat niet hadden gedaan.
Een op de vĳf mannen van 50 jaar en ouder bleek matige tot ernstige klachten te hebben 
van bemoeilĳkte mictie. Van deze mannen had slechts 60% hiervoor contact opgenomen 
met hun huisarts. De ernst van de klachten was gerelateerd met het huisartsenbezoek, 
maar bleek niet de enige factor te zĳn. Een advies uit de sociale omgeving van de patiënt 
bleek de sterkste ona�ankelĳke voorspeller te zĳn van huisartsenbezoek, gevolgd door 
informatie die via de media verkregen was. De verwachte verbetering van de klachten na 
behandeling door huisarts of specialist en de kennis die de patiënten veronderstelden zelf 
te hebben over bemoeilĳkte mictie bleken ook determinanten te zĳn in het bezoek aan de 
huisarts. De hel� van de mannen had behoe�e aan meer informatie over hun klachten en 
slechts enkele mannen waren er van overtuigd dat hun mictieklachten ernstig waren of 
werden veroorzaakt door een ernstige aandoening, ona�ankelĳk van of zĳ hun huisarts 
bezochten of niet. 
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Hoofdstuk 4 rapporteerde over een cross-sectioneel onderzoek onder urologen en 
huisartsen. De vragenlĳsten werden door 182 urologen (70%) en 261 huisartsen (55%) 
ingevuld geretourneerd. Het bekend zĳn met de Landelĳke Transmurale Afspraak 
(LTA) over bemoeilĳkte mictie bĳ oudere mannen werd hiermee geëxploreerd, evenals 
de aanwezigheid van werkafspraken tussen urologen en huisartsen en het beschikbaar 
zĳn van zogenaamde prostaat-klinieken. Deze factoren werden gerelateerd aan het 
klinisch handelen ten aanzien van een hypothetisch 50-jarige man met ongecompliceerde 
bemoeilĳkte mictieklachten.
De door huisartsen en urologen ontwikkelde en in 1998 gepubliceerde LTA was 
onder urologen beter bekend dan onder huisartsen. Urologen bleken in relatie tot de 
hypothetische patiënt meer routinematige onderzoeken aan te vragen dan huisartsen. 
Met betrekking tot de behandeling van de klachten bleken zowel door urologen als door 
huisartsen leefstĳladviezen te worden gegeven, waarbĳ urologen vaker aangaven gebruik 
te maken van voorlichtingsfolders. Urologen en huisartsen bleken vergelĳkbaar te zĳn in 
hun houding ten aanzien van behandelopties bĳ de patiënt met matige (medicatie) en met 
ernstige klachten (chirurgie).
Een klein deel van de huisartsen en urologen gaf aan de beschikking te hebben over een 
transmurale kliniek voor prostaatproblemen. De relatie van de mate van transmurale zorg 
met het klinisch handelen werd nader bestudeerd. Onder huisartsen leek de aanwezigheid 
van een transmurale kliniek te leiden tot een verschuiving van het klinisch handelen 
naar dat van de uroloog/specialist. Het bleek dat huisartsen die toegang hadden tot een 
prostaatkliniek vaker gebruik maakten van de I-PSS (een symptoomscore formulier), vaker 
laboratorium onderzoek aanvroegen (kreatinine en prostaat specifiek antigeen (PSA) 
bepalingen) en bĳ lichte klachten minder vaak een afwachtend beleid kozen. Urologen die 
gebruik maakten van een prostaatkliniek deden vaker transrectale echografieën en kozen 
vaker voor een chirurgische behandeling bĳ matige klachten.
In Hoofdstuk 5 werd een derde exploratieve studie gepresenteerd. Gedurende een 
periode van 14 maanden hadden 19 huisartsen rechtstreeks toegang tot een uroflowmetrie 
onderzoek als aanvullend onderzoek bĳ mannen met bemoeilĳkte mictie. In deze periode 
waren er 12 mannen waarbĳ daadwerkelĳk een uroflowmetrie was uitgevoerd.
Bĳ zeven van de 12 mannen was er een Qmax ≤ 10 ml/s (mogelĳke obstructie) en twee 
hadden een Qmax ≥ 15 ml/s (waarschĳnlĳk geen obstructie). Bĳ 10 patiënten werd het 
medisch handelen niet beïnvloed door het verrichten van een uroflowmetrie en werd 
medicatie voorgeschreven. Bĳ de twee andere patiënten werd er na bespreking van de 
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resultaten gekozen voor een afwachtende houding. Geen van de patiënten was verwezen 
naar de uroloog.
Met het oog op het lage aantal patiënten dat geworven werd gedurende het jaar 
van onderzoek en het beperkte effect op het medisch handelen, werd uroflowmetrie 
verondersteld niet zinvol te zĳn in de praktĳk van de huisarts.
Uit evaluatie-interviews die na de studie werden gehouden met deelnemende huisartsen 
bleek dat deze met name teleurgesteld waren over het lage aantal nieuwe patiënten 
met mictieklachten dat zich presenteerde in hun praktĳk. Hierbĳ werden de criteria 
ten aanzien van het insluiten van patiënten als te streng ervaren, met name het feit dat 
mannen die al onder behandeling waren niet mochten deelnemen. De meeste huisartsen 
gaven aan in uroflowmetrie een waardevolle aanvulling op de onderzoeksmogelĳkheden 
van de huisarts te zien. Het zou kunnen helpen om de indicatie voor behandeling beter te 
stellen en daarbĳ ook een evaluatie van de behandeling mogelĳk te maken. Zĳ gaven er 
de voorkeur aan dat de uroflowmetrie, na aanvraag door de huisarts, logistiek geregeld 
zou moeten worden door een diagnostisch centrum / huisartsenlaboratorium. Hier zou de 
patiënt na instructie het apparaat meekrĳgen en zouden de verkregen metingsresultaten 
door een specialist beoordeeld worden. Dit gezien het feit dat de deelnemers zich 
onvoldoende capabel ach�en voor een goede interpretatie.
HET IMPLEMENTEREN VAN RICHTLIJNEN
De laatste drie hoofdstukken beschreven een cluster gerandomiseerde studie. In totaal 
werden 142 huisartsen aselect verdeeld over een groep die een schri�elĳk nascholingspakket 
(interventiegroep) of een groep die een tweetal richtlĳnen over bemoeilĳkte mictie kreeg 
toegestuurd (controlegroep). Het schri�elĳk nascholingspakket omva�e een programma 
voor individuele nascholing (PIN), ondersteuningsmaterialen voor het consult (een 
plasdagboek, de I-PSS, en de klachtenscore (Bother Score: BS)), twee beslisbomen en twee 
patiëntenfolders (beide over beleid bĳ bemoeilĳkte mictie en over PSA bepalingen).
In 63 huisartsenpraktĳken (32 interventiegroep en 31 controlegroep) verspreid over 
Nederland, werden 187 patiënten ouder dan 50 die zich voor het eerst met bemoeilĳkte 
mictie klachten presenteerden, geïncludeerd.
In hoofdstuk 6 werd het medisch handelen van de huisarts als uitkomstmaat bekeken. Uit 
de registraties bleek dat er geen significant verschil was in het afnemen van de anamnese 
en het verrichten van onderzoek tussen de twee groepen. Hoewel de interventie er op 
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gericht was de huisarts en de patiënt bewust te maken van de implicaties van het bepalen 
van een PSA bleek dat het PSA in de interventiegroep in 17,6% van de gevallen vaker 
bepaald werd (hoewel niet significant). De interventie verlaagde het aantal patiënten dat in 
verband met mictieklachten naar de uroloog verwezen werd (OR 0,08 (95% CI: 0,02-0,40)). 
Er waren geen andere significante veranderingen in de interventiegroep, hoewel er wel 
een trend was naar een langer consult. De patiënten in de interventiegroep kregen vaker 
informatiefolders (52% versus 8%).
Hoofdstuk 7 had als uitkomstmaten de door de patiënten ervaren kwaliteit van zorg en 
de mate waarin ze het gevoel hadden in staat te zĳn gesteld met hun klachten om te gaan. 
Patiënten in de interventiegroep waren vaker tevreden met de consultatie dan de mensen 
in de controlegroep. Zĳ voelden zich met name meer betrokken bĳ het bespreken van de 
klachten en waren meer tevreden over de wĳze waarop de arts het te volgen beleid en de 
behandelopties besprak. Bovendien waren zĳ er vaker van overtuigd dat de behandeling 
die zĳ kregen hen zou helpen de klachten te verminderen. Verder voelden de mannen in de 
interventiegroep zich beter in staat met hun klachten om te gaan en hun zelfstandigheid te 
behouden. Er kan geconcludeerd worden dat de interventie een positieve uitwerking had 
op de zelfredzaamheid van de patiënt. Het verstrekken van patiëntenfolders bleek hierin 
een cruciale mediërende factor te zĳn.
Uit verdere explorerende analyses bleek dat patiënten die leefstĳladviezen hadden 
gekregen tevreden waren over het feit dat de huisarts hen probeerde gerust te stellen. 
Maar zĳ bleken uiteindelĳk minder zeker ten aanzien van hun gezondheid dan zĳ 
die geen adviezen hadden gekregen. Patiënten die medicatie voorgeschreven hadden 
gekregen leken minder tevreden over de wĳze waarop behandelopties besproken waren. 
Er was geen relatie tussen het testen van het PSA en een van de uitkomstmaten. Hogere 
klachtenscores waren gerelateerd aan een grotere behoe�e aan aanvullend onderzoek en 
een grotere voorkeur voor een chirurgische interventie.
In hoofdstuk 8 werd gerapporteerd van uit de optiek van de gezondheidszorg. De 
primaire uitkomstmaat waren de plasklachten die door de patiënt 3 maanden na de 
interventie gerapporteerd werden. De kosten die werden gemaakt in relatie tot de 
interventie en de geleverde medische zorg werden ook bekeken, waarbĳ uitgegaan werd 
van de standaardtarieven.
In de drie maanden na het geregistreerde consult werd een significante afname van 
de klachten gemeld door de patiënten in zowel de controle als de interventiegroep. 
Qua plasklachten bleek op het moment van inclusie en na drie maanden tussen beide 
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studiegroepen geen verschil te bestaan, er kon dus niet gesproken worden van een effect 
op gezondheidsuitkomsten.
De gemiddelde vaste kosten waren in de interventiegroep hoger dan in de controle 
groep (€ 51,62 tegen € 44,00), en dit werd met name gerelateerd aan de kosten van het 
nascholings- en consultondersteuningsmateriaal. Opvallend genoeg was de tĳd die de 
huisartsen aangaven nodig te hebben voor het bestuderen van de toegezonden materialen 
vergelĳkbaar: 79,5 minuten per huisarts in de interventiegroep en 70,0 minuten in de 
controlegroep (respectievelĳk € 33,47 en € 32,31 per patiënt). Het medisch handelen was 
in beide groepen vergelĳkbaar met uitzondering van het lagere aantal patiënten in de 
interventiegroep dat verwezen is naar de uroloog. Na een periode van 3 maanden leken 
de gemiddelde kosten in de interventiegroep lager in vergelĳking met de controlegroep, 
maar de 95% betrouwbaarheidsintervallen overlapten elkaar.
In de algemene discussie werden de belangrĳkste conclusies op een rĳtje gezet in 
samenhang met bestaande literatuur. Verder werden de methodische aspecten en de 
implicaties van de in dit proefschri� opgenomen studies nog eens overwogen.
Als appendix is de volledige tekst van de richtlĳn ‘bemoeilĳkte mictie bĳ oudere mannen’ 
opgenomen zoals deze in 2004 verschenen is.
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WOORD VAN DANK
Na vandaag zal het dan eindelĳk af zĳn. Inmiddels 7 jaar geleden kwam er een voorstel 
voor een onderzoek op mĳn weg dat uiteindelĳk hee� geleid tot dit boekje. Het feit dat 
alleen mĳn naam op de omslag staat suggereert dat het geheel een éénmansactie geweest 
is. Ik kan wel zeggen dat niets minder waar is. De vergelĳking met mĳn andere baan dringt 
zich hierbĳ op.  Een huisarts kan zich alleen als een spin in het web verplaatsen dankzĳ de 
vele steunpunten van het web buiten de muren van de spreekkamer. 
Hoewel ik ongetwĳfeld mensen zal vergeten (waarvoor mĳn oprechte excuses), is het 
belangrĳk om stil te staan bĳ het feit dat deze proeve nooit gerealiseerd had kunnen 
worden zonder de ondersteuning van velen. De volgorde waarin deze hieronder 
vernoemd worden is niet geheel willekeurig, maar zegt soms meer over mĳn associatieve 
denkpatroon (lees van de hak, op de tak) dan over het belang dat ik aan deze of gene wil 
toekennen.
Allereerst wil ik de 3803 patiënten, 441 huisartsen en 182 urologen, die bereid waren hun 
ervaringen met ons te delen,  bedanken. Zonder hun vele antwoorden op nog veel meer 
vragen waren deze studies niet mogelĳk geweest.
Richard Grol: je begeleiding was voor mĳ van grote waarde. Daar waar ik het soms niet 
meer zag zi�en ging je er vaak vaderlĳk voor zi�en om vervolgens het perspectief weer wat 
te veranderen en zo de horizon weer in beeld te krĳgen. Door je ervaring was je altĳd snel in 
staat de materie waarmee ik bezig was weer op te pikken en leken de koersveranderingen 
in analyse en interpretatie vaak kinderspel.
Chris van Weel: de man met de huisartsgeneeskundige visie. Je zorgde er steeds voor dat ik 
de huisartsgeneeskunde als mĳn ‘core business’ niet te veel uit het oog ging verliezen. De 
commentaren op de stukken die ik aanleverde kwamen in een, voor mĳ altĳd verbluffend, 
hoog tempo. Ik zal waarschĳnlĳk als een van de weinigen mĳn voordeel hebben gehad bĳ 
het feit dat je voor je reizen rond de wereld altĳd lang in het vliegtuig moest zi�en.
Jullie hebben beiden een zeer grote naam in de huisartsgeneeskundige wereld, zowel 
nationaal als tot ver buiten onze grenzen. Ik ervaar het als een eer dat jullie mĳ hebben 
willen begeleiden bĳ deze inmiddels toch wel lange weg. 
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Michel Wensing: beste Michel, zonder jouw begeleiding zou dit onderzoek nooit tot een 
proefschri� hebben geleid. Je leerde me de systematiek van het doen van onderzoek en 
was bĳ het weergeven van de resultaten altĳd in staat om met minder woorden meer 
te vertellen. Weinig onderzoekers hebben het privilege om hun werkkamer te mogen 
delen met hun directe begeleider. Deze positie gaf mĳ de mogelĳkheid om de problemen 
waarmee ik geconfronteerd werd meteen aan je voor te kunnen leggen. Je bood dan niet 
alleen een luisterend oor, maar vaak ook de meest pragmatische oplossingen en wist 
weer een relativerende opmerking te maken bĳ het tegenvallen van respons of resultaten, 
danwel bĳ de afwĳzing van een artikel.
Akke van der Bĳ en Janine Trap: jullie hebben aan de wieg gestaan van dit proefschri�. Ik 
weet dat ik het uiteindelĳk niet had kunnen redden zonder de systematiek en structuur 
die jullie aanbrachten in voorbereiden, reminden, verzamelen, opslaan en verwerken van 
de enorme datastroom. Geert Scha�enberg was hierbĳ weliswaar niet officieel gelinkt aan 
mĳn onderzoek, maar voor deze twee dames en dus ook voor mĳ een bron van onschatbare 
kennis en ervaring in het opze�en van databestanden.
De mensen in de begeleidingscommissie: Toine Lagro-Janssen, Maarten Klomp, Gert Jan 
van der Wilt, Rogier Corten en de (co)promotores wil ik bedanken voor hun hulp bĳ het 
uitze�en van de bakens voor de verschillende studies. Hoewel ik in de aanloop van deze 
bĳeenkomsten altĳd een zekere spanning voelde verliepen ze altĳd pre�ig. Ook wil ik 
jullie, alsmede Jako Burgers, Tjard Schermer, Rosella Hermens en Reinier Akkermans 
bedanken voor de waardelvolle bijdragen aan de omzetting van data naar een coherent 
verhaal.
Myrra Vernooy, er zĳn momenten geweest tĳdens het onderzoek waarop ik me afvroeg of 
ik je in het dankwoord zou noemen, als het er ooit eens van zou komen. Hoewel je eigenlĳk 
niet direct betrokken was bĳ het uiteindelĳke onderzoek, wil ik je toch bedanken voor het 
vertrouwen dat je in mĳ had toen je voorstelde om eens met Richard te gaan praten over 
een onderzoekje dat er aan zat te komen.
Ik wil Prof. Dr. Didi Braadt, Prof. Dr. Gert Jan Dinant, Prof. Dr. Wil van den Bosch, Prof 
Dr. Glyn Elwyn, Prof. Dr. Richard Baker, Prof. Dr. Toine Lagro- Janssen, Prof Dr. Bart 
Kiemeney en Dr. Ben Bo�ema bedanken dat zĳ mĳn proefschri� hebben willen beoordelen 
en vandaag in de promotiecommissie plaatsnemen.
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Hoewel de dames van secretariaat allemaal in meer of mindere mate steentjes hebben 
bĳgedragen wil ik met name Anita OudeBosch bedanken voor de regelmatige logistieke 
ondersteuning, het luisterende oor en het actieve meedenken. En Jolanda van Haren, wĳ 
(Raymond en ik) dachten het afronden van het boekje wel even zonder je te kunnen klaren, 
maar kwamen toch erg bedrogen uit; welbedankt voor de adviezen en een aanzienlĳk stuk 
van de redactie.
Zonder de pre�ige samenwerking met de mensen van het Diagnostisch Centrum Eindhoven 
(de logistieke ondersteuning bĳ de uroflowmetriestudie) en het Nederlands Huisartsen 
Genootschap (met name Cees in ‘t Veld voor het beschikbaarstellen van  het programma 
voor Individuele Nascholing bĳ de interventiestudie) had dit proefschri�  niet kunnen 
worden gerealiseerd. Mark Spigt, je was zo vriendelĳk om de reserve uroflowmeters van 
je eigen studie in Maastricht gedurende een jaar aan mĳ uit te leven.
Judith Abma, Ank van der Wiel en Nancy Christiaans wil ik bedanken voor de hulp bĳ de 
vertaling en correctie van veel van de hoofdstukken in dit boekje. 
Van mĳn mede-onderzoekers wil ik Arno Engers en Nicole Krol met name noemen. 
Doordat jullie, hoewel later begonnen en eerder klaar, min of meer in het zelfde schuitje 
zaten was het goed ervaringen te kunnen delen.
Justine Starreveld en haar jongens van de werkgroep voor de herziening van de 
Standaard (Mark Spigt, Pieter van Reedt Dortland, Ale Gercama, Maarten Klomp en Arnold 
Romeĳnders): ik wil jullie danken voor jullie inspirerende bevlogenheid om een actuelere 
Standaard te realiseren. De bĳeenkomsten in Utrecht waren voor mĳ altĳd iets om naar uit 
te kĳken.
Mireille ter Berg: van meet af aan ben ik blĳ met onze vriendschap en samenwerking in de 
afgelopen jaren. Dankzĳ jou hebben we nu een praktĳk in Elst en kon ik de weg naar de 
WOK gemakkelĳk op mĳn fietsje afleggen. Het werk in onze praktĳk zorgde ervoor dat 
ik het vak leuk ben blĳven vinden en mĳ realiseerde dat ik toch huisarts-onderzoeker was 
en niet andersom. Jouw schĳnbaar onuitpu�elĳke positieve energie hee� er mede voor 
gezorgd dat onze praktĳk is wat zĳ is. Maar ook buiten de praktĳk zĳn jĳ, Henk, Bram, Eva 
en Joep niet meer uit ons gezinsleven weg te denken. Bedankt dat je me ook vandaag als 
paranimf wilt steunen.
Marjan Grooten en Rinske Hendriks wil ik op deze plaats toch ook even genoemd hebben. 
Ik realiseer mĳ terdege dat ik het proefschri� alleen heb kunnen schrĳven doordat dankzĳ 
jullie de zaken op de praktĳk goed bleven lopen. Hierbĳ wil ik danook Chris Sluiter 
bedanken voor de vele uren die je als mĳn waarnemer in de praktĳk voor de patiënten 
hebt gezorgd.
Raymond Wetzels, eerst als Wokker, toen als HIDHA, nu als maat: je bent een verfrissende 
aanvulling in  onze praktĳk. Ik ben blĳ dat je aan het eind van je eigen studie nog even 
flink de sprint er in hebt kunnen ze�en, zodat we vandaag beiden onze boekjes kunnen 
verdedigen. Qua opleiding bleken we over een lang traject gemeenschappelĳke wortels te 
hebben en ik hoop dat we nog een tĳdje samen kunnen doorgroeien. 
Gertjan Driessen, ook wĳ delen samen een vrĳ lange geschiedenis. Je tomeloze energie is 
voor mĳ altĳd erg inspirerend geweest. Hoewel je ongetwĳfeld een goede kinderarts bent, 
ben ik er van overtuigd dat er aan jou een briljante huisarts verloren is gegaan. Ik ben blĳ 
dat je zo enthousiast was toen ik je vroeg mĳ vandaag als paranimf bĳ te staan.
Mĳn ouders en schoonouders wil ik voor vele zaken bedanken, maar binnen het kader 
van dit proefschri� voor het feit dat de deur altĳd open stond als ik op de vaste dinsdagen 
langs kwam om de kinderen weer even onder te brengen en ik rustig kon gaan schrĳven. 
Deze regelmaat is voor mĳ uiteindelĳk onontbeerlĳk gebleken. Ik ben er van uit gegaan 
dat het hier voor alle partĳen hier een echte win-win situatie betrof.
Simone en Stĳn, nu het boekje af is hoef ik voorlopig niet meer zo vaak naar school en zal 
ik wat makkelĳker achter mĳn computer weg te halen zĳn. Bedankt voor de afleiding die 
jullie boden door een lach en een traan, een luier en … weer verder gaan.
Anne�e, ik wil je bedanken voor het feit dat je mĳ de mogelĳkheid hebt gegeven om het 
proefschri� tot een goed einde te brengen. Als het even tegen zat of de dingen meer tĳd 
kosten dan ik verwacht had, heb je mĳ nooit meer met je oorspronkelĳke bedenkingen 
geconfronteerd. Je zocht altĳd mee naar wegen die vandaag mogelĳk hebben gemaakt. 
Onze weg is nog niet af.
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Dutch college of general practitioners (NHG) guideline: 
Lower urinary tract symptoms in older men 
(second revision)
René Wolters, Mark Spigt, Pieter van Reedt Dortland, Ale Gercama, Maarten Klomp, Arnold Romeijnders, Justine Starreveld
Huisarts en Wetenschap 2004;47:571-86
NB 1: The numbers between squared brackets ( e.g. [23]) refer to the footnotes as presented in the 
original text of the guideline, that can be accessed through http://nhg.artsennet.nl/upload/104/
standaarden/M42/std.htm.
NB 2: The rest of this thesis does not relate to this second revision of the guideline, but to the first 
revision as published in: Huisarts Wet 1997;40:114-24.
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The Standard has been revised since the first revision (Huisarts Wet 1997;40:114-24).
Major revisions are
• Urinary difficulty and prostate carcinoma are separate entities.
• In practice, questions about urinary difficulty and prostate carcinoma are often combined. 
Prostate carcinoma is therefore still described in this Standard, but under a separate heading.
• The term ‘urinary difficulty in older men’ means: lower urinary tract symptoms (LUTS) 
in men of older than 50 years. The term benign prostate hyperplasia is now reserved for 
histological changes in the prostate.
• Percussion of the bladder after micturition is no longer recommended.
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INTRODUCTION
The Dutch College of general practitioners guideline for urinary difficulty in older men, 
contains guidelines for the diagnostics and management of men of older than 50 years 
with urinary difficulty. The guideline does not apply to micturition problems in younger 
men, in women or children. Separate guidelines exist for urine incontinence and urinary 
tract infections [1]. The revised guideline describes new developments in the field of 
terminology, management choice and treatment options.
The paragraph Guideline for diagnostics focuses particularly on the exclusion of urinary 
infection or prostatitis and on the timely detection of possible complications of urinary 
difficulty, such as urine retention, hydronephrosis and renal function disturbances. In the 
paragraph Guideline for management, a�ention is paid to cooperative decision-making by 
the patient and general practitioner (GP), because the subjective hinder of the complaint is 
the central issue. A separate appendix is devoted to Guidelines for management and technique 
in acute urine retention.
The presence of urinary complaints does not form a reason to look for prostate carcinoma, 
because urinary difficulty is not a ‘risk factor’ for prostate carcinoma; the prevalence of 
prostate carcinoma in older men with urinary difficulty is the same as that in older men 
without urinary complaints [2]. As far as origin and prevalence are concerned, the two 
disorders are completely different entities. Diagnostic tests for prostate carcinoma (such 
as PSA analysis) in all men who consult their GP because of urinary difficulty, amount 
to screening, although it has not been established whether this is worthwhile. Owing 
to the fact that patients with urinary difficulty o�en make a connection with prostate 
carcinoma in general practice, a separate section on prostate carcinoma has been added 
to this guideline. Moreover, the suspicion of prostate carcinoma can arise during digital 
rectal examination, which would lead to a different management policy. Questions 
about screening for prostate cancer are frequently raised during consultation; specific 
knowledge is necessary to give good advice. It is expected that clarity about the policy 
concerning (questions about) prostate carcinoma will promote the implementation of the 
Dutch College of General Practitioners Guideline: ‘Urinary difficulty in older men.’
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BACKGROUND
CONCEPTS
The guideline employs the following concepts:
Urinary difficulty: changes in urination that lead to complaints such as hesitation before 
urine flow starts, weak or intermi�ent urinary stream, an urgent need to urinate, the 
feeling that the bladder has not emptied completely and increased frequency of urination 
during the day and at night. The international literature uses the term lower urinary tract 
symptoms (LUTS) [3].
Acute urine retention: inability to urinate spontaneously with a (painfully) full bladder, 
despite feeling an urgent need to urinate and multiple a�empts within a period of a few 
hours.
Benign prostate hyperplasia (BPH): nowadays the term benign prostate hyperplasia is 
reserved for histological changes in the prostate [3].
CAUSES AND PATHOPHYSIOLOGY
The cause of urinary difficulty in men older than 50 years is age-related deterioration in 
the voiding mechanism of the bladder. The reason is still partly unclear. Factors that play 
a possible role include urethral obstruction [4] and (neurogenic) bladder dysfunction, 
whether or not caused by comorbidity [5] or medication use [6].
For many years it has been believed that hyperplasia of the prostate is responsible for 
the obstruction in the urethra. Patho-anatomical research has shown that benign prostate 
Core messages
• Urinary difficulty does not form a ‘risk factor’ for prostate carcinoma.
• Urinary difficulty is caused by the combined action of static obstruction (enlarged 
prostate), dynamic obstruction (smooth muscle tissue in the neck of the bladder) and 
bladder function disturbance.
• In uncomplicated urinary difficulty, the management policy is determined by the 
subjective troublesome nature of the complaints and the patient’s wishes.
• Owing to variation in the natural course of urinary difficulty, it is recommended to 
attempt to reduce the use of α-blockers after 3-6 months.
194
NHG-GUIDELINE: ‘LOWER URINARY TRACT SYMPTOMS IN OLDER MEN (SECOND REVISION)
195
APPENDIX
hyperplasia develops from the age of 30 years onwards: at post mortem, benign prostate 
hyperplasia was found in 90% of 80-year-old men [7]. The cause of this hyperplasia 
is unknown and in principle, it is a normal degenerative process. Hyperplasia of the 
prostate does not always lead to prostate enlargement that can be felt during digital rectal 
examination. The size of the prostate does not correlate with the presence and severity of 
the complaints.
Increased or decreased activity of the detrusor urinae muscle can cause bladder 
dysfunction that is expressed as increased urgency, urinary frequency, urge incontinence 
and insufficient voiding [5].
EPIDEMIOLOGICAL DATA
Population surveys on older men showed that the prevalence of moderate to severe 
urinary complaints varied between 20% and 25% and that the prevalence increased with 
age. Furthermore, 60% of the men with urinary complaints consulted their GP [8]. These 
were not necessarily the men with the most severe complaints. Besides the severity of the 
symptoms, the decision to consult a doctor also depended on the manner in which the 
patient perceived his complaints. Important roles in the decision to consult the GP were 
played by anxiety for prostate cancer and by pressure from close family or acquaintances 
[9].
In general practice registries, the incidence varied between 2 to 4 per 1000 men per year. 
The incidence increased with age: from 4-9 in the age group 45-64 years, to 10-18 in the age 
group older than 75 years. Prevalence in these age groups were 8-19 and 36-165 per 1000 
men per year, respectively [10].
NATURAL COURSE
In older men, the frequency of urination increases with age. At the same time, the functional 
bladder capacity decreases [11]. The natural course of urinary difficulty is characterised 
by varying complaint pa�erns. Complaints can be intermi�ent, stable, progressive or 
transient [12].
Complications associated with urinary difficulty not only comprise urinary tract infections 
and acute or chronic retention, but also obstruction in the upper urinary tract, which can 
lead to hydronephrosis and renal function disturbances.
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GUIDELINES FOR DIAGNOSTICS
ANAMNESIS
The GP should ask about:
•  complaints during urination [13]: hesitation before urine flow starts, weak or 
intermi�ent urinary stream, urgent need to urinate, the feeling that the bladder has not 
emptied completely, changes in urinary pa�ern during the day and at night;
•  duration and course of the complaints: rate of onset or rate of deterioration of the 
complaints;
•  perceived troublesomeness: does it affect the night’s sleep, or cause social limitations 
during the day?
• incontinence;
• pain during urination, perineal pain;
• general malaise;
• previous urinary tract infections.
In addition, the GP pays a�ention to:
• relevant comorbidity: diabetes mellitus, neurological disorders (e.g. CVA, Parkinson’s 
disease, multiple sclerosis), sexually transmi�ed diseases (previous urethritis);
• previous urological investigations, history of urological treatment or indwelling 
catheter;
• medication that influences micturition: antipsycholics, (tricyclic) antidepressives, 
anti-Parkinson drugs, (classic) antihistamines, opiates, loopdiuretics [6].
Very o�en, anxiety for prostate carcinoma lurks behind the complaint ‘urinary difficulty’. 
There may also be sexual problems or shame about incontinence [9]. By making these 
issues discussible, a proportion of the patients may feel sufficiently reassured that further 
diagnostic tests or treatment are unnecessary.
If required, a voiding diary can be kept to record the actual amount, frequency and time of 
urination; moreover, the data in the voiding diary can be used during communication with 
the patient to help establish the degree of troublesomeness of the complaints. Urologists 
o�en use a score to measure the degree of severity (I-PSS) [13]. However, for GPs, this 
score does not have any advantage for diagnostics and policy.
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PHYSICAL EXAMINATION
During physical examination, the GP examines the lower abdomen (scar tissue, swelling) 
and the penis (phimosis). Percussion of the bladder is recommended on anamnestic 
suspicion of neurogenic bladder disease if there is comorbidity, bladder overflow (i.e. 
continuous loss of small amounts of urine without feeling the urge to urinate) and acute 
urine retention (unable to urinate despite feeling an urgent need to). If there is doubt about 
residual urine in the bladder, examination by catheter will provide a definitive answer 
[14].
Although the value of digital rectal examination is debatable, it is o�en conducted in any 
case to obtain a complete picture of the local status and to comply with the expectations 
of the patient regarding the adequate evaluation of his complaints. During digital rectal 
examination and palpation of the prostate, a�ention is paid to the shape (symmetry), 
texture (pliable and smooth or hard and nodular), size and sensitivity to pressure [15].
A prostate that feels symmetrical, smooth and firmly pliant during palpation indicates the 
normal situation without abnormalities. If there are no palpable abnormalities, but the 
prostate is sensitive to pressure, this may indicate prostatitis. An asymmetrically shaped 
prostate with an irregular texture or hard nodules is suspicious of prostate carcinoma: see 
Guideline policy in the section Prostate carcinoma.
SUPPLEMENTARY TESTS
The GP obtains a urine specimen from all the patients to look for signs of urinary tract 
infection (see NHG guideline Urinary Tract Infections). It is important to establish the 
presence or absence of a urinary tract infection, because this will have consequences on 
the management policy [16].
In patients with general malaise, frequently recurring urinary tract infections or urine 
retention, supplementary tests are indicated for the timely detection of complications 
from urinary difficulty. These tests comprise ultrasound of the urinary tract to diagnose or 
exclude hydronephrosis [17] and serum creatinine analysis [18].
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EVALUATION
There are strong indications of urinary difficulty when older men complain of urination 
problems and there are no signs of a specific cause. In this case, the GP considers the 
differential diagnosis of the following disorders:
Urinary difficulty that has developed rapidly and pain in the perineum caused by pressure 
sensitive prostate during digital rectal examination, indicates prostatitis [19].
Painful or burning frequent urination, positive nitrite test, urine sediment [20], urinalysis 
or culture form grounds to suspect urinary tract infection (see NHG guideline Urinary 
Tract Infections).
Painful, burning or irritated sensations in the urethra with discharge or leucocytosis in the 
urine indicate urethritis (see NHG guideline Sexually Transmi�ed Diseases consultation).
Urge incontinence two or more times a month, irrespective of the amount of urinary loss, 
indicates urinary incontinence.
Patients with urination problems and diabetes mellitus or a neurological disease, such 
as CVA, multiple sclerosis or Parkinson’s disease, in combination with dull percussion 
sounds or postvoiding residual urine upon catheterisation, may have a reflex bladder.
Continuous loss of small amounts of urine without feeling the urge to urinate, in combination 
with dull percussion sounds or postvoiding residual urine upon catheterisation, indicate 
an overflow bladder.
Patients with urination problems and a history of local trauma, urological intervention or 
previous urethritis, may have urethral stricture.
When a patient with a full bladder cannot urinate spontaneously, despite feeling a generally 
painful urge to do so and a�er multiple a�empts within a few hours, consideration should 
be given to urine retention.
GUIDELINE POLICY
This paragraph provides guidelines on the management policy for urinary difficulty. 
The management policy for acute urine retention is discussed in the appendix Acute 
urine retention. The management policies for acute prostatitis, urinary tract infection and 
incontinence are dealt with in the NHG guidelines Urinary tract infections and Urine 
incontinence.
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PATIENT EDUCATION
The GP explains that the complaints can be caused by age-related changes in bladder 
function and sometimes by obstruction around the urethra and in the prostate; prostate 
enlargement cannot explain the complaints. The common occurrence of the disorder, its 
benign character and varying course are discussed. Owing to the fact that certain types of 
medication can aggravate the complaints, the GP reconsiders their use [6]. In addition, the 
GP gives the following advice [21]:
• Go to the toilet regularly, especially when large amounts of fluid are being consumed 
in a short time.
• Take your time to urinate (you might wish to adopt the si�ing position).
• Take care that your bladder and penis are as empty as possible a�er urination.
• Contact the surgery immediately if you cannot urinate spontaneously in familiar 
surroundings, despite the feeling of urgency and multiple a�empts within a period of 
a few hours (acute urine retention) [22].
Contribution of the patient
The NHG Standard provides guidelines for management by GPs; thus, the GP plays a central 
role. In addition, however, factors from the side of the patient must always codetermine the 
management policy. For practical reasons, this starting point is not referred to repeatedly in the 
guideline, but is hereby considered to have been stated with sufficient explicitness.
Whenever possible, the GP specifies his/her management policy in conference with the patient, 
while taking the specific patient circumstances into consideration and while recognising the 
patient’s own responsibility, in which adequate patient education is a prerequisite.
Consideration by the GP
The personal insight of the GP is obviously an important aspect in relation with every guideline. 
Due consideration to the relevant factors in the concrete situation can justify well-reasoned 
deviation from the management policy described below, without undermining the intended 
function of this Standard as a model and aid.
Delegation of tasks
NHG Standards contain guidelines for GPs. This does not mean that the GP has to conduct all the 
tasks personally. Some of the tasks can be delegated to the practice assistant, support personnel 
or the practice nurse, on the condition that there is a basis of clear working agreements that 
dictate the situations in which the GP must be consulted and on the condition that the GP 
safeguards the quality. Owing to the fact that the choice of tasks that can be delegated depends 
strongly on the local situation, these Standards do not contain concrete recommendations.
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There is insufficient evidence of the value of pelvic floor exercises in men with urinary 
difficulty [23].
In support of the verbal advice and information, the GP can give the patient an NHG 
folder on Urinary problems in older men.
COOPERATIVE DECISION-MAKING ABOUT FURTHER MANAGEMENT
The GP explains that the choice of management policy depends strongly on the patient’s 
wishes, because the subjective troublesomeness of the complaints forms the central 
issue. Subjective troublesomeness can be more severe or sometimes less severe than 
the symptoms (actual urinary complaints). Experience has shown that the more severe 
the actual urinary complaints, the greater the benefit that can be expected from possible 
treatment. Severity is the best predictor of the success of a urological intervention [24]. 
Then the next set of issues are discussed: therapeutic options (wait-and-see, medication 
or invasive treatment), expected effects and side-effects. Generally speaking, invasive 
treatment leads to greater improvement in the complaints than medication, but it involves 
a larger risk of side-effects. The major side-effect of treatment with medication is vertigo, 
while invasive treatment can involve incontinence, erectile dysfunction and ejaculation 
problems [24]. In view of these side-effects, the GP can advise a wait-and-see policy, 
whether or not in combination with medication treatment, as some patients find it easier 
to cope with the aid of medication. In some situations, it is necessary to refer the patient, 
e.g. if there are complications (see Referral).
WAIT-AND-SEE POLICY
A wait-and-see policy for patients with urinary difficulty is a realistic option. O�en, owing 
to the variations in natural course, intervention may not be needed or necessary. In a large 
proportion of patients, the complaints will improve without therapeutic interventions 
[12;24].
TREATMENT WITH MEDICATION
Medication can be considered in patients with troublesome complaints who derive 
insufficient benefit from following their GP’s advice and are not eligible (or willing) 
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to undergo invasive treatment. Alpha-blocking sympathocolytes (α-blockers) are the 
medication of choice; they can decrease the urine outflow resistance by influencing 
the muscle tone in the prostate and urinary tract. When the medication is effective, the 
results are rapid – the largest effect is reached within two weeks. However, medication 
has a limited effect on the complaints, both compared to placebo and invasive treatment 
methods [24]. Effectiveness is expressed in symptom improvement (mean improvement 
in symptoms: 20%) and in urodynamic improvement (mean improvement in outflow: 
20-30%). All the available α-blockers are just about equally effective and safe [25]. All 
α-blockers lower the blood pressure, which can lead to orthostatic hypotension, especially 
during the initial period of use. In patients with normal blood pressure, the ultimate 
effect on blood pressure is low. Other side-effects include: nausea, vertigo, headaches, 
palpitations, rhinitis and abnormal ejaculation. Despite the comparable effectiveness and 
side-effects of α-blockers, preference is given to alphuzosine or tamsulosine [26] on the 
basis of differences in side-effects a�er discontinuation of treatment with medication.
If there is no improvement within 6 weeks, the medication is stopped. In patients who 
derive benefit, the medication is prescribed for 3 to 6 months. As li�le is known about the 
effectiveness of α-blockers in the long-term and as the natural course varies, the decision is 
taken in consultation with the patient to stop the medication to see whether the complaints 
deteriorate again.
The application of 5-α-reductase inhibitors, such as finasteride, is ruled out within 
general practice, because the clinical effect is extremely limited (even in comparison with 
α-blockers), it takes a long time to become effective (2-6 months) and is not relevant until 
the prostate has reached a certain size. At present, research is ongoing into evaluate the 
additional value of 5-α-reductase inhibitors in combination with α-blockers [27].
There are indications that plant medicines (phytotherapy) are effective, but as yet, there is 
insufficient evidence on which to base well-founded advice about their use [28].
Table 1: Dosage and use of α-blockers [26]
Alphuzosine: 10 mg tablet with regulated release once a day in the evening after meals
in the case of slight-moderate liver 
function disturbances: 2.5 mg 
tablet 1-2 times per day after meals
Tamsulosine: 0.4 mg capsule with regulated release once a day in the morning after breakfast
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INVASIVE TREATMENT
The term invasive treatment encompasses both the classic surgical interventions and other 
non invasive treatments (such as TUMT).
There are indications for invasive treatment (see Referral).
Invasive treatment can be considered further when the troublesomeness of the urinary 
difficulty is unacceptable to the patient, whether or not a�er possible treatment with 
medication has proved to be insufficiently effective. The GP can give global information 
about the advantages and disadvantages that can be expected with invasive treatment: the 
urologist can apply various treatment methods [29;30] with a global chance of 60 to 75% 
of improvement in the complaints and a risk of complications that varies according to 
the method chosen (incontinence 1-25%, erectile dysfunction 1-10%, ejaculation problems 
4-61% [24]. If the patient wishes to consider invasive treatment, the GP refers him to a 
urologist. The choice of treatment depends on the availability of the different treatments, 
the urologist’s experience with the interventions and the wishes of the patient.
CHECK-UPS
Check-ups are conducted in the case of changes or deterioration in the complaints and 
when patients are taking medication. The timing of the check-ups can be le� to the patient 
when there are changes or deterioration in the complaints. During the check-up, the GP 
investigates whether there are changes in the severity and nature of the complaint pa�ern, 
general malaise, new comorbidity or new medication. Urine analysis is performed to detect 
signs of infection. On certain indications, abdominal ultrasound scanning is performed 
and the creatinine level is tested (see Supplementary tests). If the complaints have changed 
or deteriorated, the GP reconsiders the diagnosis, adjusts the treatment with medication if 
necessary, or refers the patient on for further diagnostics or possible invasive treatment.
Check-ups related to the start of treatment with medication take place a�er 6 weeks (in 
person or by telephone) to evaluate the effect and a�er 3-6 months to discuss with the 
patient whether the medication can be stopped to judge whether the complaints increase 
again.
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REFERRAL
The GP refers older men with urinary difficulty in the following situations:
4For tests in aid of differential diagnosis:
 • on the suspicion of a neurogenic bladder disorder and/or overflow bladder;
 • on the suspicion of urethral stricture;
 •  on the suspicion of prostate carcinoma: see Guideline policy in the section Prostate 
carcinoma.
4For possible invasive/surgical treatment [31]:
 • if the patient wants invasive treatment due to perceived troublesomeness;
 • if the patient has acute urine retention;
 • if the patient has recurrent urinary tract infections;
 • if the patient has renal function disturbances and/or hydronephrosis.
A separate referral indication is formed by acute urine retention with contra indications 
for trans urethral catheterisation (see further in the appendix Acute urine retention).
APPENDIX ACUTE URINE RETENTION
GUIDELINE POLICY
The GP performs trans urethral catheterisation for acute urine retention, unless it can be 
traced back to recently or previously experienced trauma (or urethritis). In that case, it is 
followed by urgent referral to a urologist [32]. Together with the patient, the GP considers 
treatment with an α-blocker a�er catheterisation [33]. The catheter remains in situ for 48 
hours and is then removed [34].
If the patient has a urinary tract infection, constipation, medication use [6] or alcohol use, 
the catheter remains in situ until the underlying cause of the retention has been resolved. If 
urination does not occur spontaneously a�er removal of the catheter, referral to a urologist 
is the next step.
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TECHNIQUES [35]
Requirements:
• catheter set: two basins, sterile gauze, cellulose mat, gloves, anatomical forceps, catheter 
bag;
• standard catheter Charriere size 16-18, 10 cc syringe + (distilled) water;
• anaesthetic lubricant (sterile packaging in syringe or flask);
• disinfectant (chlorhexidine 0.05%).
MANAGEMENT:
• Role back the foreskin.
• Disinfect the glans penis and urethral opening.
• Slowly inject a liberal quantity of anaesthetic lubricant (15-30 ml.) into the urethra 
using a syringe.
• Coat the catheter tip in anaesthetic lubricant and carefully introduce the catheter 
into the bladder. The tip of the catheter points ventral. Introduction of the catheter 
is facilitated by tilting the penis slightly upwards, by pressing a finger against the 
perineum and by the patient slowly breathing in and out. If the catheter has trouble 
passing through the prostate, the penis is tilted caudal to simplify passage.
• To pass the neck of the bladder, push the catheter 3 to 4 cm further when the first urine 
enters the catheter. To avoid damaging the membranous urethra or the neck of the 
bladder, a minimum of 24 cm of the catheter must be inserted before the balloon is 
filled with (distilled) water. The balloon can then be filled with the stipulated amount 
of (distilled) water.
• Pull the catheter back gently until resistance is felt and the balloon is resting against 
the neck of the bladder. The catheter is connected to the collection bag and fixed to the 
patient’s upper leg or abdomen.
• If catheterisation is unsuccessful, the patient is referred immediately to a urologist.
Bear in mind that the following complications can occur during trans urethral 
catheterisation:
• Lesions in the urethra, neck of the bladder or prostate due to a fausse route or filling 
the balloon while it is in an incorrect position;
• Infection of the urethra, bladder, prostate or epididymis.
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ORIGINATION
In June 2003, a working group started the second revision of the NHG Guideline for Urinary difficulty 
in older men. The working group comprised: R.J. Wolters, GP in Elst and scientific researcher at the 
Centre for Quality of Care Research (WOK), UMC St Radboud (Nijmegen), M.G. Spigt, health science 
and scientific researcher in the capacity group at the University of Maastricht, P.F.H. van Reedt Dortland, 
GP in Breda, A.J. Gercama, GP in Rijsenhout and university lecturer in general practice medicine VUMC 
and M.L.F. Klomp, GP in Eindhoven and education coordinator of General Practitioner Training at the 
UMC St Radboud.
In April 2004, a concept of the guideline was sent to 50 GPs for review, their addresses had been 
picked at random from the NHG membership list. Twenty comment forms were returned. In addition, 
comments were received from a focus group of 8 GP tutors and a number of referees. These referees 
comprised: professor J.L.H.R. Bosch, urologist, professor C.H. Bangma, urologist, dr. T.J.M. Schlatmann, 
urologist, dr. M.H. Blanker, GP, T. Christiaens, GP on behalf of the scientific foundation of Flemish GPs, B.J. 
de Boer, GP on behalf of the commission to promote sexology, J. van Engeldorp Gastelaars, pharmacist 
on behalf of WINAp Medication Information, Mrs. J. Heymans, GP and editor of the Diagnostisch Kompas, 
A.C. van Loenen, clinical pharmacologist and chief editor of the Farmacotherapeutisch Kompas and L. 
Dijkstra on behalf of the Foundation Contact Group for Prostate Cancer. Name entry as a referee does 
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APPENDIX
PROSTATE CARCINOMA
INTRODUCTION
Prostate carcinoma grows slowly and usually develops in the periphery of the prostate, far 
remote from the urethra. It generally does not express itself, or not until an advanced stage, with 
the consequences of bone metastases or urethral obstruction. Statistics show that 42 out of 
every 100 men will develop a form of prostate cancer;10 will develop physical symptoms;3 will 
die from the disease [36].
Treatment for prostate carcinoma is a tricky issue: it has never been confirmed that treatment for 
prostate carcinoma prolongs life, whereas the treatment can involve side-effects [37]. This means 
that an individual patient might benefit from treatment, but sometimes might also only encounter 
disadvantages. In the case of metastasized prostate carcinoma, antihormonal treatment can lead 
to considerable temporary reduction in symptoms and improved quality of life [38].
When choosing a management policy, patients suspected of having prostate carcinoma are 
distinguished from those without suspicion and questions about screening.
SUSPECTED PROSTATE CARCINOMA
GUIDELINE POLICY
Prostate carcinoma is suspected when digital rectal examination reveals an asymmetrical prostate, 
an irregular texture or hard noduli. About half of the cases actually have prostate carcinoma. 
The GP discusses this with the patient [39]. In this situation, PSA analysis is of very limited 
value, because an increased value does not confirm the diagnosis and a normal value does not 
exclude the diagnosis. Moreover, interpretation of a PSA analysis has various pitfalls [40]. To be 
certain of the diagnosis, secondary care diagnostics are necessary [41]. The question of whether 
it is worthwhile to follow this path and initiate intervention depends on a number of factors. 
When assessing the point of performing therapeutic interventions with curative intent, the life 
expectancy of the patient plays a central role [42]. In the case of palliative therapy, the presence of 
complaints from metastases plays a central role. The prognosis on the basis of the natural course 
[43], the effectiveness of a treatment [44], treatment-related complications [37] and expectations 
regarding morbidity [45] must be weighed against each other.
The following practical guidelines apply to the GP:
First, the GP establishes whether there are clinical indications of metastases (general malaise, 
weight loss, bone pain in the back, hips). Patients with a life expectancy of more than ten years are 
referred to a urologist for further diagnostics and evaluation of the therapeutic options.
In patients with a life expectancy of less than ten years – generally patients of older than 72 
years [46], or younger patients in whom comorbidity has a negative influence on life expectancy 
– without clinical indications of metastases, it is debatable whether further diagnostics are 
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worthwhile. The GP explains that if the patient does prove to have prostate cancer, this generally 
grows very slowly. Moreover, life expectancy and quality of life will probably not improve much 
through medical intervention, whereas there is a considerable risk of side-effects. After receiving 
all the relevant information, these patients might choose to follow a wait-and-see policy, but if 
they choose to undergo further diagnostics and evaluation of the therapeutic options, they will 
have to be referred to a urologist.
If there are clinical indications of metastases, PSA analysis can be worthwhile: a PSA value of 
>50 ng/ml strengthens the suspicion of metastasized prostate carcinoma [47]. The GP refers the 
patient to a urologist for further diagnostics and evaluation of the therapeutic options [38]. 
In practice, the majority of patients will (want to) be referred. The GP can make it clear to the 
patient that it is also possible to be referred only for further diagnostic tests and that after 
confirmation of the diagnosis, the patient can still choose a wait-and-see policy.
SCREENING FOR PROSTATE CARCINOMA
GUIDELINE POLICY
The GP explains the following to a patient without complaints who asks to undergo tests for 
prostate carcinoma:
Prostate carcinoma is a common tumour in older men, but it only gives rise to symptoms in 10 
out of the 100 men and forms the ultimate cause of death in even fewer (3 out of 100 men). 
Thus, far more men die with prostate carcinoma than from it. When prostate cancer is found by 
chance, it is not easy to predict whether it will become clinically relevant in individual cases. There 
is no evidence that the early detection and treatment of patients with asymptomatic prostate 
carcinoma actually decreases morbidity and mortality [48]. However, false-positive results do 
involve the burden of (unnecessary) diagnostic tests, while diagnostics and treatment involve co 
morbidity and complications.
Research has shown that patients with a positive family history have an increased risk of 
developing prostate carcinoma [49]. In these men, the value of performing early diagnostics for 
prostate carcinoma has never been demonstrated. This also applies to men from a family with 
hereditary prostate carcinoma.
In support of this explanation, the GP can give the patient the NHG patient folder: Should we or 
should we not screen for prostate cancer?
If a complaint-free patient still wishes to be screened for prostate cancer despite having 
received extensive information, the GP can agree to comply. The GP then performs digital rectal 
examination (DRE) in combination with PSA analysis. The risk of prostate carcinoma is small 
when the DRE findings are normal and the PSA value is <4 ng/ml. If either of the tests provide 
suspicion for prostate carcinoma, then it is best to refer the patient. If the DRE findings are 
normal and the PSA value is between 4 and 10 ng/ml, then after discussing the matter with the 
patient, it might be decided to repeat the PSA analysis at a later date, which could ultimately still 
lead to referral to a urologist [50].
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